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 Summary (CZE) 
V této dizertační práci jsme se zaměřili na objasnění molekulárních mechanismů 
radiosensibilizace leukemické buněčné linie MOLT-4 specifickou inhibicí kináz z rodiny 
fosfatidylinositol-3-kináza příbuzných kináz (PIKKs). Byly testovány dva vysoce účinné a 
selektivní inhibitory VE-821 (inhibitor ATR) a KU55933 (inhibitor ATM) pro jejich 
účinky na proliferaci, viabilitu a buněčný cyklus neozářených a ozářených buněk MOLT-4. 
Aplikace obou inhibitorů způsobila radiosensibilizaci MOLT-4 buněk a 10 µM VE-821 
navíc působil jako silné antiproliferativní agens i v neozářených MOLT-4 buňkách. 
K dalšímu popisu mechanismů, které jsou zodpovědné za radiosensibilizaci 
MOLT-4 buněk VE-821 inhibitorem, byly použity metody využívající hmotnostní 
spektrometrii. Pomocí metod kvantitativní proteomiky jsme identifikovali a kvantifikovali 
změny v proteomu a fosfoproteomu (tj. změny na úrovni fosforylace proteinů) buněk, které 
byly způsobeny účinkem inhibitoru v ozářených buňkách. Protože detekce a kvantifikace 
fosforylovaných peptidů v komplexních vzorcích je komplikována mimo jiné jejich 
relativně nízkým zastoupením, zaměřili jsme se nejprve na výběr optimální metody pro 
jejich selektivní izolaci ze směsi s nemodifikovanými peptidy. Optimalizovaný protokol 
byl pak dále využit ke studiu změn v buňkách radiosensibilizovaných VE-821. Dle 
očekávání inhibitor hodinu po ozáření nevyvolal žádné změny na úrovni proteomu. Při 
studiu fosfoproteomu jsme ale nalezli 623 signifikantně změněných fosforylačních míst, 
z nichž většina (431) byla zvýšeně fosforylována. Pomocí bioinformatických nástrojů jsme 
identifikovali změny v signálních drahách a aktivitách kináz přímo odpovídajících na 
poškození DNA, ale také v signálních drahách a kinázách primárně souvisejících s regulací 
buněčného metabolismu. Detekovali jsme snížení v aktivitě mTOR kinázy, které bylo 
nejspíše způsobené nespecifickým působením inhibitoru v 10 µM koncentraci. Tato 
snížená aktivita může pravděpodobně přispívat k zástavě proliferace buněk po podání 
vysoké dávky inhibitoru. Vliv VE-821 na metabolismus ozářených buněk byl dále 
zkoumán pomocí cílené metabolomické analýzy. V této analýze bylo kvantifikováno 206 
intermediárních metabolitů. Při následné analýze dat bylo zjištěno, že VE-821 potencuje 
rozvrat energetického metabolismu a může ovlivňovat odpověď na oxidační stres 
způsobený ozářením. Dále jsme ukázali, že obnova poškozených deoxynukleotidů 
by mohla být negativně regulována VE-821.  
V této práci jsme tedy komplexně popsali, jaké signální a metabolické dráhy 
by mohly být závislé na ATR nebo spuštěny ATR inhibicí VE-821 v ozářených MOLT-4 
buňkách. Výsledky této práce mohou být dále použity jako zdroj informací pro další 




 Summary (ENG)  
In the presented doctoral thesis, we aimed to elucidate molecular mechanisms 
underlying radiosensitization of MOLT-4 cell line (T-ALL) by specific inhibition 
of kinases from the phosphatidylinositol-3 kinase-related kinases (PIKKs) family. We 
tested two highly potent inhibitors of ATR and ATM, VE-821 and KU55933, respectively, 
for their effects on proliferation, viability, and cell cycle of sham-irradiated and irradiated 
MOLT-4 cells. Both inhibitors proved to radiosensitize MOLT-4 cells and furthermore, 
10 µM VE-821 was shown to act as a strong antiproliferative agent in sham-irradiated 
MOLT-4 cells. 
To further describe cellular mechanisms underlying the VE-821-mediated 
radiosensitization of MOLT-4 cells, we employed high-resolution mass spectrometry 
to identify and quantify changes in proteome and phosphoproteome of irradiated VE-821-
treated cells. As the detection and quantification of phosphorylated peptides in complex 
biological samples is challenging due to their low stoichiometry, we first compiled and 
optimized protocol for their enrichment. The protocol was then applied to study changes 
in radiosensitized MOLT-4 cells. In concordance with our expectations, VE-821 did not 
cause any significant changes on the proteome level one hour after irradiation. However, 
we detected 623 differentially regulated phosphorylation sites; most of them (431) were 
upregulated in response to VE-821 treatment. Using bioinformatic tools, we revealed 
changes in DDR related pathways and kinases, but also pathways and kinases involved 
in maintaining cellular metabolism. Notably, we found downregulation of mTOR, the main 
regulator of cellular metabolism, which was most likely caused by an off-target effect 
of the inhibitor, and we proposed that mTOR inhibition could be one of the factors 
contributing to the phenotype observed after treating MOLT-4 cells with 10 µM VE-821. 
To investigate the potential modulation of cellular metabolism, we performed a targeted 
metabolomic analysis of irradiated MOLT-4 cells pre-treated by 10 µM VE-821. In this 
analysis, 206 intermediary metabolites were quantified. Subsequent data analysis showed 
that VE-821 potentiated metabolic disruption induced by IR and affected response to IR-
induced oxidative stress. Our data indicated that upon IR, recovery of damaged 
deoxynucleotides might be affected by VE-821, hampering DNA repair by their 
insufficiency. 
Thus, in this thesis we described a complex scenario of cellular events that might 
be dependent on ATR or triggered by ATR inhibition by VE-821 in irradiated MOLT-4 
cells. Importantly, data presented in this work might serve as a resource for follow-up 
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DNA damage induction by either radio- or chemo-therapy has been the most widely 
used approach in oncology exploiting one of the hallmarks of cancer: genomic instability. 
However, these therapies are very unspecific and often accompanied by collateral damage 
to healthy tissues. In recent years, much effort has been put on discovery and development 
of tumour specific treatment, which would specifically target cancer cells and not affect the 
normal tissues. A promising approach that has been developed recently is to take advantage 
of tumour specific abnormalities in DDR. Most of the cancer cells possess defects in one 
or more DDR pathways and suffer from elevated levels of replication stress due 
to dysregulated oncogenic signalling and increased levels of endogenous DNA damage. 
Importantly, given the vast number of the DDR genes mutated in cancers, it has been 
emphasized that to effectively exploit the DDR targets in cancer treatment, the therapy 
should be individually tailored to patients lacking specific DDR functions based on the 
synthetic lethality principle. 
Two promising examples of such treatment strategies are targeting the S and G2/M 
DNA damage checkpoints in G1/S DNA damage checkpoint-deficient cells and specific 
targeting of proteins and protein kinases involved in replication stress response. Inhibition 
of the ATR/Chk1 pathway has been shown to be synthetically lethal in both above 
mentioned scenarios. In several studies, it has been shown that inhibiting this pathway is 
selectively toxic in cells with high levels of oncogene-induced replication stress (1–7). On 
the other hand, there have been several papers published, in which the authors emphasized 
the efficiency of ATR inhibition in combination with genotoxic therapy in p53- or ATM-
deficient cells (8–12). Therefore, selective targeting of the ATR/Chk1 pathway offers a 
promising therapeutic approach for cancer treatment in a broad range of tumours in both 
monotherapy and for selectively sensitizing cancer cells towards current genotoxic 
treatment. 
In order to reveal molecular mechanisms involved in such therapeutic approach, we 
decided to describe changes in phosphoproteome in a given cellular model. Our efforts 
were driven by the fact that protein phosphorylation is a transient, reversible PTM 
with dynamic nature enabling it to be the major steering force of most of the cellular 
processes which require rapid and tightly regulated signalling. These processes include 
cellular signalling and communication, proliferation, differentiation, metabolism, 




The presence of phosphorylation in specific regions of a protein molecule is believed 
to induce conformational changes in the target protein, which influence its behaviour 
within a cell. Such conformational changes can modulate activity of an enzyme (such as 
phosphorylation in an activation loop in a protein kinase), subcellular localization of a 
protein, or its stability (14). Phosphorylation is mediated by protein kinases, which 
compose one of the largest enzyme superfamilies in higher eukaryotes. The reverse 
reaction, dephosphorylation, is mediated by protein phosphatases. Tight cooperation 
of protein kinases and protein phosphatases is essential for regulation of biological 
processes in a cell, and dysregulation of these processes has been described to contribute 
to multiple diseases including cancer (15). Technological advances in the recent past led 
to development of phosphoproteomic approaches that allow researchers to identify 
aberrantly activated signalling pathways in a particular disease state, and establish 
appropriate therapeutic targets that can be exploited as specific targets for small molecule 
inhibitors (16).  
In this thesis, we aimed to elucidate molecular mechanisms underlying 
radiosensitization of MOLT-4 cell line (T-ALL) by specific inhibition of kinases from the 
phosphatidylinositol-3 kinase-related kinases (PIKKs) family using two highly potent and 
selective inhibitors of ATR and ATM, VE-821 and KU55933, respectively. To do so, we 
decided to combine multiple approaches: cell biology techniques to investigate the 
inhibitor-induced phenotypes, phosphoproteomics to study protein phosphorylation 
triggered by irradiation and its modulation by kinase inhibitors, and metabolomics to reveal 
drug-induced changes in metabolome of irradiated cells. Since the detection and 
quantification of phosphorylated peptides in complex biological samples is challenging due 
to their low stoichiometry, we also dedicated a part of this doctoral thesis to selection of an 
optimal method for phosphopeptide enrichment.  
That said, we present here different data of various nature, and thus the Results and 
Discussion sections are organized into several blocks. Furthermore, the nature of “omic” 
data implies a complicated data analysis and implementation of multiple bioinformatic 
tools and database searches in order to interpret the data. Therefore, the Results section 
differs from the theses based on the approach of “classical” biochemistry or biology and it 
comprises of a brief overview of the acquired results, and their detailed description is given 
in the Discussion section where they are discussed in context of all data presented in this 





1.1. Characterization of DNA damage induced 
by ionizing radiation 
The term ionizing radiation (IR) describes a radiation that has enough energy 
to liberate an atomic particle from an originally electrically neutral atom or molecule, 
ionizing it. The ionization can occur either directly or indirectly. The direct ionization is 
mediated by any charged massive particle that carries sufficient kinetic energy (e.g. alpha 
and beta particles) to ionize atoms or molecules. On the other side, gamma rays, X-rays, 
and neutrons are referred to as the indirectly ionizing radiation. Since they have no 
charge, their effects are induced secondary by liberation of directly ionizing particles. 
When cells are exposed to IR, cellular structures can be damaged by ionization 
directly by deposition of energy (this mechanism dominates in cells with a low water 
content), but also indirectly by ionization of water molecules in cells with a high water 
content – by a mechanism called water radiolysis. Such ionization leads to generation 
of highly reactive oxygen species (ROS), which secondary attack DNA and other 
biomolecules (reviewed in (17,18)). 
There is a wide range of DNA lesions typically occurring in response to IR. It has 
been previously estimated that the irradiation of a mammalian cell by a dose of 1 Gy results 
in approximately 1000-2000 damaged bases, 800-1600 damaged deoxyriboses, 500-
1000 single-strand breaks (SSBs), and most importantly, 20-40 double-strand breaks 
(DSBs), which are the most deleterious damage to the mammalian DNA, and thus they 
represent the biggest threat to genomic integrity amongst all types of DNA lesions (19).  
DSBs are assumed to be the most lethal class of DNA damage since a failure 
to repair just a single DSB can result in cell death (20) implying the importance of DSB 
repair for cell viability. Moreover, both repair and misrepair of DSBs can lead to mutations 
and chromosomal rearrangements, potentially resulting in cancer development. Since 
genetic alterations have such a significant impact on cell survival and viability, cells have 
evolved robust, but finely regulated molecular mechanisms that include detection of DNA 




checkpoints. Altogether, these mechanisms are summarized under the term DNA damage 
response (DDR). 
The key components of DDR, which trigger cellular response to detected DNA 
lesions, are protein kinases that belong to phosphatidylinositol 3-kinase (PI3K) family 
class IV, better known as phosphatidylinositol-3 kinase-related kinases (PIKKs; 
reviewed in (21)). 
1.2. Phosphatidylinositol-3 kinase-related kinase 
family 
The PIKK family comprises 6 proteins with most of the members possessing 
serine/threonine kinase activity: ataxia telangiectasia mutated kinase (ATM), ataxia 
telangiectasia and Rad3 related kinase (ATR), DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs), mammalian target of rapamycin (mTOR), suppressor 
with morphological effect on genitalia family member (SMG-1), and 
transactivation/transformation-domain-associated protein (TRRAP). All 6 members of the 
PIKKs family show considerable similarities in their domain architecture and extensive 
sequence homology, particularly in their C-terminal kinase domains FAT (FRAP-ATM-
TRAP) and FATC (FAT- C-terminal), both of them particularly important for their kinase 
activity and its regulation (22,23). On the contrary, the N-terminal region is poorly 
conserved and thus believed to be responsible for regulation of interactions 
with differential substrates and adaptor proteins (24).  
Among the PIKKs, ATM, ATR, and DNA-PK act as the main regulators 
of cellular response to DNA damage and DNA replication stress. They share the same 
phosphorylation motif (as shown in figure 1, they predominantly phosphorylate their 
targets on serine and threonine residues followed by Gln (25)) and many substrates such as 
the histone variant H2AX (26–28); however, they are activated by different types of DNA 
lesions and act in distinct pathways, which are partially overlapping, but non-redundant - 
the crosstalk between the pathways often occurs as a consequence of the inter-conversion 
of the activating lesions. A large scale proteomic study investigating proteins that are 
inducibly phosphorylated on a consensus site recognized by ATM and ATR after exposure 
to IR identified 900 phosphorylation sites in 700 proteins, demonstrating for the first time 




in response to DNA damage (29). The distinct roles of each of ATM and ATR will be 
further discussed. 
The importance of DNA-PK mainly derives from its essential role in non-
homologous end joining (NHEJ), which is considered to be the major DSB repair pathway. 
A detailed description of DNA-PK, its role in NHEJ, and its potential as a drug target 
for the support of radiotherapy is beyond the extent of this dissertation thesis; more details 
are given in our publication (30).  
 
Figure 1: Overview of the visualised phosphorylation motifs of the PIKKs members. 
Sequence logo for each one of the PIKKs was generated using manually curated 
phosphorylation sites from the PhosphoSitePlus database (June 2016) with known 
experimentally assessed kinase responsible for their phosphorylation. The sequence motifs 
(STY ± 7 AA) for ATM, ATR, DNA-PK, and mTOR are depicted together with the number 
of their substrates annotated in the database. 
The protein kinase mTOR is the principle regulator of cellular metabolism 
promoting anabolic processes and inhibiting catabolic processes such as autophagy. It 
integrates signals from different upstream pathways triggered by a wide variety of signals 
including nutrients, hormones, growth factors, and also cellular stresses to regulate cell 
growth, metabolism, cell survival, protein synthesis, and transcription (reviewed in (31)). 
Although mostly known for its metabolism-regulating functions, mTOR is also an integral 
member of DDR playing an important role in the determination of cell faith after DNA 
damage induction (reviewed in (32)). A direct link has been shown between DNA damage 




is mediated by ATM-activated AMP-activated protein kinase (AMPK), which in turn both 
directly and indirectly inhibits mTOR (reviewed in (33)). Indeed, mTOR inhibition has 
been also shown to affect radiosensitivity and DDR in irradiated cells (34,35).  
TRRAP has been shown to have an important role in embryonic development, cell-
cycle progression, and mitotic control (36). Interestingly, it is the only member of this 
family that lacks serine/threonine kinase activity. SMG-1 is the newest member of the 
PIKKs family. It plays a critical role in the mRNA quality control system, termed nonsense-
mediated mRNA decay, which protects cells from an accumulation of aberrant mRNAs 
(37).  
1.2.1. Ataxia-telangiectasia mutated kinase (ATM)  
ATM is the best known as the chief mobilizer of the vigorous cellular response 
to DSBs; however, recent studies have indicated that ATM is also involved in signalling 
pathways maintaining cellular homeostasis in response to hypoxia, oxidative stress, and 
regulation of cellular metabolism (reviewed in (38)). 
The ATM gene was originally identified in ataxia-telangiectasia (A-T), a human 
genome instability disorder inherited in an autosomal recessive manner. All A-T patients 
carry mutations in the ATM gene which encodes the ATM protein (39). The hallmarks 
of this disease include progressive cerebellar degeneration that develops into severe 
neuromotor dysfunction (ataxia), telangiectasia (dilation of blood vessels observed 
primarily in the eyes), immunodeficiency, hypersensitivity to ionizing radiation, and 
increased incidence of malignancies, mostly lymphoreticular (40). On the cellular level, 
A-T is characterized by increased chromosomal instability, premature senescence 
of cultured primary fibroblasts, and hypersensitivity to DNA damaging agents. The disease 
phenotype can be attributed to the abrogation of the cellular response to DSBs.  
Activation of ATM is one of the first steps in response to DSBs caused by the 
exposure to ionizing radiation (40). In undamaged cells, inactive ATM exists in a form of a 
homodimer, which dissociates into active monomers after activation. The activation is  
associated with autophosphorylation at Ser1981 (41), which is a marker of activated 
ATM. However, there are more post-translational modifications (PTMs) accompanied 
with ATM in its catalytically active state; to date, three additional autophosphorylation 
sites (42–44) and one acetylation site (Lysine 3016; (45,46)) have been identified in fully 




The full and timely activation of ATM is dependent on the Mre11/Rad50/Nbs1 
(MRN) complex, an evolutionary conserved protein complex composed of Mre11, 
Rad50, and Nbs1 proteins (47). Mutations of each one of the genes coding these three 
proteins result in genetic disorders characterized by symptoms similar to A-T (48–50). The 
indispensability of this complex to cells is affirmed by the fact that null mutation of either 
one of the three genes causes embryonic lethality in mice (51). MRN is one of the first 
complexes recruited to DNA DSBs, where it functions as a damage sensor and a physical 
bridge spanning the DSB ends (52). In addition to ATM recruitment and retention at the 
DSB sites, it is also required for both NHEJ and homology-directed recombination (HDR) 
repair of DSBs - the DSB-end resection mediated by MRE11 nuclease activity is one of the 
first steps in HDR. Moreover, MRN is also phosphorylated by ATM, which is important 
for activation of different DDR pathways and may create a positive feedback loop that 
maintains ATM activity (reviewed in (38)). In addition to MRN complex, there are other 
proteins important for timely ATM activation, such as mediator of DNA damage 
checkpoint protein 1 (MDC1), which interacts with both ATM and phosphorylated H2AX 
(γH2AX) and facilitates the phosphorylation of additional H2AX by ATM, creating 
another positive feedback loop (53).  
A vast functional network of proteins is precisely orchestrated by ATM-mediated 
phosphorylation. In this network, the proteins often undergo direct phosphorylation 
mediated by ATM as well as phosphorylation by other kinases whose activity is ATM-
dependent. Frequently, these proteins phosphorylated by ATM are targeted by other PTMs, 
such as ubiquitylation or sumoylation, and together, these PTMs contribute to the 
regulation of ATM-dependent DDR signalling pathways (54). Nowadays, the map of ATM 
targets contains hundreds of proteins, some of them have been extensively studied and 
validated in multiple studies; however, many of them were discovered by proteomic and 
phosphoproteomic screenings and need further evaluation (29,42,55–57). In June 2016, the 
largest phosphorylation sites database PhosphoSitePlus® (58) contained 240 manually 
curated substrates of ATM (as can be also seen in figure 1 as a number of input sequences 
for sequence motif visualization). Figure 2A depicts a map of ATM interactors 
downloaded from STRING v10.0 database (June 2016; STRING interaction score > 0.9); 
selected statistically overrepresented KEGG pathways in which the proteins from are 
involved are also given (figure 2B). Predictably, many of the interactors are proteins 




there are also pathways usually more referred in the context with cellular metabolism (such 
as PI3K-Akt, AMPK, or mTOR signalling pathways), demonstrating the aforementioned 
overlap between the DDR- and cellular metabolism- regulating functions of ATM. 
One of the most important examples of ATM phosphorylated and regulated proteins 
involved in DDR is the tumour suppressor protein p53. Under normal conditions, p53 is 
present in a latent form with low affinity to specific sequences of DNA; however, 
following DSBs formation, its transcriptional activity increases substantially, and this 
increase is to a great extent ATM-dependent. p53 is regulated by ATM in a multi-layered 
manner – both direct phosphorylation by ATM and indirect, but ATM-dependent 
phosphorylation, contribute to the rapid activation and stabilization of p53 in response 
to DNA damage (59). ATM directly phosphorylates p53 on serine (Ser) 15 (60), but the 
Ser 20 located on the same (transactivation) domain is phosphorylated by activated 
checkpoint kinase 2 (Chk2 ; (61,62)), a key downstream target of ATM (63). This 
phosphorylation events stabilize p53 by preventing its murine double minute protein-2 
(Mdm2)-mediated ubiquitylation and degradation (64,65). Moreover, ATM also 
phosphorylates Mdm2 on Ser 166 and Ser 395 (66,67), which further contribute to the 
accumulation of p53.  
The ATM-dependent activation and stabilization of p53 are central to the 
modulation of the cellular transcriptome following IR-induced DSBs formation. The 
activated p53 directly drives the expression of many genes, including the cell cycle 
regulating cyclin dependent kinases (CDKs) inhibitor  p21 (68,69) and pro-apoptotic 
proteins BAX, PUMA, and NOXA (70). Additionally, p53 also indirectly negatively 
regulates transcription of a number of genes, including those encoding anti-apoptotic 
proteins BCL-2 and MCL-1 (71). Thus, p53 is a crucial ATM target, regulating cell cycle 
progression (mostly the G1/S checkpoint) and cell death after genotoxic stress. 
Besides p53, ATM also regulates other transcription factors such as NF-κB (72)), 
protein kinases (e.g. Chk2 (73), DNA-PK (74), protein kinase B (AKT ; (75))), and a large 
number of other proteins and members of protein complexes involved in DSBs repair 
(e.g. H2AX , Artemis (76), CtBP-interacting protein  (CtIP ; (77)), or the members the 
MRN complex (78–81)). 
Chk2 is a serine/threonine protein kinase, which is a downstream effector of ATM 
orchestrating the cell cycle arrest after DSBs induction (63). It regulates the cell cycle 




their activity and promoting their degradation (82). Consequently, these phosphatases 
cannot remove inhibitory phosphorylation on CDK-cyclin complexes and thus promote 
the cell cycle arrest (reviewed in (83)).  
 
Figure 2: ATM-interacting network. Proteins interacting with ATM were downloaded 
from the STRING database v10.0 (June 2016). Only those interactions with STRING score 
> 0.9 (i.e. high confident interactions) are depicted (A). Proteins depicted in the network 
were subjected to functional annotation over-representation analysis. Selected over-




1.2.2. ATM-Rad3 related kinase (ATR) 
While activation of ATM is triggered by DSBs and is active throughout the cell 
cycle, ATR responds to single stranded DNA (ssDNA) structures and acts primarily in S 
and G2 phases. It is the central kinase responding to replication stress, which cells undergo 
during DNA replication as well as after exposure to genotoxic events. DNA damage 
induced by IR, UV, chemotherapeutic drugs, or inhibitors of DNA replication causes the 
DNA-polymerases to stall at DNA lesions while the replicative helicases continue 
to unwind the DNA helix ahead of the replication fork leading to generation of long ssDNA 
stretches. Additionally, ssDNA structures can be formed at DSB sites after 5’ to 3’ 
nucleolytic degradation of one of the chains, a step required for DSBs repair 
by homologous recombination (reviewed in (9,84)). ATR is an essential protein; 
homozygous mutation of ATR caused peri-implantation embryonic lethality in mice 
(85,86), and no living human completely lacking ATR has been identified. Nevertheless, a 
hypomorphic ATR mutation is responsible for the Seckel syndrome – a recessive 
autosomal hereditary disorder characterized by microcephaly and mental- and growth- 
retardation (87). 
Similar to ATM, which is recruited to DSB indirectly via MRN complex, ATR 
requires specific protein complexes for its localization to ssDNA and subsequent 
activation. Cortez et al. identified ATR-interacting protein (ATRIP; (88)), which 
interacts with the N-terminus of ATR to form a protein complex. ATRIP is responsible 
for localization of the ATR/ATRIP complex at ssDNA sites via its interaction with a 
heterotrimeric protein complex - Replication protein A (RPA), which coats most forms 
of ssDNA in cells including the ssDNA that is formed during DNA replication and damage 
(89). After the recruitment of ATR/ATRIP to ssDNA stretches, ATR needs to be activated, 
and this activation is dependent on co-localization of the ATR/ATRIP complex with the 9-
1-1 complex (RAD9/RAD1/HUS1), a heterotrimeric ring-shaped molecule that serves as 
a docking site of DNA topoisomerase II-binding protein-1 (TOPBP1). The co-
localization of these two complexes is mediated by Rad17-containing, RFC-like ‘clamp 
loader’ that recognizes the RPA-ssDNA and dsDNA junctions and loads the 9-1-1 complex 
to DNA (90,91). TOPBP1 contains an ATR activation domain, which has been confirmed 
to be the actual activator of ATR kinase (90,92–94). As in other the case of other PIKKs, 
ATR is transformed into a hyperphosphorylated state upon activation; however, only Thr 




1989 autophosphorylation is the crucial step in ATR activation; it enables the binding 
to the ATR activation domain of TOPBP1 and ATR activation (95).  
As in the case of other PIKKs, ATR phosphorylates many substrates bearing the 
typical S/TQ motif (figure 1). As visualized in the network in figure 3A, the list of direct 
ATR-interacting proteins downloaded from STRING database v10.0 (June 2016, STRING 
score > 0.9) contained 105 proteins. The structure of the network is in concordance 
with known biological roles of ATR; many of the interactors are organized into densely 
interconnected clusters as they form ATR-regulated protein complexes essential for DNA 
replication and response to DNA replication stress (i.e. Replication factor A, Replication 
factor C, Minichromosome maintenance complex, Origin recognition complex). Besides 
these complexes, there are also proteins involved in DDR pathways such Fanconi anaemia 
pathway, Homologous recombination, Mismatch repair, and other KEGG pathways listed 
in figure 3B.  
Checkpoint kinase 1 (Chk1) is often described as the primary target and main 
downstream effector of activated ATR. However, it has been repeatedly reported that ATR- 
and Chk1- inhibition provided different outcomes when combined with genotoxic stress 
in cancer cells (96,97) suggesting that despite being the main effector, Chk1 is not 
responsible for all downstream signalling of activated ATR.  
To fully activate Chk1, several ATR-driven steps are necessary. First, Rad17 is 
phosphorylated by ATR, which promotes its association with Claspin (98). Claspin is 
subsequently also phosphorylated by ATR, which enables its interaction with Chk1. 
Finally, Chk1 brought to the proximity of the activated ATR is phosphorylated in its kinase 
activation loop region, which in turn leads to its activation (99). Two Chk1 sites have been 
described to be ATR-phosphorylated during this activation step – Ser 345 and Ser 317; 
however, only Ser 345 is considered and often monitored as a specific marker of ATR 
activation, and it is also the essential phosphorylation site required for Chk1 function while 
the latter is considered to be rather contributory (10,100,101). Chk1 is then 
autophosphorylated at Ser 296 and released from chromatin to trigger cell cycle 
checkpoints signalling, which is of a great importance for damaged cells as it allows time 
for repair to occur.  
Two downstream protein phosphatases cdc25a and cdc25c are the two main Chk1 
targets responsible for S and G2/M arrests, which occur after their inactivation by Chk1 




from CDKs/cyclin complexes to maintain normal cell cycle progression. When inactivated, 
the activity of CDKs decreases to slow down cell cycle progression. Another Chk1 target 
that contributes to CDKs inhibition, and thus cell cycle arrest after ATR activation, is the 
Wee1 protein kinase, which is stabilized by Chk1-mediated phosphorylation. 
 
Figure 3: ATR-interacting network. Proteins interacting with ATR were downloaded 
from the STRING database v10.0 (June 2016). Only those interactions with STRING score 
> 0.9 (i.e. high confident interactions) are depicted (A). Proteins depicted in the network 
were subjected to over-representation analysis of functional annotation. Selected over-




 As in the case of its upstream kinase, the list of known Chk1 targets is relatively 
long, comprising 192 manually curated substrates (as listed in the PhosphoSitePlus® 
database, June 2016). In addition to its DNA damage checkpoint functions mentioned 
above, Chk1 has been shown to regulate the mitotic spindle checkpoint, contribute 
to several DNA damage repair pathways (HDR, Fanconi anaemia pathway), and repression 
of transcription after DNA damage induction (reviewed in (103)).  
1.3. Targeting DDR as a promising strategy 
in oncology 
DNA damage induction by either radio- or chemo- therapy has been the most 
widely used approach in oncology exploiting one of the hallmarks of cancer: genomic 
instability. However, such treatment is very unspecific and often accompanied by collateral 
damage to healthy tissues. In recent years, much effort has been put on discovery and 
development of tumour specific treatment, which would only specifically target cancer 
cells and not affect the normal tissues. A promising approach that has been developed 
recently is to take advantage of the tumour specific abnormalities in DDR.  
In a current study (104), manually curated data stored in signalling pathways and 
protein-protein interactions databases were analysed to compile a list of 450 human DDR 
genes, which were further examined in terms of their association with individual cancer 
types to identify deregulated components of the DDR, discover novel therapeutic targets 
within the DDR network, and predict their druggability. Given the vast number of the DDR 
genes mutated in cancers, the authors of the study emphasized that to effectively exploit 
the DDR targets in cancer treatment, the therapy should be individually tailored to patients 
lacking specific DDR functions based on the synthetic lethality principle. This principle 
was originally presented in Drosophila, and it describes two genetic loss-of-function events 
- each one of them still compatible with cell viability; however, they are lethal when both 
of them occur in the same cell (105). In the context of cancer treatment using DDR proteins 
inhibitors, one of the two events is cancer-specific and cannot be found in normal cells; the 
second one is achieved pharmacologically by the targeted inhibitor treatment. A clinically 
validated example of a successful use of this approach is the application of poly(ADP-
ribose) polymerase (PARP) inhibitors (olaparib) in BRCA-deficient cancer cells (106,107).  
Moreover, the synthetic lethality term can be also used more loosely to describe 




combination of therapeutic agent (such as chemo- or radio- therapy) and DDR-targeting 
compound – i.e. the DDR inhibitor can be used for a specific radio- or chemo- 
sensitisation of the cancer cells. The key differences in DDR between cancer cells and 
normal cells that can be exploited to develop a specific therapy comprise following aspects: 
most of the cancer cells have defects in one or more DDR pathways, suffer from elevated 
levels of replication stress due to dysregulated oncogenic signalling and increased levels 
of endogenous DNA damage (caused for instance by increased intrinsic ROS generation 
(108); reviewed in (109)) .  
A promising example of such a strategy is targeting the S and G2/M DNA 
damage checkpoints in G1/S DNA damage checkpoint deficient cells (110). A recent 
study investigated mutational profiles in 3,281 tumours across 12 tumour types, identified 
127 significantly mutated genes, and categorized them based on cellular processes they are 
involved in (111). The TP53 tumour suppressor gene was affected by mutations in 42.0 % 
of cancer cells sequenced in this study, and thus it was the most frequently mutated gene 
in cancer genome. The list of the 127 significantly mutated genes in cancer also contained 
other members of the ATM/Chk2/p53 pathway - ATM and Chk2 kinases were found to be 
targeted by mutations in 3.3 % and 0.9 % of cancer cells analysed, respectively. As this 
pathway is essential for maintaining the G1/S DNA damage checkpoint after IR, the results 
of this study suggested that targeting the remaining DNA damage checkpoints might be a 
promising strategy in a considerable portion of solid tumours conventionally treated using 
radiotherapy (111).  
Another promising strategy is to target proteins and protein kinases involved 
in replication stress response (7). Elevated level of DNA replication stress has been 
recently proposed as a hallmark of cancer because it is present in almost all cancers 
from the earliest stages (112). The mutations in genes controlling cellular growth and 
proliferation are responsible for this phenomenon – cancer cells deficient in G1/S 
checkpoint or with mutations deregulating replication origin firing suffer from premature 
entry into S-phase, and thus DNA replication can start before the necessary resources have 
been generated, which leads to triggering the replication stress response. Examples of such 
mutations that are common in cancers are RB1 deficiency, CDKN2A deletion, Cyclin D1 
or Cyclin E amplifications, KRAS mutations, or MYC amplifications (111,112).  
Inhibition of the ATR/Chk1 pathway has been shown to be synthetically lethal 




pathway is selectively toxic in cells with high levels of oncogene-induced replication stress 
(1–7). On the other hand, there have been several papers published, in which the authors 
emphasized the efficiency of ATR inhibition in combination with genotoxic therapy 
in p53- or ATM- deficient cells (8–12). Taken together, selective targeting of the 
ATR/Chk1 pathway offers a promising therapeutic approach for cancer treatment in a 
broad range of tumours in both monotherapy and for the purpose of selectively sensitizing 
cancer cells to current genotoxic treatment.   
1.3.1. The preclinical and clinical development of ATR 
inhibitors  
Given their importance in DDR, small molecule kinase inhibitors have been 
synthesised for each one of the kinases from the PIKKs family to investigate their potential 
for development of a cancer-specific treatment. The preclinical and clinical development 
of current inhibitors of DNA-PK, ATM, and ATR has been extensively reviewed in two 
papers we published recently (30,113); therefore, for the purpose of this dissertation thesis, 
we will only discuss the development and use of ATR inhibitors.   
The first ATR inhibitor identified proven to radiosensitize cancer cells was caffeine 
(1,3,7-trimethylxanthin) (114,115). However, caffeine is a low potent and unspecific 
inhibitor of ATM, ATR (IC50 (ATM): 0.2 mM; IC50 (ATR): 1.1 mM), and the rest of the 
PIKKs family. Moreover, the concentration that is required to radiosensitize human cancer 
cells is toxic. Another natural compound that has been identified as an ATR inhibitor is 
schisandrin B (1,2,3,13-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydrobenzo[3',4']cyclo-
octa[1',2':4,5]benzo[1,2-d][1,3]dioxole), which was isolated from the mature fruits 
of Schisandra Chinensis, a herb used in Chinese medicine (116,117). Although schisandrin 
B is more ATR-specific than caffeine (IC50 (ATR): 7.25 µM), it is weaker than the newly 
synthesised chemical inhibitors, so its use has been only evaluated in two preclinical 
studies.  
NU6027 (2,6-diamino-4-cyklohexyl-methyloxy-5-nitroso-pyrimidine) was 
originally identified as a CDK2 inhibitor (IC50(CDK2): 10 µM); however, Harrison et al. 
noticed that this inhibitor sensitised cancer cells to cisplatin independently on its CDK2 
inhibitory activity (118). Further study revealed that NU6027 is a more potent inhibitor 
of ATR than of CDK2 (IC50(ATR): 6.7 µM), and it was the ATR inhibition that was 




Importantly, the results of this breast cancer study indicated that ATR-inhibitor treatment 
could be efficient in cancer cells with XRCC1 polymorphism and thus showing for the first 
time a synthetic lethality of ATR inhibition and a loss of a specific DNA repair protein. 
This XRCC1-ATR inhibition relationship has been further confirmed in another study 
(119); however, further evaluation of NU6027 in in vivo experiments is hampered by its 
poor solubility in water.  
In a cell-based screening of 623 compounds previously reported to have some 
activity towards PI3K (120), Toledo at el. identified two compounds with a marked 
potency against ATR – ETP-46464 (IC50(ATR): 25 nM) and NVP-BEZ235 (IC50(ATR): 
100 nM) (6), but these compounds also presented substantial activity towards ATM, PI3K, 
mTOR, and DNA-PKcs and thus lacked selectivity against ATR. Prior to this screening, 
NVP-BEZ235 had been proposed as a PI3K and mTOR inhibitor (121) and shown 
to radiosensitize Ras-overexpressing tumours (122). However, considering another study 
that had reported cytotoxicity of ATR suppression in cells overexpressing Ras (2), the 
radiosensitization of cells in the aforementioned study was more likely to be dependent 
on the ATR inhibitory activity of NVP-BET235 rather than on PI3K/mTOR inhibition. 
Altogether, these reports confirmed the potential of chemical ATR inhibition in cells 
suffering from elevated levels of replication stress caused by dysregulated oncogenic 
signalling. The more selective compound – ETP-46464 – has been further proven 
to sensitize cancer cells to IR and platinum drugs (123,124). Unfortunately, it has been 
shown to have poor pharmacological properties in mice and thus is not suitable for further 
in vivo evaluation. 
The first potent and selective inhibitors of ATR that may offer a great promise 
in cancer treatment were presented by Vertex Pharmaceuticals in 2011. Charrier et al. 
reported the discovery of selective ATR inhibitors from the series of 3-amino-6-
arylpyrazines (125). In the following studies, two compounds from this series were further 
evaluated – VE-821 and VE-822 (or VX-970).  
VE-821 (3-amino-6-(4-(methyl-sulfonyl)phenyl)-N-phenylpyrazine-2-
carboxamide; IC50(ATR): 26 nM, Ki(ATR): 13 nM, Ki(mTOR) > 1 µM, Ki(DNA-PK): 
2.2 µM, Ki(ATM): 16 µM) has been shown to be able to selectively induce irreversible 
growth arrest in several cancer cell lines that were either p53-deficient or p53-wt, but 
with dysfunctional ATM/Chk2/p53 pathway, while inducing only reversible growth arrest 




including cross-linking drugs, antimetabolites, topoisomerase I and II poisons, and ionizing 
radiation. The dependence on the functionality of ATM signalling for the sensitivity 
to ATR inhibition was confirmed in experiments with A-T primary skin fibroblasts, 
in normal cells treated with ATM inhibitor KU-55933 or with knockdown of p53 
expression (11). These results were confirmed in 2012 by Pires et al., who mostly focused 
on the radiosensitizing effect of ATR inhibition. In this study, the radiosensitization using 
VE-821 was proven in a variety of cell lines from a number of different tumour types 
suggesting that this effect is independent of tumour type. Moreover, VE-821 was shown 
to increase radiation-induced DNA damage and loss of viability of cancer cells under 
hypoxic conditions (126), which is of particular interest, as hypoxic tumours have been 
reported to be more resistant to radiotherapy (127). The ability of VE-821 to sensitize 
pancreatic cancer cell lines to radiotherapy or antimetabolites-based chemotherapy under 
both normoxic and hypoxic conditions was further confirmed by Prevo et al. (128). Since 
then, VE-821 has been consistently shown in several studies to sensitize a variety 
of different tumour types to different genotoxic events (97,129–135). Interestingly, 
Huntoon et al. compared the sensitization of ovarian cancer cells using VE-821 and a Chk1 
inhibitor (MK-8776). Unexpectedly, even though these two kinases are reported as 
members of one ATR/Chk1 signalling pathway, where Chk1 serves as a downstream 
effector of ATR, the inhibition of each one of these kinases provided differential 
sensitization of the cancer cells to commonly used chemotherapy agents.  
In 2012, Fokas et al. presented VE-822, which is a close analogue of VE-821 
with increased potency against the ATR kinase (IC50 (ATR): 19 nM), excellent ATR 
selectivity, and most importantly, good pharmacokinetic properties. In their study, VE-822 
was tested for in vitro and in vivo radiosensitization of pancreatic ductal adenocarcinoma 
cell lines. As in the case of VE-821, VE-822 did not affect the chemo- and radio- sensitivity 
of normal cells. In vivo experiments performed in mice bearing PDAC xenografts proved 
the efficiency of combination of VE-822 and chemo/radiotherapy without affecting normal 
tissue homeostasis (8). Furthermore, VE-822 has been tested in combination with cisplatin 
drugs in a panel of lung cancer cell lines and a panel of xenografts models derived 
from primary human non-small cell lung cancer (NSCLC) samples. Notably, VE-822 
in combination with cisplatin caused tumour growth inhibition even in tumours that were 
originally non-responsive to cisplatin. Experiments performed in the NSCLC cell line 




and Chk1 inhibition (136). Based on the consistently promising data from the preclinical 
in vitro and in vivo testing and its favourable pharmacokinetic properties, which allow 
intravenous administration of the drug to humans, VE-822 (as VX-970) is currently tested 
in phase I clinical trials to assess its safety and tolerability in combination with cytotoxic 
drugs (ClinicalTrials.gov Identifier: NCT02157792). Several expansion phase I and phase 
II trials are planned and currently recruiting patients to evaluate applications of VX-970 
in different carcinomas and combination with genotoxic treatment (ClinicalTrials.gov 
Identifiers: NCT02595931, NCT02567422, NCT02589522, NCT02595892, 
NCT02627443, NCT02723864, NCT02487095).  
The second series of highly potent and selective ATR inhibitors was developed 
by AstraZeneca. The first compound from the series of sulfonyl-morpholino-pyrimidines 
reported and shown to suppress tumour growth in mice xenografts after oral administration 
of the drug was AZ20 (IC50(ATR): 50 nM, IC50(mTOR): 2.4 µM, IC50(other PIKKs)> 
30 µM; (137).  
An analogue of AZ20, AZD6738 has a significantly improved ATR selectivity 
(IC50 (ATR): 74 nM, IC50 (mTOR): 23 µM, IC50 (ATM, DNA-PK) > 30 µM), solubility, 
and pharmacokinetic properties and thus is more suitable for oral dosing. It has been shown 
to be efficient in monotherapy as well in combination with chemotherapy in NSCLC cell 
lines and xenografts, especially in ATM-deficient cell lines (12) and also proven to be 
synthetically lethal in p53- or ATM- defective chronic lymphocytic leukaemia cells in vitro 
and in vivo (138,139). Due to its oral bioavailability and tolerability proven in in vivo 
xenografts models, AZD6738 is the second ATR inhibitor that has been subjected 
to clinical trials. The initial study testing the safety and tolerability in patients 
with leukaemia has been completed (ClinicalTrials.gov Identifier: NCT01955668), and 
three phase I trials are currently ongoing focused on the combination of AZD6738 
with radio- and chemo- therapy in patients with advanced malignancies (ClinicalTrials.gov 
Identifier: NCT02264678, NCT02630199, NCT02223923).  
1.4. Protein phosphorylation and its role in eukaryotic 
cells 
Several hundred of PTMs of proteins have been described so far; among them, 
protein phosphorylation is one of the most studied as it is one of the most important PTMs 




of phosphorylation enables being the major driving force of most of the cellular processes 
which require rapid and tightly regulated signalling. These processes include cellular 
signalling and communication, proliferation, differentiation, metabolism, transcriptional 
and translational regulation, degradation of proteins, and cell survival (13). It is one of the 
most widespread regulatory mechanisms; it has been originally estimated that more than 
50 % of proteins in mammalian cells are phosphorylated at some point during their life time 
(140). However, in a recent study conducted by Sharma et al., more than 75 % of cellular 
proteins were found to be phosphorylated (141). Cellular protein phosphorylation events 
are site-specific, often occur at multiple sites within a phosphoprotein, and more than 100 
000 phosphorylation sites may exist in the human proteome (142). Some of them are 
always quantitatively phosphorylated whereas the occupancy of many phosphosites is very 
low.  
There are four distinct types of phosphorylation known: O- phosphorylation, which 
occurs on serine, threonine, and tyrosine residues, N- (143), S- (144), and acyl- (145) 
phosphorylation, which are far less common and occur on histidine, lysine, cysteine, 
aspartic, and glutamic residues. In eukaryotic cells, it is the O- phosphorylation on serine, 
threonine, and tyrosine residues, which is considered to be predominant (146). 
Phosphorylation of histidine residues has been also described; it has been estimated that 6 
% of the total phosphorylation in eukaryotes occurs on histidine residues (147). However, 
phosphohistidines are usually not observed in proteins due to rapid hydrolysis of the 
phosphoryl group under acidic conditions (148). The proportions of phosphoserine (pS), 
phosphothreonine (pT), and phosphotyrosine (pY) sites in a phosphoproteome were 
reported for the first time by Hunter and Sefton (1980), who determined them in chicken 
cells as 92.19 %, 7.77 %, and 0.03 %, respectively (149). Since then, several studies have 
been performed reporting similar trends: about 85-90 % of pS, 10-15 % of pT, and 0.5-5 % 
of pY. Substantial differences in the phospho-amino acids proportions are introduced 
by different model organism studied, degree of perturbation of a phosphoproteome 
by treatment conditions used in a particular study, and various methodological approaches 
used for a phosphopeptide enrichment and detection. In a recent label-free 
phosphoproteomic study, an intriguing trend was reported showing that the proportion 
of pY drastically decreases as coverage of the studied phosphoproteome increases, while 
pS and pT saturate only for technical reasons. Moreover, in comparison to pS and pT, 




of any specific stimuli. Based on these observations, the authors proposed that pY should 
be considered a functionally separate PTM (141).  
The presence of phosphorylation in specific regions of a protein molecule is 
believed to induce conformational changes in the target protein, which influence its 
behaviour within the cell. Such conformational changes can modulate activity of an enzyme 
(such as phosphorylation in an activation loop in a protein kinase), subcellular localization 
of a protein, or its stability (14). Phosphorylation is mediated by protein kinases, which 
compose one of the largest enzyme superfamilies in higher eukaryotes; it has been 
estimated that 2-3 % of all eukaryotic genes are coding protein kinases (150). The reverse 
reaction, dephosphorylation, is mediated by protein phosphatases. Tight cooperation 
of protein kinases and protein phosphatases is essential for regulation of biological 
processes in a cell, and dysregulation of these processes has been described to contribute 
to multiple diseases including cancer (15). Technological advances in the recent past led 
to development of phosphoproteomic approaches that allow researchers to identify 
aberrantly activated signalling pathways in a particular disease state, and establish 
appropriate therapeutic targets that can be exploited as specific targets for small molecule 
inhibitors (16). 
Despite being such a widespread regulatory mechanism, the analysis of protein 
phosphorylation is hampered by several facts: (1) phosphorylated peptides are relatively 
low abundant in comparison to the non-phosphorylated peptides pool in cells; thus, it is not 
feasible to study phosphoproteome from an unfractionated peptide sample; (2) due to its 
dynamic nature, only a subfraction of cellular phosphoproteome is phosphorylated in a 
particular time; (3) techniques used to study protein phosphorylation have a limited 
dynamic range; therefore, it might be difficult to detect phosphopeptides from low 
abundant phosphoproteins; (4) the presence of the modification on the peptide alters its 
behaviour during liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
analysis, which can affect phosphopeptide identification and phosphorylation site 
localization; (5) quantification of phosphorylation might be difficult as it relies only on one 
modified peptide and a phosphopeptide might contain several phosphorylation sites, which 
can be differentially phosphorylated in response to a specific treatment. However, in the 
last decade, numerous techniques have been developed to overcome the aforementioned 
difficulties. To address the low stoichiometric nature and limited dynamic range of the 




enrichment and fractionation of phosphopeptides have been established. New 
fragmentation methods for mass spectrometry analysis have been established to improve 
the phosphopeptide identification and site localization. Quantification techniques have 
been optimized to be suitable for phosphopeptide quantification. Moreover, the 
improvements in identification and quantification software for the interpretation of mass 
spectrometry data and development of specific programs and algorithms 
for phosphorylation site localization and further data interpretation enabled the use 
of phosphoproteomic methods in wide range of biological applications.  
In following chapters, the methods for enrichment of phosphorylated proteins and 
peptides will be discussed as well as the techniques for their detection and quantification.  
1.5. Strategies for the enrichment of phosphorylated 
proteins 
Although in bottom-up proteomics, the enrichment of phosphorylated peptides is 
far more common than the enrichment on the protein level, enrichment of phosphoproteins 
is still adequate in some specific applications. As it was mentioned above, the amount 
of tyrosine phosphorylated peptides in a phosphoproteome is relatively very low 
in comparison to pS and pT. Therefore, in studies specifically focusing on tyrosine 
phosphorylation driven signalling in cells, there is a need to use a method that would 
specifically enrich for phosphorylated tyrosine residues. The current method of choice is 
the immunoprecipitation of tyrosine-phosphorylated proteins using phospho-tyrosine 
specific antibodies (151–154). Although antibodies against specific phosphorylated motifs 
in phospho-threonine and phosphoserine have been also used in some studies (155,156), 
immunoprecipitation is not applicable to a high-throughput enrichment of pS and pT 
containing proteins as there are no pan-pS or pan-pT antibodies available. For such studies, 
the method of choice is the enrichment on peptide level.  
In addition to the antibody based approaches, phospho-proteins can be also 
precipitated using lanthanum ions (157,158) or enriched with affinity chromatography 
using metal oxides as the affinity media. Commercial kits for the enrichment 
of phosphoproteins e.g. Phosphoprotein Purification Kit (QIAGEN, Hilden, 
Germany;(159)) or Thermo Scientific Pierce Phosphoprotein Enrichment Kit (Thermo 





There are also methods available to specifically capture protein kinases using 
immobilized low-molecular weight inhibitors, e.g. bisindolylmaleimide compounds (161), 
or to immunopurify their substrates using an antibody raised against their substrate motif 
(162). 
1.6. Overview of fractionation and enrichments 
methods used for the phospho-enrichment 
on peptide level 
Multiple methods for the bottom-up phosphoproteomics have been developed so 
far. Broadly speaking, these methods either exploit the presence of a phosphate group in a 
peptide to chemically introduce an affinity tag (i.e. chemical derivatization methods), the 
affinity of a phosphate group for Lewis’ acids such as metal ions and their compounds (i.e. 
affinity enrichment methods), or physicochemical properties of phosphorylated peptides 
that can be used to more or less specifically fractionate their mixture with unmodified 
peptides (i.e. chromatographic fractionation methods). Nevertheless, none of them 
capable of yielding comprehensive information about the phosphoproteome of a complex 
biological sample. Therefore, the approaches described thereinafter are often combined 
to obtain complete information about the phosphopeptide pool in analysed samples. 
The affinity enrichment and separation methods include IMAC (Immobilized metal 
affinity chromatography), MOAC (Metal oxide affinity chromatography), HAP 
(Hydroxyapatite chromatography), SCX (Strong cation-exchange chromatography) and 
SAX (Strong anion-exchange chromatography), HILIC (Hydrophilic interaction 
chromatography) and ERLIC (Electrostatic repulsion hydrophilic interaction 
chromatography). 
1.6.1. Chemical derivatization methods 
In chemical derivatization techniques, phosphorylated amino acids residues are 
chemically modified by adding a tag that is selectively captured by affinity 
chromatography. Most of the methods take advantage of the lability of phosphate groups 
on serine and threonine residues under alkaline conditions. In the presence of a strong base 
(e.g. NaOH or Ba(OH)2), phosphoserines and phosphothreonines undergo a β-elimination 




Michael acceptors. β-elimination is followed by Michael addition reaction with different 
nucleophiles such as ethanedithiol (163–166), dimethylaminoethanethiol (167), or 
mercaptoethylpyridine (168), which can be linked to an affinity tag (e.g. biotin; (165)) or 
immobilizing agent (e.g. dithiopyridine resin; (169)). The major drawbacks of methods 
based on the β-elimination reaction are associated with nonspecific labelling of cysteines 
and O-glycosylated peptides and inability of phosphotyrosines to undergo the 
β-elimination. The nonspecific labelling can, however, be reduced by blocking the 
sulfhydryl group of cysteines by alkylation or oxidation or by performing enzymatic 
deglycosylation in case of O-glycosylated peptides. 
Another covalent chemical derivatization technique is a carbodiimide catalysed 
condensation reaction with excess amine to form phosphoramidate (i.e. phosphate with the 
hydroxyl group replaced by NR2). In comparison with the β-elimination chemistry, 
phosphoramidate chemistry-based approach is also capable of enrichment of tyrosine-
phosphorylated peptides. Zhou et al. (170) for the first time presented this method in a 
multistep approach (six steps), where cystamines attached to phosphate groups by a 
condensation reaction were further reduced to form free sulfhydryl groups, which provided 
the attachment of phosphopeptides to a solid phase by reacting with iodoacetyl groups 
immobilized on glass beads. Although the final yield was only about 20 % due 
to considerable sample loss, this approach was very selective providing contaminant-free 
phosphopeptides. The complicated multistep procedure was further simplified in the 
Aebersold’s lab; the simplified method included the methylation of the carboxyl groups, a 
condensation reaction with a dendrimer (synthetic polyamine) in the presence 
of carbodiimide and imidazole, and finally an acidic hydrolysis of the phosphoramidate 
bonds between phosphopeptides and the dendrimer (171). This method provided higher 
recovery of phosphopeptides than the previous approach, however, wider utilization of it 
was hampered by extremely slow conversion during the carbodiimide catalysed 
condensation step.  
Another approach suitable for phosphorylated serine, threonine, and tyrosine 
peptides that included chemical derivatization was presented in 2004. Carboxylic groups 
were protected by methylation and the peptide mixture was subjected to the reaction 
with αdiazo functionalized resin, which resulted in the formation of a covalent 




1.6.2. Chromatographic fractionation methods used 
in phosphoproteomics - SCX, SAX, HILIC, and ERLIC 
1.6.2.1. Strong Cation Exchange Chromatography (SCX) 
In SCX chromatography, the interaction between positively charged peptides and 
negatively charged column resin is responsible for the retention of the analytes. Under 
acidic conditions, with pH typically lower than three, tryptic peptides become positively 
charged by protonation at the peptide N-termini and side chains of arginine, lysine, and 
histidine residues whereas carboxyl groups and the C-termini become neutrally charged. 
Phosphoryl group stay negatively charged at such pH conditions, and thus peptides 
containing phosphoryl groups exhibit a lower affinity for the negatively charged SCX resin. 
Hence, phosphopeptides are eluted in the early fractions during SCX fractionation (173).  
SCX was originally presented as a component of a multidimensional protein 
identification technology for shotgun proteomics (174,175). In 2004, SCX was for the first 
time described for phosphopeptide enrichment of HeLa cell nuclear phosphoproteins as a 
standalone method resulting in identification of 2002 phosphorylation sites from 967 
proteins (176). Since then, SCX has been frequently used as a fractionation method 
in combination with other phosphopeptide enrichment methods:  IMAC (177–181) or 
titanium dioxide enrichment (182–186), but also as a single method for phosphopeptide 
enrichment after combined cleavage with Lys-N and trypsin (187,188). 
1.6.2.2. Strong Anion Exchange Chromatography (SAX) 
SAX chromatography is the second ion exchange method used for peptide 
fractionation, and as opposed to SCX, the negatively charged peptides are more likely 
to retain on the chromatographic resin during the separation. Dependent on pH of the 
solvents used for the separation, acidic and phosphorylated peptides are retained on the 
chromatographic resin and elute in later fractions, and thus the use of SAX 
for phosphopeptide fractionation typically results in lower loss of phosphopeptides than 
SCX. Another significant advantage of using SAX over SCX for phosphoproteome 
analysis is that SAX has a better ability to fractionate phosphopeptides in multiple fractions 
(189).  
In 2003, Nühse et al. successfully used SAX chromatography with salt gradient 




phosphoproteins (190). More recently, SCX and SAX fractionation were combined 
for sequential fractionation of samples (flow-through fractions from SCX were further 
subjected to SAX) and the collected fractions were analysed by RPLC-MS/MS. Such 
approach was named yin-yang multidimensional liquid chromatography tandem mass 
spectrometry method (Yin-yang MDLC−MS/MS; (191)), and led to improved 
identification of phosphopeptides than it is common in a proteomic experiment (13 256 
unmodified peptides and 849 phosphopeptides were identified). The yin-yang MDLC-
MS/MS approach in combination with quantification using stable isotope labelling 
with amino acids in cell culture was further successfully used for the quantification 
of phosphoproteome changes during adipocyte differentiation (192).  
SAX has been shown to be complementary with Fe3+-IMAC. However, 
when comparing these two techniques, more peptides, especially monophosphorylated, 
were identified by SAX approach than by Fe3+-IMAC as the monophosphorylated peptides 
were probably lost because of the weaker interaction with Fe3+ IMAC. Enrichment and 
fractionation of phosphopeptides by SAX itself was then applied to phosphoproteomic 
analysis of human liver tissue (189). SAX chromatography has been also compared with a 
method combining SCX and titanium dioxide (TiO2) enrichment. The SAX system 
preferred to identify more acidic and multiphosphorylated peptides than SCX/TiO2, and it 
also covered a more complete series of phosphorylation states of peptides (193). AFET 
(Anion exchange followed by flow-through enrichment with TiO2) is a phosphopeptide 
enrichment and identification strategy, where SAX is used as the first step for the pre-
separation of peptides that are further subjected to TiO2 chromatography and RPLC-
MS/MS detection of the enriched phosphopeptides (194).  
1.6.2.3. Hydrophilic Interaction Chromatography (HILIC) 
HILIC has been more commonly used for small polar solutes (e.g. pharmaceuticals, 
saponins, urea, aminoglycoside antibiotics, glucosinolates, sugars and glycans, folic acid 
and its metabolites, nicotine and its metabolites, and glycoalkaloids) than for peptides 
fractionation. The retention of an analyte is believed to be based on partitioning between a 
water- enriched layer of stagnant eluent which hydrates the polar stationary phase and a 
relatively hydrophobic bulk eluent, with mobile phase usually being 10-40% water 
in acetonitrile. In this settings, the retention of an analyte increases with the increasing 
polarity of the peptide (Alpert, 1990), and thus phosphorylated peptides are retained by the 




has been demonstrated that HILIC has the highest degree of orthogonality to the reversed 
phase liquid chromatography (RPLC) among all commonly used peptides fractionation 
techniques (197).  
McNulty and Annan (2008) used HILIC in 2D separation approach with IMAC 
being the second dimension. Applying this approach, they identified more than 700 novel 
phosphorylation sites in HeLa cells phosphoproteome. Additionally, they revealed that 
HILIC performed prior to the IMAC enrichment (HILIC-IMAC) improved dramatically 
the selectivity of IMAC while HILIC performed after IMAC enrichment (IMAC-HILIC) 
was found to be a less beneficial approach (198). Contrary to this finding, Albuquerque et 
al. (2008) performed IMAC enrichment before HILIC prefractionation followed by RPLC-
MS/MS with acceptable results; thousands of phosphopeptides (8764) from yeast 
phosphoproteome were identified using this settings (199).  
1.6.2.4. Electrostatic Repulsion- Hydrophilic Interaction Chromatography (ERLIC) 
The most novel chromatographic approach that was developed specifically for the 
enrichment and fractionation of phosphopeptides is the electrostatic repulsion- 
hydrophilic interaction chromatography. This approach combines the electrostatic 
attraction with hydrophilic interactions to selectively capture phosphopeptides. At low pH 
(pH < 2) phosphate groups still retain their negative charge whereas carboxyl groups 
of acidic amino acids become neutrally charged and basic amino groups are charged 
positively. Phosphate groups are electrostatically bound to the column; nevertheless, their 
affinity would not be sufficient to overcome electrostatic repulsion from the positively 
charged amino groups from the N-terminus and basic amino acids. Therefore, hydrophilic 
interactions of the phosphate group are to be enhanced by using high concentrations of an 
organic solvent increasing the hydrophobicity of mobile phase (e. g. 70% acetonitrile; 
(200)).  
In a study performed on HeLa cells, SCX, HILIC, and ERLIC based fractionation 
methods were combined for phosphopeptides separation prior to sequencing by RPLC-
MS/MS. A total of 9069 unique phosphopeptides were identified with only 1697 
phosphopeptides (18.7 %) overlap between the phosphopeptides identified by each one 
of the three fractionation methods, which indicated that these three techniques are 
complementary to each other and can be combined for more comprehensive 
phosphoproteome analysis (201). In a phosphoproteomic study investigating Marek’s 




fractionation step followed by IMAC enrichment of phosphopeptides in the ERLIC 
separated fractions and RPLC-MS/MS identification of enriched peptides (202). 
1.6.3. Immobilized Metal Affinity Chromatography  
IMAC is the oldest affinity chromatography method for phosphopeptide 
enrichment that was originally used for affinity purification of His-tagged proteins (203). 
However, in 1986, the binding of phosphoproteins and phosphorylated amino acids 
to ferric ions immobilized on a iminodiacetate-agarose gel was demonstrated for the first 
time (204), and since then, IMAC technique has been further optimized and widely used 
for enrichment of phosphopeptides prior to MS analysis. 
 IMAC takes advantage of a high affinity of positively charged metal cations (Fe3+, 
Al3+, Ga3+, Zr4+, or Co2+) to negatively charged phosphopeptides. Metal ions are typically 
chelated by nitriloacetic acid or imidoacetic acid coated matrix to form the IMAC material. 
Several kinds of matrices including polymer beads (205), the inner wall of capillaries (206), 
and monoliths (207) have been successfully used for metal ion immobilization. Despite 
being a relatively old method, IMAC is still widely used presumably due to its ease of use 
and availability of well optimized and robust protocols. Nowadays, the most common 
variant is Fe3+-IMAC used for both single step purification or in combination with a 
prefractionation method.  
The most significant drawback of IMAC is a high level of nonspecific binding 
of nonphosphorylated proteins containing multiple acidic amino acid residues, which co-
elute with phosphopeptides during the enrichment of highly complex peptide samples. 
However, this problem can be overcome by extensive optimization as the phospho-
selectivity seems to be dependent on multiple parameters including on the type of metal 
ions, pH value, ionic strength, and organic phase which can be adjusted to develop a robust 
protocol (reviewed in (208)). Another approach to increase the efficiency of IMAC is the 
prefractionation of the peptide samples by various chromatographic methods (described 
therein before). In addition to the low specifity, IMAC has some other disadvantages. It has 
been reported that IMAC favours multiphosphorylated peptides over monophosphorylated 
ones since multiply phosphorylated peptides are more strongly retained on the IMAC resin 
(209). However, this disadvantage can be also taken as an advantage when the enrichment 
of multiply phosphorylated peptides is desired (210). The technique can be also affected 




molecular biology procedures. Therefore, pre-purification steps are necessary prior 
to IMAC enrichment, which might lead to an increased sample loss (208). 
Sequential elution from IMAC (SIMAC) strategy was designed to separate 
monophosphorylated and multiply phosphorylated peptides from complex biological 
samples. Monophosphorylated peptides were eluted from the IMAC resin using acidic 
solution (1% trifluoroacetic acid, 20% acetonitrile) while multiphosphorylated peptides 
were subsequently eluted under basic conditions (NH4OH solution, pH 11.3). The first 
acidic eluent was further enriched using TiO2 chromatography to sequester the pool 
of monophosphorylated peptides from acidic nonphosphorylated peptides (210).  
A similar procedure including TiO2 enrichment of the flow-through fractions 
from IMAC was used for the characterization of human T lymphocytes phosphoproteome 
(211). Other study used a combination of IMAC and TiO2 enrichment to produce a large 
data set with only small degree of overlap between these two methods suggesting the 
complementary nature of these methods (212). Some of the recent phosphoproteomic 
studies employing IMAC for phosphopeptide enrichment were mentioned above since they 
applied two dimensional enrichment settings using pre- or post-fractionation with one 
of the chromatographic methods (177–181,198). Other studies used IMAC enrichment 
without any prefractionation only followed by LC-MS/MS for identification of the 
enriched peptides. For instance, Chen L. et al. studied phosphoproteome of human prostate 
cancer specimens obtained from tissue depository to evaluate feasibility 
of  phosphoproteomics for biomarker discovery from archived tumour specimens (201).  
Recent promising innovation to IMAC technique has been the introduction 
of immobilized titanium ion affinity chromatography (Ti4+-IMAC). A phosphate 
polymer was applied to immobilize Ti4+ through the chelating interaction between 
phosphate groups on the polymer and Ti4+. The resulting Ti4+-IMAC resin was compared 
to other enrichment methods including Fe3+-IMAC, Zr4+-IMAC, TiO2, and ZrO2, and 
demonstrated superior selectivity and efficiency of Ti4+-IMAC for the isolation and 
enrichment of phosphopeptides (213,214). Matheron at al. recently compared performance 
and biases of TiO2 enrichment and Ti
4+ IMAC using a very large synthetic library and a 
tryptic digest of a cellular lysate (HeLa cells). Their data revealed that there are no clear 
differences between the two enrichment methods considering biochemical and biophysical 
parameters such as peptide length, sequence surrounding the site, hydrophobicity, and 




phosphopeptides was rather similar except for the preferential enrichment of multiply 
phosphorylated peptides by Ti4+-IMAC (215), which was in concordance with previously 
reported tendencies of IMAC resins to efficiently enrich multiply phosphorylated peptides. 
Ti4+-IMAC has been successfully applied for phosphopeptide enrichment 
in phosphoproteomic studies: for instance, in a label-free quantitative phosphoproteomic 
study of Jurkat T-cells stimulated by prostaglandin E2 (216) or a targeted quantitative 
proteomics study of phosphorylation dynamics of the PI3K-mTOR and MAPK signalling 
pathways (217).  
1.6.4. Metal Oxide/hydroxide Affinity Chromatography 
MOAC is one of the most powerful and promising approaches for phosphopeptide 
enrichment. Metal oxides have been shown to have affinity for phosphate ions at acidic pH; 
the mechanism of phosphate-metal oxide interaction is described as ion-exchange, where 
metal oxide acts as a Lewis acid, and the phosphate group behaves as a Lewis base (218–
220). 
The mechanism of this interaction implicates that phosphopeptides are most 
effectively enriched under low pH conditions. It has been established that especially 
nonphosphorylated- peptides containing greater proportions of aspartic and glutamic acid 
bind non-specifically (221). Therefore, various additives have been tested to increase 
binding specifity to selectively capture phosphorylated peptides. Namely, trifluoroacetic 
acid (TFA) or formic acid (FA) have been used to establish low pH (typically in a range 
of 2-3); relatively high acetonitrile concentrations (50-70%) have been used in the 
“buffers” to prevent hydrophobic interactions with the sorbent, and different 
monocarboxylic or dicarboxylic acids have been tested as “buffer” additives to compete 
for binding sites with non-phosphorylated peptides but to not decrease the binding affinity 
of phosphopeptides. The first one presented was 2,5-dihydroxybenzoic acid (DHB; (222)); 
nevertheless, lactic acid (LA; (223)), glutamic acid (Glu; (192)), or ammonium glutamate 
(224) have also been reported to increase the selectivity of MOAC. Naturally, the 
concentration of these additives might have a strong influence on the nature 
of phosphopeptides that are enriched. Using high concentration during the binding step 
may improve specifity, but more weakly bound mono-phosphorylated phosphopeptides 
could be lost. A variety of pH conditions during the binding or the elution step have been 




to minimize the level of nonspecifically bound peptides is chemical derivatization before 
the enrichment, e. g. methyl esterification of peptides (209,226).  
Two different settings have been used to enrich phosphopeptides using MOAC. The 
most common experimental approach is the use of MOAC beads in an off-line strategy. 
Metal oxide particles can be embedded in pipette tips or mixed and incubated with peptides 
in a microtube, and the enrichment protocol proceeds through multiple steps performed 
manually. The second is an on-line strategy, which does not allow so much flexibility in the 
protocol in comparison with the off-line strategy, but it has other undeniable advantages 
such as automation, higher sensitivity, and repeatability. In the on-line strategy, the metal 
oxides are integrated into the LC-MS/MS system in the form of pre-columns prior to the 
RPLC-MS/MS (e.g. (227,228)). 
A variety of metal oxides have been used for phosphopeptide enrichment so far 
comprising aluminium hydroxide (229), gallium oxide (230), iron oxide (183), niobium 
pentoxide (231), tin dioxide (232,233), hafnium oxide (234), tantalum oxide (235), 
zirconium dioxide (236),  and titanium dioxide (227); among them the last two have been 
the most commonly used in phosphoproteomic studies.  
1.6.4.1. Titanium dioxide enrichment 
Titanium dioxide enrichment (in text referred as TiO2 enrichment) was the first 
MOAC method discovered (227), and even though there were many other metal oxides 
in different forms proven to have affinity for phosphopeptides, it became the most popular 
metal oxide resin used for phosphopeptide enrichment presumably due to its favourable 
enrichment behaviour, chemical stability, and commercial availability. TiO2 is highly 
selective to preferentially bind phosphopeptides under optimal conditions during sample 
loading, washing, and peptide elution steps. One of the advantages of TiO2 enrichment is 
that TiO2 is more robust and tolerant towards many reagents normally used in biochemistry 
and cellular biology than conventional IMAC, which is sensitive to common buffers or 
detergents - various detergents have been actually demonstrated to enhance the efficiency 
of TiO2 enrichment (237).  
TiO2 enrichment was introduced already more than a decade ago, in 2004, as a novel 
promising strategy for selective phosphopeptide enrichment prior to RPLC-ESI-MS/MS 
(227). In this setup, TiO2 was used in a form of an on-line TiO2 pre-column coupled to a 
reversed phase capillary column; loading solution contained 0.1 M acetic acid, and the 




were successfully enriched; nevertheless, the selectivity of the enrichment was not 
sufficient and needed further optimization. 
Larsen et al. examined the effect of different loading “buffer” composition 
on phospho-selectivity of TiO2 packed in home-made microcolumns. Different aromatic 
and aliphatic carboxylic acids were added to the loading buffer and the selectivity of the 
enrichment was evaluated using MALDI-TOF MS (matrix-assisted laser 
desorption/ionization-time of flight mass spectrometry). DHB and other substituted 
aromatic carboxylic acids (salicylic acid, phthalic acid) showed the best efficacy 
in inhibition of adsorption of nonphosphorylated peptides followed by monofunctional 
carboxylic aromatic and aliphatic acids (benzoic acid, cyclohexanecarboxylic acid, 
phosphoric acid, trifluoroacetic, and acetic acid) (222). DHB was also found to be the most 
potent additive in a study performed by Yu et al. minimizing the inference 
from nonphosphorylated peptides. (238). These results indicated the importance of a 
hydroxyl group in ortho- position of a benzene ring that is probably more relevant 
for reducing the nonspecific peptide binding than a hydroxyl group in meta- position; 
presumably because the interactions between substituted aromatic carboxylic acid and TiO2 
surface are based on a coordination bond that forms a chelating bidentate (239). 
On the other hand, DHB has been shown to cause problems when analysing the 
samples using an RPLC-ESI-MS/MS system, reducing the number of identified 
phosphopeptides and affecting the performance of the LC-MS/MS system. When 
comparing the effect of hydroxy acids (DHB, glycolic acid, lactic acid, malic acid, tartaric 
acid, and hydroxypropanoic acid) on the phosphopeptide enrichment with various MOAC 
tips, lactic acid and hydroxypropanoic acid were the most effective for both TiO2 and ZrO2 
enrichment. Furthermore, aliphatic hydroxy acids are hydrophilic enough to be removed 
during the desalting step, and thus they did not appear to affect the LC-MS/MS system as 
it was described in the case of DHB (223). 
Jensen and Larsen also compared the effect of hydroxy acids, namely phthalic, 
glycolic, oxalic, lactic, gallic, and citric acid. In their comparison, 1 M glycolic acid was 
shown to be the most beneficial for the minimization of nonspecific absorption of acidic 
nonphosphorylated peptides without any effect on the binding of phosphopeptides to TiO2 
(237).  Contrary to their report, Aryal and Ross revealed that the addition of glycolic acid 
to the loading solution reduced the specifity towards phosphopeptides (240). A possible 




There are many commercial products available provided by different companies, which 
might vary because of different technology used for their production. For instance, it has 
been shown that structure and retention properties of titania are strongly dependent on the 
calcination temperature of the beads (241).  
The optimized protocol for the TiO2 enrichment presented by Wu et al. included the 
addition of glutamic acid in the sample loading buffer as an effective nonphosphopeptide 
excluding agent (186). Other investigations showed that loading buffer consisting of a 
combination of high concentrations of 1-octanesulfonic acid and low concentrations 
of DHB also improved the selectivity for phosphopeptides without affecting the LC-MS 
system as it was observed also when DHB was used as nonphosphopeptide excluding 
additive alone in a high concentration (242). This protocol was further optimized with the 
addition of heptafluorobutyric acid (243).   
Peptide-to-TiO2 ratio has been also investigated as a substantial factor for the 
selectivity of the phosphopeptide enrichment. The optimum ratio for HeLa cell lysate was 
from 1:2 to 1:8 (mass/mass); less or more TiO2 beads used for the enrichment decreased 
the selectivity. Interestingly, multiple phosphorylated peptides were identified by deficient 
TiO2 beads while with the increasing beads dosage, the monophosphorylated peptides 
became dominant (244). Similar findings were obtained for acute myeloid leukaemia cell 
line P31 in a quantitative label-free phosphoproteomic study (245). 
The TiO2 enrichment method has been further improved by developing various 
nanoparticles, nanocomposites, and microspheres. For instance, nano-titanium dioxide 
composites were synthesized from TiO2 nanoparticles via photopolymerization in the 
presence of a diacrylate cross-linker.  The enrichment efficacy of these nanocomposites 
was evaluated to be up to five times larger compared to 5µm TiO2 particles. Moreover, the 
cross-linking of the TiO2 nanoparticles helps to prevent loss of the particles from the 
packed cartridges during washing procedures (246). Lin and co-workers deposited a thin 
TiO2 layer onto the inner surface of capillary column by liquid phase deposition technique. 
This TiO2 nanoparticle-deposited capillary column was then used in an off-line setup 
with MALDI-TOF MS or on-line with ESI-QTOF MS and nano-LC-ESI-MS/MS, and a 
good capability for enriching of phosphopeptides was demonstrated, i.e. phosphopeptides 
from α-casein were detected in a mixture of tryptic peptides from α-casein and BSA at the 
femtomole level (247). Mesoporous nanostructured TiO2 clusters were also employed 




and then further modified to form submicrometer clusters with relatively uniform 
mesoscale pores and hydrophilic and negatively charged surface that enhanced the water 
dispersibility of the clusters. The incorporation of various components that further 
facilitated the separation of phosphopeptides, e. g. superparamagnetic nanocrystals, was 
demonstrated to be feasible because of the self-assembly process (248). The affinity 
material particles can also be immobilized on MALDI plates. The on-plate enrichment 
for subsequent MALDI-MS analysis has been shown to have some advantages 
in comparison with the conventional resin-based techniques such as minimal sample 
handling and thus lower sample loss (e.g. (249–251)). 
1.6.4.2. Zirconium dioxide enrichment 
The application of zirconium dioxide (ZrO2) enrichment for phosphopeptide 
isolation prior to MS analysis was first demonstrated by Kweon and Håkansson in 2006. 
Phosphoselectivities of ZrO2 and TiO2 were compared; both materials were highly specific 
for phosphopeptides. Nonetheless, ZrO2 provided more selective enrichment 
for monophosphorylated peptides whereas TiO2 was more selective 
for multiphosphorylated peptides (236). The observed difference in binding selectivity 
between ZrO2 and TiO2 was explained by the fact that under acidic conditions, ZrO2 is a 
stronger Lewis acid than TiO2, together with different coordination numbers of zirconia 
and TiO2 in crystalline forms (7 and 6, respectively; (236)).  
As in the case of TiO2, the ZrO2 enrichment method has been further improved 
by using various loading, washing, and elution conditions in the enrichment protocols, and 
by preparing different ZrO2 containing microspheres, nanoparticles, or nanocomposites. 
For instance, in the study published by Sugiyama and his co-workers, previously 
mentioned in context with TiO2 enrichment, β-hydroxypropanoic acid was shown to be the 
most effective non-phosphopeptide excluder for zirconium dioxide chromatography among 
all the hydroxy acids tested (223). Lo et al. presented iron oxide nanocomposites 
of magnetic particles coated with zirconia with high surface-to-volume ratio improving the 
trapping capacity and reducing the time required for enrichment; phosphopeptides could be 
enriched by pipetting the sample with the particles for only 30 seconds. Moreover, 
magnetic property enabled easy isolation by application of an external magnetic field 
(252). Li et al. prepared Fe3O4/ ZrO2 core-shell microspheres with well-defined core-shell 
structure and higher selectivity than ZrO2 coated magnetic particles (with no core-shell 




selective in comparison with commercially available IMAC material (PHOSselect- iron 
affinity beads, Sigma; (253)). In 2009, mesoporous ZrO2 nanomaterial with very large 
surface areas and many surface sites that provide higher loading capacity for binding 
of phosphate groups than micro- and nano- particles was first applied for phosphopeptide 
enrichment (254). However, mesoporous ZrO2 had some disadvantages including its 
thermal instability and hence mesoporous silica microspheres coated with zirconia layer 
were synthesized with improved thermal stability. Due to the interactions of metal oxide 
and silica support, the physicochemical properties of metal oxide differed greatly to the 
bulk crystalline metal oxides and enabled high phosphopeptide recovery, especially 
for multi-phosphorylated peptides, which was shown to be even higher than that of the 
widely used commercial TiO2 microparticles (GL Sciences, Tokyo, Japan; (255)). 
1.7. Detection of phosphorylation 
Mass spectrometry is a current method of choice to detect dynamic changes 
in protein phosphorylation. However, a direct MS analysis of phosphorylation 
from unfractionated peptide samples is still not feasible because of relatively low 
abundance of phosphorylated proteins in eukaryotic cells. Also, the ionization efficiency 
used to be frequently reported as a reason for difficulties in phosphopeptide identification. 
It was suggested that ionization efficiencies and thence, signals of phosphopeptides in MS, 
are lower compared with their nonphosphorylated analogues (256,257). Contrary to these 
reports, in a more recent study, Steen et al. tested the ionization/detection efficiencies of the 
synthetic peptide/phosphopeptide pairs by using online LC-ESI-MS/MS. In this study, it 
was shown that the statement about lower ionization efficiency is not valid in general, and 
it is highly dependent on the MS instrumentation used in the particular study. Based 
on their results, the authors concluded that phosphopeptides are difficult to identify 
in protein digests because of the substoichiometric nature of phosphorylation, not because 
of their low ionization efficiencies (258). Nonetheless, it is of a great importance to choose 
an appropriate “phosphate-friendly” fragmentation method to preserve phosphorylation 
during peptide fragmentation. It has been shown that during that the most common 
fragmentation method used in proteomics, collision-induced dissociation (CID) operated 
in positive-ion mode, the phospho-amino acid containing peptides will typically undergo 
β-elimination of phosphoester bond resulting in a loss of the phosphate group and limited 




method such as high-energy CID (HCD; (259)), electron capture dissociation (ECD; 
(260)), or electron transfer dissociation (ETD; (261)) leads to more efficient fragmentation 
without the cleavage of the phosphoester bond and thus allows more confident peptide 
identification and localization of the modification. More details on the appropriate 
selection of fragmentation method for a phosphoproteomic analysis are given in our 
publication (262). 
1.8. Quantification techniques for phosphoproteomics 
Quantitation in proteomics has become very robust in recent years; there are 
multiple well established quantitation techniques that provide very precise and accurate 
quantification of proteins in samples and allow comparison of samples coming 
from different origin. Quantification of PTMs has also become relatively feasible – but it 
is important to consider that the quantification of modifications is more difficult than and 
not as straightforward as quantification of whole proteins. The quantification of PTMs 
usually rely on one modified peptide, contrary to proteins with more peptides available 
(and usually required). Additionally, a modified peptide can bear multiple modifications 
with different degree of regulation, further complicating the analysis. In this chapter, a brief 
overview of the most popular quantification techniques for phosphoproteomics is provided.  
1.8.1. Label-free quantification  
As the name of the quantification approach implies, label-free quantification is the 
“simplest” quantification method that does not require any labelling step in the 
experimental workflow and only relies on spectral counting or MS1 intensity of the 
quantified feature. The unnecessity to use any isotopic label provides this method several 
attractive benefits: the implementation costs are low; there are no additional steps in the 
workflow that may introduce undesirable biases into the analysis, and the number 
of treatment conditions and replicates is basically unrestrained allowing relative flexibility 
in the experimental designs. On the other hand, the absence of multiplexing increases the 
total number of samples to be measured, and thus longer acquisition time costs must be 
considered when choosing this strategy.  
The most of the challenges occur within the post-acquisition analysis of the 
recorded data. A common problem in shotgun proteomics are missing values. The data-




peptide ions and choosing the most intense peptides for subsequent fragmentation. This 
stochastic sampling approach then leads to a high number of missing values, which might 
hamper subsequent data analysis. In fact, missing values can be imputed using various 
imputation methods (reviewed in (263)). However, label-free quantitation software has 
been improved in recent years, for instance MaxQuant (MaxLFQ algorithm (264,265)); 
these developments increased the robustness of label-free quantitation workflows and 
provided tools that can salvage many quantitative values from the unidentified spectral 
features, so the imputation is usually still used, but it is required for a lower number 
of missing values. 
Although labelling-dependent quantitation approaches provide more confident 
quantification and multiplexing, label-free approaches have become popular too and have 
been used in several phosphoproteomic studies. Especially, the largest phosphoproteomic 
studies identifying up to 50,000 of phosphorylation sites were conducted using this 
quantitation technique. However, it is important to point out that quantification of label free 
phosphoproteomics data is still challenging as the quantification of a phosphorylation site 
is usually dependent on one peptide (common issue in phosphoproteome quantification) 
and the normalization of acquired data is not as straightforward as in the case of label-based 
proteomics. Furthermore, to conduct a label-free phosphoproteomic experiment, it is 
essential to have a robust and reproducible phospho-enrichment protocol to avoid possible 
biases introduced in the sample preparation step.  
In 2010, Huttlin et al. published a large phosphoproteomic study of difference 
between 9 mouse tissues to identify common and tissue-specific phosphorylation. In this 
study, 6296 phosphoproteins harbouring nearly 36,000 phosphorylation sites were 
identified (266). In the largest phosphoproteomic study conducted so far, more than 50,000 
distinct phosphorylation sites were detected in HeLa cell line with more than 75 % 
of cellular proteins revealed to be phosphorylated. Importantly, this study provided an 
intriguing insight into differences between pS/pT and pY signalling, and presented a large-
scale quantification of site occupancies using label-free data in MaxQuant (141). The 
unnecessity of additional steps within the workflow makes label-free quantitation very 
attractive to use in high-throughput automated sample preparation workflows. EasyPhos 
was designed to allow rapid quantification of phosphoproteomes in cells and tissues at a 
depth of more than 10,000 phosphorylation sites per analysis without the need of any pre-




(267). In a recent study, a multi-protease based approach was presented for protein 
digestion markedly increasing the coverage of the studied phosphoproteome. The authors 
pointed out that there is a bias in phosphopeptides detected in phosphoproteomic studies 
caused by the fact that trypsin is usually used for sample digestion providing the same set 
of tryptic peptides (268).  
1.8.2. Metabolic labelling 
In metabolic labelling, the labels are incorporated into every protein during cell 
growth and division. Consequently, the isotopic label is introduced in the earliest possible 
step of the experiment, thereby eliminating systematic errors that could arise from sample 
handling. The most widely used metabolic labelling method in both proteomics and 
phosphoproteomics – stable isotope labelling with amino acids in cell culture (SILAC) 
was introduced in 2002 (269).  
In classical SILAC, isotopically labelled lysine and arginine (containing 13C or 15N) 
are typically used as a component of cell culture media, in which the cell are cultivated 
for at least six cell doublings to ensure a complete incorporation of labels into the proteins 
of growing cells (270). As the most common protease in proteomics is trypsin alone or 
in combination with Lys-C, the digestion of cellular proteins in the ideal case leads 
to generation of peptides that contain one lysine or arginine and thus contain one isotopic 
label. Relative quantification is then achieved on MS1 level by comparing the intensities 
of two co-eluting isotopic clusters (i.e. labelling pair) which are distinguished by their m/z 
value. The disadvantages of SILAC are limited multiplexing (only 2 or 3 samples are 
maximally combined in a typical SILAC experiment) and the increase of complexity 
of MS1 spectra, which can in turn limit sampling depth. Another problem might be caused 
by metabolic turnover of labelled amino acids – typically arginine, which can be converted 
to proline – but this issue can be avoided by careful optimization of the arginine and lysine 
concentration in cell culture media, choosing an appropriate experimental design and 
arginine isotope (271), or adding high amounts of proline to limit the metabolic conversion 
of arginine by a negative feedback loop (272).  
The first phosphoproteomic studies that employed SILAC as a quantification 
technique were conducted in Mann’s lab. Blagoev et al. studied phosphotyrosine-mediated 
signalling events in epidermal growth factor (EGF) stimulated cells using an antibody-




triple-labelling states experiments (i.e. double-triple SILAC), an activation profile of 81 
signalling proteins early after EGF receptor (EGFR) stimulation was obtained, and thus it 
was for the first time demonstrated that SILAC can be employed to study cellular signalling 
in a high-throughput phosphoproteomic study (151). In a complementary study using the 
same labelling approach (i.e. double-triple SILAC) to generate five-time-points profiles 
for the detected phosphorylation sites and the same stimulation using EGF, Olsen et al. 
for the first time demonstrated that SILAC could be used to study pS and pT mediated 
signalling pathways. Using a two dimensional chromatographic approach including SCX 
as a prefractionation technique prior to TiO2 enrichment, 6,600 phosphorylation sites 
on 2,244 proteins were detected (273). In these initial studies, stringency criteria for only 
accepting 1.5 fold changed sites as regulated were set (151) and classification 
of phosphorylation sites based on their localization probability calculated by MaxQuant 
was developed with only accepting class I sites (i.e. localization probability > 0.75) 
for downstream bioinformatic analysis (273); both of these criteria are still widely used 
in current phosphoproteomic studies. Since then, classical SILAC has been used 
for quantification in many phosphoproteomic studies mainly because of the high precision 
and accuracy of quantification achieved by this technique as well as the early introduction 
of the labelling into the experiment.  
Furthermore, Mann’s lab has developed new techniques based on the classical 
SILAC labelling that further expanded experimental designs that are applicable 
to quantitative proteomics and phosphoproteomics using SILAC. In a so-called pulsed 
SILAC, all experimental groups are cultivated in a SILAC “light” cell culture medium (i.e. 
a medium that contains non-labelled versions of amino acids) and the “heavy” isotopes are 
only added for a certain period of time to pulse-label the newly synthesized proteins. As a 
consequence, protein turnover can be estimated from the obtained SILAC rations (274). To 
be able to analyse primary tissues and compare a higher number of samples than in the 
classical SILAC approach, spike-in SILAC (sometimes referred as super-SILAC) was 
developed. The idea of spike-in SILAC is to produce a representative super-SILAC 
mixture of different SILAC-labelled cell lines to develop an internal standard for a 
subsequent comparison of multiple samples (275,276). Further development also enabled 
the use of SILAC for the purpose of in vivo studies by introducing SILAC labelled model 




These modifications of the classical SILAC approach have been also used 
in quantitative phosphoproteomics. Phosphoproteomes of insulin treated and untreated 
mice liver were compared using the spike-in method. In this study, the super-SILAC mix 
was composed of a mixture of peptides prepared by tryptic digestion of six mouse liver cell 
lines treated or untreated with insulin. Using this mixture as an internal standard, 10,000 
of phosphorylation sites were compared in response to insulin treatment, which provided a 
considerable deep insight into cellular signalling in an in vivo system (279). In addition 
to in vivo phosphoproteomic studies, spike-in SILAC also enabled a quantitative 
comparison of tumour samples obtained from different donors. Schweppe et al. established 
a super-SILAC internal standard derived from NSCLC cell lines, which was further used 
to relatively quantify phosphopeptides from two tumours to determine pathways that differ 
between the two tumours (280). The SILAC mouse technology was used to investigate 
cancer progression through distinct stages of skin cancer providing a detailed insight into 
molecular pathways altered during skin carcinogenesis obtained in an in vivo system (281).  
1.8.3. Chemical labelling 
In chemical labelling approach, the isotopic labels are incorporated into the proteins 
later in the experimental workflow – either on the protein level (possible, but not widely 
used), or much more often on the peptide level. In principle, any reactive group within the 
amino acid residues might be used to chemically attach a label to a peptide; however, most 
of the current labelling techniques take advantage of the reactivity of primary amines and 
target either peptide N-terminus or ε-amino group of lysine. The later incorporation of the 
label might introduce a systematic bias into the experiment; on the other hand, chemical 
labelling is feasible also in cases when the labelling on the growing culture level is not 
possible (e.g. in primary cells, human, animal, or plant tissues, and biological fluids) or not 
applicable to a desired experimental design (e.g. when a higher level of multiplexing is 
desired). The relative (or absolute) quantification using the chemical labelling approach 
can be conducted either on the MS1 level by comparing intensities of the differentially 
labelled peptides or on the MS2 level via comparing differentially isotope encoded reporter 




1.8.3.1. MS2 quantitation 
The MS2 quantitation methods are based on chemical labelling using isobaric tags. 
That means that peptides labelled with different labels have the same mass, and thus they 
co-elute from the LC system, cannot be distinguished based on their m/z on the MS1 level, 
and co-fragment during MS/MS. The quantification of the peptides in samples is then 
achieved by comparing the intensities of reporter ions that are recorded in the lower mass 
range of the MS/MS spectra.  The fact that including multiple labelling states does not 
increase complexity of the samples provides a considerable advantage of this approach – it 
enables parallel quantification of more than two or three samples that are usually combined 
in MS1 labelling based experiments (up to ten samples). Furthermore, the quantification 
using chemical labelling and MS/MS detection of the tags is usually very precise; 
nonetheless, there is a possible bias in accuracy that has to be considered when using these 
approaches – the fold changes measured in highly complex samples are often smaller than 
the “real” fold changes. This phenomenon, called as ratio compression effect, happens 
due to the co-isolation of peptide ions during the MS2 precursor selection. As most of the 
proteome/phosphoproteome usually remains unperturbed by applied treatment, the ratios 
of co-isolated reporter ions are most likely to be close to 1, and thus they might “dilute” the 
real differences between the regulated peptides. However, there are already methods 
available that have been designed to overcome this issue enabling more confident use 
of these techniques for proteome quantification (282,283).  
The most common isobaric labelling techniques used in quantitative proteomics and 
phosphoproteomics are tandem mass tags (TMT; (284)) and isobaric tag for relative and 
absolute quantitation (iTRAQ; (285,286)). In phosphoproteomics, prefractionation and 
enrichment steps are typically included into the experimental design as additional steps that 
might potentially introduce systematic errors into the analysis; therefore, including the 
labelling in the earliest possible step of the experiment is desired, ideally immediately after 
the cells are harvested (or samples collected - in case of samples of different than cell 
culture origin). On the other hand, the low abundance of phosphorylated peptides 
implicates the necessity of higher amount of starting material ranging from hundreds 
of micrograms to several milligrams, which might be costly, especially when replicate 
experiments are conducted. Therefore, labelling of isolated phosphopeptides might be an 





Zhang et al. used pre-enrichment iTRAQ labelling as a relative quantification 
method in a time-course study using the EGFR model system. Tryptic peptides from four 
different EGFR stimulation time points were labelled with four isoforms of the iTRAQ 
reagent, and after mixing of the samples, tyrosine-phosphorylated peptides were 
immunoprecipitated with an anti-phosphotyrosine antibody and further enriched by IMAC 
before LC-MS/MS analysis. The analysis led to the identification of 78 tyrosine 
phosphorylation sites on 58 proteins from a single analysis (287). Another instance of a 
study that also used iTRAQ labelling of peptides prior to application of phospho-
enrichment (TiO2) was a phosphoproteomic analysis of porcine hearth mitochondria 
to study pyruvatdehydrogenase (PDH) phosphorylation (288). In 2010, Wu et al. 
demonstrated that post-enrichment iTRAQ labelling of phosphopeptides was possible 
to achieve confident identification and quantification of phosphopeptides in HeLa-S3 cells 
tryptic digest. In their workflow, phosphopeptides were reproducibly enriched using a 
chromatographic column packed with TiO2 beads (289). 
Another application of iTRAQ to phosphoproteome investigation developed 
recently is the use of isobaric labelling to study phosphorylation stoichiometry and absolute 
quantification of phosphopeptides. In Phospho-iTRAQ, peptide samples are split in two 
identical parts and differentially labelled prior to phosphatase treatment of one of the parts. 
After de-phosphorylation, the samples are pooled together and analysed by LC-MS/MS. 
The reporter ions intensities are then used to calculate phosphorylation stoichiometries 
of detected phosphopeptides, and due multiplexing, this method also allows multiple 
samples comparison and relative quantification of unmodified peptides in the same run. 
However, additional confirmation of the identified phosphopeptides with complementary 
techniques remains necessary, since using this approach, it is not possible to exactly 
localize the phosphorylation site when there are multiple STYs in a peptide available (in a 
non-phospho-enriched mixture, only the non-phosphorylated counterparts are usually 
fragmented providing no information about the site localization; (290,291)). Multiplex 
Absolute Regressed Quantification with Internal Standards (MARQUIS) is a different 
method employing iTRAQ for absolute quantification of phosphorylated peptides. In this 
approach, isobaric tags are combined with synthetic heavy-labelled standard peptides 
to construct internal standard curves for phospho-peptides of interest. The standard labelled 
heavy peptides are added to biological samples – cell lysates – in a different concentration 




MS/MS. The fragmentation of the heavy-labelled peptides then provides an internal 
standard curve, which serves as a reference for the reporter ions produced by fragmentation 
of the endogenous (non-labelled) counterpart of the heavy peptide and thus enables 
absolute quantification of a particular phospho-peptide across different conditions (292).  
TMT has been also used for both absolute quantification of phosphorylation 
stoichiometries (293) and in studies that required a higher level of multiplexing such as a 
phosphoproteomic study of genistein treated triple-negative breast cancer cell line MDA-
MB-231 (294), a study investigating changes in brain-phosphoproteome of VX (neurotoxic 
agent) treated rats (295), or a study that provided an insight into molecular pathways 
triggered by nicotinic acetylcholine receptor ligands in pancreatic cells (296). 
1.8.3.2. MS1 quantitation  
MS1 quantitation using chemical labelling is an alternative to SILAC labelling 
in cases when SILAC is not applicable (as listed above), or it is too expensive. The most 
widely used MS1 chemical labelling quantitation methods in proteomics are mTRAQ and 
stable-isotope dimethyl labelling.  
mTRAQ is basically a non-isobaric variant of iTRAQ. Thus, it uses the same 
chemistry, but the differentially labelled peptides are already distinguishable in MS1 
spectra as in the case of SILAC labelling. Initially, mTRAQ was used to label standard 
peptides for multiple reaction monitoring to quantify potential markers for endometrial 
cancer (297); however, studies applying mTRAQ to study phosphorylation dynamics also 
emerged more recently. Mertins et al. compared iTRAQ- and mTRAQ-based quantification 
and revealed that iTRAQ quantified almost threefold more phosphopeptides than mTRAQ 
(12,129 versus 4,448, respectively). Furthermore, iTRAQ was shown to be less variable 
and had an additive effect on precursor intensities. The loss of accuracy caused by co-
fragmentation of peptides in the same isolation window and ratio compression was 
observed in iTRAQ; however, the authors suggested that since logarithmic iTRAQ and 
mTRAQ ratios were linearly correlated, the iTRAQ ratios could be corrected by an average 
compression factor to achieve more accurate results (298). Oppermann et al. compared two 
MS1 quantification methods – metabolic labelling by SILAC and chemical labelling 
by mTRAQ. They reported that mTRAQ was a comparable alternative to SILAC that 
enabled quantification of almost as many significant changes in phosphorylation after a 
kinase inhibitor treatment, although mTRAQ was shown to be slightly less precise than 




Stable isotope labelling of primary amino-groups using deuterium-labelled-
formaldehyde in combination with reduction of the initially formed Schiff base 
with deuterium-labelled-cyanoborohydride – stable-isotope dimethyl labelling - is 
another labelling technique attractive enough to be widely used in many studies (300–302); 
the method is relatively cheap, fast, and robust. The main limitation of this technique is the 
use of deuterium as a heavy part of the label, which can lead to retention time shifts of the 
heavy labelled peptides in LC-MS/MS, and thus the labelling pair might not co-elute 
precisely. Since 2006, when it was for the first time used in combination with IMAC 
to study uteri of pregnant rats (303), reductive dimethylation has been used in multiple 
phosphoproteomic studies. Dimethyl labelling has been used in combination 
with immunoaffinity purification of tyrosine-phosphorylated peptides to study tyrosine 
phosphorylation in EGF treated HeLa cells   (304). In TiSH, three different phospho-
fractionation methods were employed to maximally increase the coverage of a studied 
phosphoproteome: TiO2, SIMAC, and HILIC. In this three dimensional fractionation, 
dimethyl labelling was applied after the first TiO2 enrichment step (305). Wilson-Grady 
at al. presented a modified lower-pH dimethylation protocol as a quantification technique 
that can be used for quantitative proteomics and phosphoproteomics in animal tissues 
(306). Dimethyl labelling has been also employed, as well as other approaches, 
for calculation of phosphorylation stoichiometries. Combined with kinase reaction, the 







2.1. Optimization of experimental workflow for the enrichment, detection, and 
quantification of phosphorylated peptides using mass spectrometry:   
 Selection of MOAC resin and protocol for enrichment of phosphorylated 
peptides using standard peptide mixtures 
 Application of the best performing protocols to the enrichment 
of phosphorylated peptides from a real complex sample and to the analysis 
of the selected model system (irradiated SILAC-labelled MOLT-4 cells) 
2.2. Characterization of cellular mechanisms underlying the VE-821-mediated 
radiosensitization of MOLT-4 cells on three levels:  
 Characterization of the response of MOLT-4 cells to VE-821 and its 
combination with IR using cell biology methods 
 Application of the optimized phospho-enrichment workflow to analyse 
phosphorylation response of irradiated MOLT-4 cells and its modulation 
by VE-821 
- Detection of phosphorylation sites responsive to VE-821 treatment 
- Functional annotation of regulated phosphorylation sites and 
identification of potentially perturbed signalling pathways and 
biological processes 
- Analysis of phosphorylation motifs surrounding detected 
phosphorylation sites and identification of activated/inhibited protein 
kinases 
 Description of VE-821-induced metabolome alterations in irradiated 
MOLT-4 cells using targeted metabolome analysis 
- Identification of metabolites with abundance changes induced 
by VE-821 treatment in irradiated MOLT-4 cells 
- Functional characterization of regulated metabolites, detection 
of modulated metabolic pathways 





3. Materials and Methods 
3.1. Materials and Instrumentation 
3.1.1. Cell lines  
HeLa (American Type Culture Collection (University Blvd., Manassas, USA)) 
MOLT-4 (European Collection of Animal Cells Cultures (Porton Down, Salisbury, UK)) 
3.1.2. Kinase inhibitors 
VE-821 – ATR inhibitor, 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-
carboxamide (APIs Chemical Co., Ltd., Shanghai, China) 
KU55933 – ATM inhibitor, 2morpholin4yl6thianthrene1ylpyran4-one (Merck KGaA, 
Darmstadt, Germany) 
3.1.3. Cell culture media, chemicals and solvents 
Acetic acid (no. 49199, Sigma-Aldrich, St. Louis, MO, USA) 
Acetone for HPLC (no. 270725, Sigma-Aldrich, St. Louis, MO, USA) 
Acetonitrile LiChrosolv® hypergrade for LC-MS (no. 100029, Merck KGaA, 
Darmstadt, Germany) 
Acetonitrile CHROMASOLV® Plus (Acn; no. 34998, Sigma-Aldrich, St. Louis, MO, 
USA) 
Acetonitrile CHROMASOLV® gradient grade for HPLC (no. 34851, Sigma-Aldrich, 
St. Louis, MO, USA) 
Acrylamide, minimum 99 % (no. A5667, Sigma- Aldrich, St. Louis, MO, USA) 
Albumin, from bovine serum (BSA; no. A2153, Sigma-Aldrich, St. Louis, MO, USA) 
Albumin, from bovine serum (BSA; no. A8022, Sigma-Aldrich, St. Louis, MO, USA) 
Ammonium bicarbonate (ABC; no. 09830, Sigma-Aldrich, St. Louis, MO, USA) 
Ammonium hydroxide solution ≥99.99% (no. 338818, Sigma-Aldrich, St. Louis, MO, 
USA) 
L-Arginine (R0; no. A8094, Sigma-Aldrich, St. Louis, MO, USA) 




Asialofetuin, from foetal calf serum (no. A4781, Sigma-Aldrich, St. Louis, MO, USA) 
Bensonase® Nuclease (no. E1014, Sigma-Aldrich, St. Louis, MO, USA) 
Blotting-Grade Blocker (no. 170-6404, BIO-RAD) 
α-Casein, from bovine milk (no. C6780, Sigma-Aldrich, St. Louis, MO, USA) 
CHCA Matrix (CHCA; α-cyano-4-hydroxycinnamic acid recrystallized, no. M101, 
Laserbio Labs) 
Complete™ Mini, EDTA-free Protease inhibitor cocktail (no. 11836170001, Roche, 
Manheim, Germany) 
DHB Matrix (2,5-dihydroxybenzoic acid recrystallized, no. M103, Laserbio Labs) 
2,5-dihydroxybenzoic acid (DHB; no. 149357, Sigma-Aldrich, St. Louis, MO, USA) 
Dimethyl sulfoxide ≥ 99.5% (DMSO; no. D5879, Sigma-Aldrich, St. Louis, MO, USA) 
DL-Dithiothreitol BioXtra ≥99.0% (DTT; no. 5545, Sigma-Aldrich, St. Louis, MO, 
USA) 
Dodecylsulfate. Na-salt (SDS; no. 20760, SERVA) 
Dulbecco’s modified eagle medium, high glucose, L-glutamine (DMEM; no. 11965-
092, Gibco® by Life technologies™, Thermo Fisher Scientific) 
Ethanol absolute p.a. (no. 603-002-00-5, PENTA s.r.o., Prague, Czech Republic) 
Ethyl acetate for HPLC (no. 439169, Sigma-Aldrich, St. Louis, MO, USA) 
Foetal bovine serum (FBS; no. 10270-106, Gibco® by Life technologies™, Thermo 
Fisher Scientific) 
Foetal bovine serum, dialyzed by ultrafiltration (no. F0392, Sigma-Aldrich, St. Louis, 
MO, USA) 
Formic acid, eluent additive for LC-MS (FA; no. 56302 FLUKA, Sigma-Aldrich, St. 
Louis, MO, USA) 
L-Glutamic acid (Glu; no. 49449, Sigma-Aldrich, St. Louis, MO, USA) 
L-Glutamine solution, 200 mM (no. G7513, Sigma-Aldrich, St. Louis, MO, USA) 
Glycerol Ultrapure, MB grade (no.16374, USB Corporation, Cleveland, OH, USA) 
Iodoacetamide (IAA; no. I6125, Sigma-Aldrich, St. Louis, MO, USA) 
Iscove’s modified Dulbecco’s media without L-glutamine (no. E15-018, PAA 
Laboratories GmbH, Pashing, Austria)  
Iscove’s modified Dulbecco’s media (IMDM; no. 12440-053, Gibco® by Life 
technologies™, Thermo Fisher Scientific) 




Lactic acid solution (LA; no. L1875, Sigma-Aldrich, St. Louis, MO, USA) 
L-Lysine (K0; no. L5501, Sigma-Aldrich, St. Louis, MO, USA) 
L-13C6-Lysine (K6; no. 608041, Sigma-Aldrich, St. Louis, MO, USA) 
Magnesium chloride anhydrous ≥ 98 % (no. M8266, Sigma-Aldrich, St. Louis, MO, 
USA) 
Methanol LC-MS CHROMASOLV® (no. 34966, Sigma-Aldrich, St. Louis, MO, USA) 
Methanol LiChrosolv® hypergrade for LC-MS (no. 106035, Merck KGaA, Darmstadt, 
Germany) 
N, N’-Methylenebisacrylamide (no. 66667, Sigma-Aldrich, St. Louis, MO, USA) 
Myoglobin from equine heart (no. M1882, Sigma-Aldrich, St. Louis, MO, USA) 
N-Octyl-β-D-glucopyranoside, BioXtra, ≥ 98% (no. O9882, Sigma-Aldrich, St. Louis, 
MO, USA) 
Orthophosphoric acid solution, 85 wt % in H2O (no. W290017, Sigma-Aldrich, St. 
Louis, MO, USA) 
Penicillin-Streptomycin for cell culture (no. P0781, Sigma-Aldrich, St. Louis, MO, 
USA) 
Phosphatase inhibitor cocktail 2 (no. P726, Sigma-Aldrich, St. Louis, MO, USA) 
Phosphatase inhibitor cocktail 3 (no. P044, Sigma-Aldrich, St. Louis, MO, USA) 
Phosphate buffer saline, pH 7.4 (no. 10010015, Gibco™, Thermo Fisher Scientific) 
Precision Plus Protein™ Standards Kaleidoscope (no. 161-0375, BIO-RAD) 
L-proline (no. P5607, Sigma-Aldrich, St. Louis, MO, USA) 
Propidium iodide (PI; no. 81845, Sigma-Aldrich, St. Louis, MO, USA) 
Ribonuclease A, from bovine pancreas (no. R6513, Sigma-Aldrich, St. Louis, MO, USA) 
Sequencing grade modified trypsin, frozen (no. V5113, Promega Corporation, Madison, 
WI, USA) 
Sequencing grade modified trypsin, lyophilized (no. V5111, Promega Corporation, 
Madison, WI, USA) 
Sodium chloride, for molecular biology (NaCl; no. S3014, Sigma-Aldrich, St. Louis, 
MO, USA) 
Sodium deoxycholate (no. 30970, Sigma-Aldrich, St. Louis, MO, USA) 
Sodium fluoride, BioXtra, ≥ 99% (NaF; no. S7920, Sigma-Aldrich, St. Louis, MO, USA) 
Sodium orthovanadate, 99.98%, trace metal basis (Na3VO4; no. 450243, Sigma-




Trifluoroacetic acid LC-MS grade (TFA; no. 85183, Thermo Scientific) 
Trifluoroacetic acid ≥99% (TFA; no. 299537, Sigma-Aldrich, St. Louis, MO, USA) 
Trizma® base (no. T6066, Sigma-Aldrich, St. Louis, MO, USA)  
Trizma® hydrochloride (Tris-HCl; no. T5941, Sigma-Aldrich, St. Louis, MO, USA) 
Triton® X-100 for molecular biology (no. T8787, Sigma-Aldrich, St. Louis, MO, USA) 
Trypan blue (no. T6146, Sigma-Aldrich, St. Louis, MO, USA) 
Trypsin-EDTA 0.25% (no. 25200-072, Gibco® by Life technologies™) 
Tween® 20 (no. P1379, Sigma-Aldrich, St. Louis, MO, USA) 
Water LiChrosolv® LC-MS Grade (no. 115333, Merck KGaA, Darmstadt, Germany) 
Westran® S (no. 10413096, GE Healthcare Life Sciences Whatman™) 
3.1.4. Antibodies 
3.1.4.1. Primary antibodies: 
Monoclonal Mouse Anti-β-actin Antibody (no. A5316, Sigma-Aldrich, St. Louis, MO, 
USA) 
Monoclonal Mouse Anti-Chk1 Antibody (no. 2360, Cell signalling Technology®) 
Monoclonal Rabbit Anti-Phospho-Chk1 (Ser245) Antibody (no. 2348, Cell signalling 
Technology®) 
Polyclonal Rabbit Anti-Chk2 Antibody (no. 2662, Cell signalling Technology®) 
Monoclonal Rabbit Anti-Phospho-Chk2 (Thr68) Antibody (no. 2197, Cell signalling 
Technology®) 
Monoclonal Rabbit Anti-p70 S6 Kinase Antibody (no. 2708, Cell signalling 
Technology®) 
Monoclonal Rabbit Anti-p70 S6 Kinase Antibody (no. 9234, Cell signalling 
Technology®) 
3.1.4.2. Secondary antibodies:  
Polyclonal Goat Anti-Mouse Immunoglobulins/HRP (no. P0447, Dako, Glostrup, 
Denmark) 





3.1.5.  Commercial kits and assays 
Apoptest™-FITC kit (no. K2350, DakoCytomation, Copenhagen, Denmark) 
QuantiPro™ BCA Assay Kit (no. QPBCA, Sigma-Aldrich, St. Louis, MO, USA) 
BM Chemiluminescence Western Blotting Kit (no. 11500708001, BM 
Chemiluminescence-POD, Roche) 
Cell Proliferation Reagent WST-1 (no. 11644807001, Roche Diagnostics, Mannheim, 
Germany) 
3.1.6.  Chromatographic material 
3M EmporeTM C18 Extraction disk (no. 66883, Supelco®, Bellefonte, PA, USA) 
3M EmporeTM C18-SD 4 mm/1 ml Extraction disk cartridge (no. 66871-U, Supelco®, 
Bellefonte, PA, USA) 
3M EmporeTM C18-SD 7 mm/3 ml Extraction disk cartridge (no. 66872-U, Supelco®, 
Bellefonte, PA, USA) 
C18 PepMap100, 3 µm, 100 A, 0.075 × 20 mm capillary trap column (Dionex, Thermo 
Scientific™, Bremen, Germany) 
C18 PepMap RSLC, 2 µm, 100 A, 0.075 × 150 mm capillary separation column 
(Dionex, Thermo Scientific™, Bremen, Germany) 
NuTip® (TiO2/ZrO2 1:1) (no. NT2TIZR, Glygen, Columbia, MD, USA) 
Oasis® HLB SPE cartridges (Waters, Manchester, UK) 
Oligo™ R3 reversed-phase material (no. 1133903, Applied Biosystems™, Foster City, 
CA) 
Supelco C18 SPE cartridges 500 mg (Supelco Analyticals, Bellefonte, PA, USA) 
Titansphere® 5 μm particles (no. 5020-75000, GL Sciences, Japan) 
TopTip® (TiO2, TiO2/ZrO2 1:1, and ZrO2) (Glygen, Columbia, MD, USA) 
TSKgel® Amide-80 HR 5 μm 4.6 × 25 cm separation column (Tosoh Biosciences, 
Stuttgart, Germany) 
TSKgel® Amide-80 HR 5 μm 4.6 × 1 cm guard column (Tosoh Biosciences, Stuttgart, 
Germany) 
3.1.7.  Instrumentation 
60Co gamma-ray source (VF, Černá Hora, Czech Republic) 




FACS analyser CyAn DakoCytomation (Beckman Coulter, USA) 
PARADIGM™ Detection Platform (Beckman Coulter, Brea, CA, USA) 
Q Exactive™ Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (Thermo 
Scientific™, Bremen, Germany) 
Thermo Scientific™ Dionex Ultimate™ 3000 RSLCnano system (Thermo Scientific™, 
Bremen, Germany) 
Waters® Alliance Separations Module e2695 (Waters, Milford, MA, USA) 
3.1.8.  Commercial software 
Summit v4.3 software (Beckman Coulter, Miami, FL, USA) 
GPS Explorer TM Software vision v3.6 (Applied Biosystems, USA) 
3.2. Optimization of Metal Oxide Affinity Enrichment 
of Phosphorylated Peptides from Standard Peptide 
Mixtures 
3.2.1. Model proteins and peptide mixtures 
α-casein, asialofetuin, BSA, and myoglobin were dissolved in 50 mM ABC buffer 
(pH 7.8), reduced with 10 mM DTT, alkylated with 20 mM IAA, and subjected to trypsin 
digestion at an enzyme to protein ratio 1:50 at 37 °C overnight. Digested samples were 
desalted using Oasis® HLB SPE cartridges.  
Peptide mixture A contained tryptic peptides originating from α-casein, 
asialofetuin, BSA, myoglobin in a molar ratio of 1:1:5:5 (i.e. 40 pmol of each 
phosphorylated protein α-casein and asialofetuin and 200 pmol of each non-phosphorylated 
protein BSA and myoglobin)  
Peptide mixture B contained tryptic peptides originating from α-casein, 
asialofetuin, BSA, myoglobin in a molar ratio of 1:1:50:50 (i.e. 40 pmol of each 
phosphorylated protein α-casein and asialofetuin and 2 nmol of each non-phosphorylated 




3.2.2.  Standard HeLa sample preparation 
HeLa cells were cultured in DMEM supplemented with 10% FCS, 100 UI/ml 
penicillin, and 0.1 mg/ml streptomycin at 37 °C under controlled 5% CO2 and humidified 
atmosphere. The cells were harvested at about 80 % density. Whole cell extracts were 
prepared using an ice-cold lysis buffer containing 137 mM NaCl, 10% glycerol, 1% n-
octyl-β-glucopyranoside, 50 mM NaF, 20 mM Tris-HCl, (pH=8), and 1 mM Na3VO4, 
followed by centrifugation at 14 000 g for 30 min at 4 °C. 0.5 mg of extracted proteins were 
diluted with 50 mM NH4HCO3 to a final concentration of 2 mg/ml, reduced with 10 mM 
DTT, alkylated with 20 mM IAA, and subjected to trypsin digestion at an enzyme 
to protein ratio 1:50 at 37 °C overnight. Peptides were desalted using Oasis HLB SPE 
cartridges (30 mg sorbent per cartridge). Enriched phosphopeptides were desalted using 
3M EmporeTM C18-SD 4 mm/1 ml Extraction disk cartridges.  
3.2.3.  MOLT-4 sample preparation 
MOLT-4 cells well cultured in IMDM for SILAC containing 20% dialyzed foetal 
bovine serum. Media were further supplemented with either unlabelled L-lysine (100 mg/l, 
K0) and L-arginine (84 mg/L, R0) or equimolar amounts of L-13C6-lysine (K6) and L-
13C6-
arginine (R6). L-proline (300 mg/L) was added to cell culture media avoid metabolic 
conversion of arginine to proline (272). For complete incorporation of labelled amino 
acids, cells were cultured for at least six cell doublings (308). The “heavy” cells (K6/R6) 
were irradiated by a dose of 1.5 Gy using a 60Co gamma-ray source; the “light” cells 
(K0/R0) served as sham-irradiated controls. After irradiation, the flasks were placed into 
an incubator and the cells were harvested one hour after irradiation. Whole cell extracts 
were prepared using an ice-cold lysis buffer containing 137 mM NaCl, 10% glycerol, 1% 
n-octyl-β-glucopyranoside, 50 mM NaF, 20 mM Tris-HCl, (pH=8), and 1 mM Na3VO4, 
followed by centrifugation at 14 000 g for 30 min at 4 °C. 1 mg of extracted proteins (0.5 
mg of “light” + 0.5 mg of “heavy” pooled together) were precipitated using acetone 
precipitation O/N (100 % acetone pre-cooled at -20 °C and added to the samples at 4:1 
acetone: sample volume ratio), resolubilized in 8 M Urea/ 50 mM ABC, reduced 
with 10 mM DTT, alkylated with 20 mM IAA, and after dilution with 50 mM ABC 
subjected to trypsin digestion at an enzyme to protein ratio 1:50 at 37 °C overnight. Tryptic 
peptides were desalted using 3M EmporeTM C18-SD 7 mm/3 ml Extraction disk cartridges. 




phosphopeptides were desalted using 3M EmporeTM C18-SD 4 mm/1 ml Extraction disk 
cartridges. 
3.2.4. Phosphopeptide enrichment protocols 
3.2.4.1. NuTip® enrichment 
10- to 200-μl TiO2/ZrO2 NuTip® (Glygen, Columbia, MD, USA) was washed 
with 100 μl of loading buffer (LB). Phosphopeptides were enriched by repetitive pipetting 
(20x) of 10 μl aliquots of sample dissolved in 100 μl of LB. The Tip was then washed twice 
with 200 μl of LB, three times with 200 μl of washing buffer 1 (WB 1) and three times 
with 200 μl of washing buffer 2 (WB 2). Phosphopeptides were then eluted five times 
with 10 μl aliquots of elution buffer (EB) by repetitive pipetting (20x) and the eluted 
fraction was then acidified with a mixture of 100% FA and 10% TFA (to final pH < 2).  
3.2.4.2. TopTip® enrichment 
10- to 200- μl TopTips® (Glygen, Columbia, MD, USA) packed with TiO2, ZrO2, 
or a mixture of both TiO2 and ZrO2 were tested for their phosphopeptide enrichment 
efficiency. The packed beads were washed with 200 μl of LB. The sample was dissolved 
in 200 μl of LB and loaded on the column two times. The washing procedure included two 
consecutive washes with 200 μl of LB, two washes with 200 μl of WB 1, and two washes 
with 200 μl of WB 2. Phosphopeptides were eluted with 200 μl of EB and the eluted 
fraction was then acidified with a mixture of 100% FA and 10% TFA (to final pH < 2). 
3.2.4.3. Titanium dioxide enrichment using Titansphere® TiO2 particles 
Titansphere® TiO2 particles (5 μm diameter; GL Sciences, Torrance, CA) were 
used for phosphopeptide enrichment using a “microtube approach”. The sample was 
dissolved in 200 μl of LB and incubated with TiO2 particles (peptide-to-TiO2 ratio 1:8; 
mass/mass) on a shaker for 20 minutes. TiO2 beads were then washed with 200 μl of LB, 
200 μl of WB 1, and twice with 100 μl of WB 2. Phosphopeptides were eluted with 50 μl 
of EB and the eluted fraction was acidified with a mixture of 100% FA and 10% TFA (to 




3.2.5. Buffer conditions 
Each of the chromatographic resins mentioned above: commercial tips NuTip 
packed with TiO2/ZrO2 (1:1), TopTips packed with TiO2, TiO2/ZrO2 (1:1) or ZrO2, and 
TiO2 particles (Titansphere 5 μm) were employed for the enrichment of phosphopeptides 
under different buffer conditions following four published protocols with some minor 
modifications. LA, DHB, and Glu were used as the buffer additives to enhance the specifity 
of metal oxides towards phosphorylated peptides.  
Every procedure for each peptide mixture, buffer condition, and phosphopeptide 
enrichment media was performed in 3 replicates.  
3.2.5.1. Buffer conditions 1 – 5% TFA 
Peptides were loaded onto commercial columns/mixed with TiO2 particles in 80% 
acetonitrile and 5% TFA (LB). The columns/TiO2 particles were then washed with 80% 
acetonitrile/ 1% TFA (WB 1) and then with 20% acetonitrile and 0.5% TFA. Peptides were 
eluted with NH4OH pH 11 (EB).  
3.2.5.2. Buffer conditions 2 – 1M LA 
Peptides were loaded onto commercial columns/mixed with TiO2 particles in 80% 
Acn/5% TFA/1 M LA (LB). The columns/TiO2 particles were then washed with 80% 
Acn/ 1% TFA (WB 1) and then with 20% Acn/0.5% TFA (WB 2). Peptides were eluted 
with NH4OH pH 11 (EB).  
3.2.5.3. Buffer conditions 3 – 350 mg/ml DHB 
Peptides were loaded onto commercial columns/mixed with TiO2 particles in 65% 
Acn/2% TFA/350 mg/ml DHB (LB) according to Larsen’s lab (222). The columns/TiO2 
particles were then washed with 65% Acn/ 2% TFA (WB 1) and then with 20% Acn/0.5% 
TFA (WB 2). Peptides were eluted with NH4OH pH 11 (EB). 
3.2.5.4. Buffer conditions 4 – 100 mM Glu 
Peptides were loaded onto commercial columns/mixed with TiO2 particles in 65% 
Acn/2% TFA/0.1 M glutamic acid (LB) according to Wu et al. (309).The columns/TiO2 
particles were then washed with 65% Acn/ 0.5% TFA (WB 1) and then with 65% 




3.2.6.  Purification and concentration of eluted peptides 
Eluted fractions were concentrated and desalted prior to MALDI analysis using 
custom made microcolumns prepared from Geloader tips packed with 3M EMPORE C18 
disc and Poros Oligo R3 reversed phase material.  
Acidified eluates from the columns/TiO2 particles were loaded onto desalting 
columns. The columns were then washed twice with 50 μl of 0.1% TFA. Peptides were 
eluted with 10 μl of 60% Acn/ 0.1% TFA. 
3.2.7.  Chromatography and mass spectrometry 
MALDI-TOF-MS/MS analysis was performed using an ABI 4800 mass 
spectrometer. Spectra were recorded in positive MS and MS/MS reflector mode. Acquired 
raw data files were processed using GPS Explorer TM Software vision v3.6 connected 
to MASCOT server v.2.1. CHCA matrix (5 mg/ml) in 60% Acn/0.1% TFA or DHB matrix 
(5 mg/ml) in 30% Acn/0.1% TFA and 1% phosphoric acid were used as MALDI matrices. 
Phosphoric acid was used as a matrix additive to improve phosphopeptides mass resolution 
(310).  
UV-VIS chromatography: Peptides were separated by reversed phase 
chromatography using Dionex Ultimate 3000. Peptides were loaded in solvent A (2% Acn, 
0.1% TFA) onto a capillary column (C18 PepMap RSLC, 2 µm, 100 Å, 0.075 × 150 mm) 
followed by 115-min multi-step gradient to 95% solvent B (80% Acn, 0.1% TFA) and 
detected using Dionex Ultimate 3000 Variable Wavelength detector. 
RPLC-ESI-MS/MS analysis of the complex samples (HeLa cells lysate, SILAC 
labelled irradiated MOLT-4 cells) was performed on Thermo Scientific Dionex Ultimate™ 
3000 RSLCnano system coupled through Nanospray Flex ion source with Q Exactive mass 
spectrometer. TiO2-enriched peptide sample was dissolved in 20 μl of 2% Acn/0.05% TFA 
and 3-8 μl according to estimated peptide sample concentration were injected into 
RSLCnano system. Peptides were loaded on capillary trap column (C18 PepMap100, 3 µm, 
100 Å, 0.075 × 20 mm) by 2% Acn/0.05% TFA mobile phase at flow rate 5 µL/min for 5 
min and then eluted and separated on capillary column (C18 PepMap RSLC, 2 µm, 100 Å, 
0.075 × 150 mm). Elution was carried out by step linear gradient of mobile phase B (80% 
Acn/0.1% FA) over mobile phase A (0.1% FA); from 4% to 36% B in 19 min and 
from 36% to 55% B in 6 min at flow rate 300 nl/min. Temperature of the column was 40 




kV and heated capillary temperature was 220 °C. The mass spectrometer was operated 
in the positive ion mode performing survey MS (range 300 to 1800 m/z) and data-
dependent MS/MS scans performed on the six most intense precursors with dynamic 
exclusion window of 40 s. MS scans were acquired with 70,000 resolutions at 200 m/z 
from 1 × 106 accumulated charges (maximum fill time was 100 ms). The lock mass at m/z 
445.12003 ([(C2H6SiO)6 + H]
+) was used for internal calibration of mass spectra. Intensity 
threshold for triggering MS/MS was set at 1 × 105 for ions with z ≥ 2 with a 3 Da isolation 
window. Precursor ions were accumulated with AGC of 1 × 105 (maximum fill time was 
100 ms) and normalized collisional energy for HCD fragmentation was 27 units. MS/MS 
spectra were acquired with 17,500 resolution (at 200 m/z). Raw files were processed 





3.3. Radiosensitization of MOLT-4 cells 
3.3.1.  Cell culture and cell culture conditions 
MOLT-4 cells were cultured in IMDM containing 20% foetal bovine serum, 2 mM 
glutamine, 100 UI/mL penicillin, and 0.1 mg/mL streptomycin at 37 °C under controlled 
5% CO2 and humidified atmosphere. The cultures were split every other day by dilution 
to a concentration of 2x105 cells/ml. Cell counts were assessed by a haemocytometer, and 
cell membrane integrity was assessed by the Trypan Blue exclusion technique.  
For the quantitative proteomic and phosphoproteomic experiments, MOLT-4 cells 
well cultured in IMDM for SILAC containing 20% dialyzed foetal bovine serum. Media 
were further supplemented with either unlabelled L-lysine (100 mg/l, K0) and L-arginine 
(84 mg/L, R0) or equimolar amounts of L-13C6-lysine (K6) and L-
13C6-arginine (R6). 
L-proline (300 mg/L) was added to cell culture media avoid metabolic conversion 
of arginine to proline (272). For complete incorporation of labelled amino acids, cells were 
cultured for more than six cell doublings, usually 10 (308). 
3.3.2.  Cell treatment (kinase inhibition and gamma-
irradiation) 
A selective inhibitor of ATR kinase, 3-amino-6-(4-(methylsulfonyl)phenyl)-N-
phenylpyrazine-2-carboxamide (VE-821), and a selective inhibitor of ATM kinase, 
2-morpholin-4-yl-6-thianthrene-1-yl-pyran-4-one (KU55933), were dissolved in dimethyl 
sulfoxide (DMSO) to a concentration of 10 mM, and the aliquots were stored at −20 °C. 
Additional dilutions (1 mM, 2 mM, 5 mM, and inhibitor combinations as indicated) were 
also prepared in DMSO to maintain the same concentration of DMSO in all inhibitor-
treated samples. In all experiments presented in this study, the inhibitors were added to cell 
culture 30 minutes prior to gamma irradiation. The inhibitors were washed out after one 
hour or 24 hours when indicated. Cells were irradiated using a 60Co gamma-ray source 
with a dose rate of 0.5-0.45 Gy/min. Since MOLT-4 cells are relatively sensitive to gamma 
irradiation, the doses of irradiation were carefully chosen based on our previous 




3.3.3. Electrophoresis and western blotting 
Cells were pre-treated by different concentrations of inhibitors or DMSO (control) 
and irradiated by an indicated dose of IR. One or six hours after irradiation, cells were 
washed with cold phosphate buffer saline (PBS), and whole cell extracts were prepared 
by lysis in 500 µL of lysis buffer per 1x107 cells (137 mM NaCl; 10% glycerol; 50 mM 
NaF; 20 mM Tris-HCl, pH = 8; 1% n-octyl-β-glucopyranoside; 1 tablet of protease 
inhibitors Complete™ Mini/ 10 ml, 1:100 Phosphatase inhibitor cocktail 2 and 3). The 
lysate was clarified by centrifugation, and protein concentration was measured by a 
bicinchoninic acid protein assay. The lysates containing equal amount of protein (30 µg) 
were loaded onto a 12% SDS polyacrylamide gel. After electrophoresis, proteins were 
transferred to a polyvinylidene difluoride membrane and hybridized with an appropriate 
antibody: anti-Chk1 (1:500), anti-phospho-Chk1 (Ser345, 1:500), anti-Chk2 (1:250), anti-
phospho-Chk2 (Thr68, 1: 250), anti-p70s6k (1:1000), anti-phospho p70s6k (Thr389; 
1:1000) and beta actin (1: 20,000). After washing, the membranes were incubated 
with secondary peroxidase-conjugated antibody, and the signal was developed using a BM 
Chemiluminescence Western Blotting Kit. 
3.3.4. Cell proliferation/viability WST-1 assay 
Proliferation of MOLT-4 cells was evaluated by WST-1 (4-[3-(4-iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulphonate) colorimetric assay (Roche 
Diagnostics, Mannheim, Germany). The assay is based on cleavage of WST-1 
by mitochondrial dehydrogenases, and the absorbance of the cleavage product correlates 
with the number of viable cells. Prior to treatment, MOLT-4 cells were placed in 96-well 
microplates; the number of cells plated into each well were 3x104, 1x104, and 2.5x103 
for 24, 72, and 144 hours long experiments, respectively. After the addition of inhibitors 
and subsequent irradiation, the microplates were placed in an incubator and cultivated at 37 
°C. Finally, WST-1 was added, and the plates were incubated for three hours at 37 °C. 
Absorbance of samples was then measured at 440 nm using a PARADIGM™ Detection 
Platform. Controls were normalized to 100 % for each assay, and all values were expressed 




3.3.5. Cell cycle analysis and apoptosis detection by flow 
cytometry  
 For cell cycle analysis, cells were collected 24 hours after irradiation by a dose of 3 
Gy (± inhibitor pre-treatment), washed with ice-cold PBS, and fixed with ice-cold 70% 
ethanol. Prior to flow cytometry, cells were washed with ice-cold PBS, and DNA was 
stained using Vindelov’s solution (10 mM Tris-HCl pH=7.6, 0.6 mg/ml NaCl, 0.01 mg/ml 
Ribonuclease A, 0.05 mg/ml PI).  
For apoptosis detection, an Apoptest-FITC kit was used. The kit contains Annexin 
V, which binds to phosphatidylserine at the surface of apoptotic cells, and PI to detect cells 
with increased cell membrane permeability. Cells were pre-treated by the inhibitors and 
irradiated by a dose of 1 Gy. The proportion of apoptotic cells in each condition was 
measured 24 hours and 72 hours after IR according to the manufacturer’s instructions.  
Flow cytometric analysis was performed on a FACS analyser CyAn 
DakoCytomation. At least 20,000 cells were analysed per sample. Listmode data were 
analysed using Summit v4.3 software.  
3.3.6. Sample preparation for quantitative proteomic and 
phosphoproteomic experiment 
MOLT-4 cells well cultured in IMDM for stable SILAC containing 20 % 
of dialyzed foetal calf serum for at least six cell doublings as described above (308). Thirty 
minutes before irradiation, VE-821 was added to the “heavy” cells (K6/R6) at a 
concentration of 10 μM; the “light” cells (K0/R0) were mock treated with DMSO, whose 
final concentration in culture was lower than 0.1 %. Both groups were irradiated using a 
60Co gamma-ray source by a dose of 1.5 Gy. After irradiation, the flasks were placed into 
an incubator. Three biological replicates were analysed. 
One hour after irradiation, the cells were washed with ice-cold PBS and lysed as 
was published (314) with minor modifications. Briefly, the cells were thoroughly 
resuspended in 2 ml ice-cold lysis buffer/1x107 cells (50 mM ammonium bicarbonate, 1% 
sodium deoxycholate, 1:100 Phosphatase inhibitor cocktail 2 and 3). The lysate was 
immediately placed into boiling water bath, and after 5 min incubation, the samples were 
cooled down to room temperature on ice. To cleave nucleic acids and decrease the viscosity 




samples. The lysate was then clarified by centrifugation at 14,000 rpm, and protein 
concentration was measured by bicinchoninic acid assay. Sample volumes corresponding 
to 2 mg of “light” proteins and 2 mg of “heavy” proteins were pooled together to make a 
1:1 protein sample.  
The protein samples for phosphoproteomic analyses were diluted in lysis buffer and 
reduced with 10 mM DTT, alkylated with 20 mM IAA, and digested O/N with trypsin at an 
enzyme-to-substrate ratio of 1:60 (sequence grade modified trypsin). Sodium deoxycholate 
was then extracted by ethyl acetate as described earlier (315); tryptic peptides were desalted 
via 500 mg Supelco C18 SPE cartridges according to the manufacturer’s instructions and 
dried using SpeedVac. 
Sample preparation for the proteome analysis followed the protocol described 
above with minor modifications to adjust the volume and concentration of chemicals to a 
smaller sample amount (10+10 μg of the “heavy” and “light” samples).  
3.3.7. Hydrophilic interaction liquid chromatography 
fractionation 
Dried peptide samples were fractionated by HILIC according to a protocol that has 
been published previously (198) using the 4.6 × 25 cm TSKgel® Amide-80 HR 5 μm 
particle column with the TSKgel® Amide-80 HR 5 μm 4.6 × 1 cm guard column operated 
with Waters Separations Module 2695 at 0.5 mL/min. Briefly, 3.5 mg of evaporated 
samples were reconstituted in 80% B and loaded onto the HILIC column. Peptides were 
then separated by a gradient of A over B from 80% to 60% B in 40 min and from 60% 
to 0% B in 5 min. Across the gradient, 22 fractions were collected (2 × 2 and 20 × 1 mL) 
from each replicate. Mobile phase B consisted of 98% Acn/0.1% TFA; mobile phase A 
consisted of 2% Acn/0.1% TFA.  
3.3.8. Phosphopeptide enrichment 
Each HILIC fraction was enriched for phosphopeptides using titanium dioxide 
chromatography (222) using a protocol optimized in previous experiments. At first, each 
fraction was supplemented with TFA and glutamic acid to reach final concentrations of 2% 
TFA and 100 mM glutamic acid. Titanium dioxide particles (Titansphere® 5 μm particles) 
were suspended in loading solution (65% Acn, 2% TFA, 100 mM glutamic acid), and a 




and phosphopeptides in a particular fraction (based on previous experiments) was added 
to each sample. Microparticles with bound phosphopeptides were washed with 200 μl 
of loading solution, 200 μl of washing solution 1 (65% Acn/0.5% TFA), 200 μl of washing 
solution 2 (65% Acn/ 0.1% TFA) and 100 μl of washing solution 2. Phosphopetides were 
eluted by 150 μl of elution solution (20% Acn/NH4OH, pH 11.5) in two sequential 
elutions. Late fractions were subjected to the second enrichment. Eluates from the first and 
second enrichment were pooled together, acidified with 100% formic acid, and placed in a 
SpeedVac until all crystals of ammonium formate were evaporated.  
3.3.9. Mass spectrometric analysis 
LC-MS/MS analyses were performed on Thermo Scientific Dionex Ultimate™ 
3000 RSLCnano system (Thermo Scientific, Bremen, Germany) coupled through 
Nanospray Flex ion source with Q Exactive mass spectrometer (Thermo Scientific, 
Bremen, Germany). TiO2-enriched HILIC fractions were dissolved in 18 μl of 2% 
Acn/0.05% TFA and 3-8 μl according to estimated peptide sample concentration were 
injected into RSLCnano system. Peptides were loaded on capillary trap column (C18 
PepMap100, 3 µm, 100 Å, 0.075 × 20 mm) by 2% Acn/0.05% TFA mobile phase at flow 
rate 5 µL/min for 5 min and then eluted and separated on capillary column (C18 PepMap 
RSLC, 2 µm, 100 Å, 0.075 × 150 mm). Elution was performed by step linear gradient 
of mobile phase B (80% Acn/0.1% FA) over mobile phase A (0.1% FA) from 4% to 34% 
B in 48 min and from 34% to 55% B in 15 min at a flow rate 300 nl/min. Temperature 
of the column was 40 °C and eluent was monitored at 215 nm during the separation. 
Spraying voltage was 1.7 kV and heated capillary temperature was 250 °C. The mass 
spectrometer was operated in the positive ion mode performing survey MS (range 300 
to 1800 m/z) and data-dependent MS/MS scans performed on the six most intense 
precursors with dynamic exclusion window of 40 s. MS scans were acquired with 70,000 
resolutions at 200 m/z from 1 × 106 accumulated charges (maximum fill time was 100 ms). 
Intensity threshold for triggering MS/MS was set at 5 × 104 for ions with z ≥ 2 with a 1.6 
Da isolation window. Precursor ions were accumulated with AGC of 1 × 105 (maximum 
fill time was 100 ms) and normalized collisional energy for HCD fragmentation was 27 




3.3.10. Mass spectrometry data processing and bioinformatic 
analysis 
3.3.10.1. Raw data processing 
Raw data files acquired by LC-MS/MS were processed with MaxQuant v1.5.2.8 
(316). Peak lists were searched against the human SwissProt database (November 2015) 
using Andromeda search engine (317). Minimum peptide length was set to seven amino 
acids, and two missed cleavages were allowed. Carbamidomethylation of cysteine was set 
as a fixed modification while oxidation of methionine, protein N-terminal acetylation, and 
phosphorylation of serine, threonine, and tyrosine residues were used as variable 
modifications. Additionally, appropriate SILAC labels were selected (R6, K6), and the 
labelled amino acid filtering was disabled. Mass tolerances of 10 and 20 ppm were allowed 
for MS and MS2 peaks, respectively. Only proteins, peptides, and phosphorylation sites 
with false discovery rate (FDR) lower than 0.01 were accepted. For modified peptides, a 
minimal score (40) and minimal delta score (6) were set as additional cut-offs. For protein 
quantification, only unmodified peptides, peptides oxidized at methionine residues, or 
acetylated at N-terminus were accepted; both razor and unique peptides were used 
for calculation of protein H/L ratios. The Re-quantify function was disabled whereas Match 
between runs was enabled during the search.  
3.3.10.2. MaxQuant output data filtering and identification of significantly changed 
phosphorylation sites 
Potential contaminants and hits from the reversed database were removed before 
further data processing, and data were further manually inspected to look for possible 
misquantifications caused by the labelling status (K6/R6) and disabled “Filter labelled 
amino acids” option in MaxQuant. Global rank test (GRT) was used to find differentially 
regulated phosphorylation sites. Only phosphorylation sites quantified in all three 
replicates were subjected to GRT, and FDR was estimated non-parametrically as described 
by Zhou et al. (318). The significance cut-off for differentially regulated sites was set 
to FDR < 0.005. 
3.3.10.3. Gene ontology and signalling pathways over-representation analyses 
Gene ontology (GO) and signalling pathways over-representation analyses were 




the GO terms over-representation, proteins containing differentially regulated 
phosphorylation sites (both up- and down-) were tested against a custom background 
reference set comprising all phosphoproteins with at least one quantified phosphorylation 
site that was subjected to GRT (i.e. all phosphoproteins with at least one phosphorylation 
site quantified in all three biological replicates). Statistical significance of the over-
representation analysis was estimated using hypergeometric testing with Benjamini-
Hochberg FDR correction of calculated p-values, and the cut-off was set to FDR < 0.05. 
For the signalling pathways over-representation analysis, phosphoproteins with at least one 
regulated phosphorylation site were mapped to signalling pathways from three different 
databases: KEGG (321,322), REACTOME (323), and PID (324). Pathway-coverage was 
calculated for overrepresented pathways (FDR < 0.05, tested against a default background 
reference set comprising all Uniprot proteins included in at least one signalling pathway 
from a corresponding database).  
3.3.10.4. Network analysis 
Log2 transformed SILAC H/L ratios of phosphorylation sites quantified in all three 
biological replicates were normalized (z-score calculation) and subjected to SubExtractor 
algorithm (325). Human protein-protein interactions with STRING score above 900 were 
used as the second input for the algorithm, and regulated subnetworks were extracted 
(FDR = 0.005, α = 0.2, σ = 4). Extracted networks were visualized using Cytoscape v3.2.1 
(326).  
3.3.10.5. Sequence motif analyses 
To analyse and visualize sequence motifs surrounding phosphorylation sites 
identified and quantified in our study, we employed iceLogo tool (327) and motif-x 
algorithm (328). In both motif analyses, amino acid sequences (± 7 residues) surrounding 
either significantly up- or down-regulated phosphorylation sites were tested against a 
background reference set composed of sequences surrounding non-regulated 
phosphorylation sites detected in our study (as evaluated using GRT) that reached a 
minimal localization probability of 0.75 (i.e., “class I phosphosites” (273)). Motif-x was 
employed to extract significantly enriched linear motifs. Search parameters were set 
to at least 10 occurrences of a motif, and the significance level to p < 0.00003 (which 





3.3.10.6. Identification of protein kinases responsible for the observed protein 
phosphorylations and evaluation of global changes in their activities 
Class I phosphorylation sites quantified in all three biological replicates were 
annotated with previously known kinase-substrate relationships downloaded from the 
PhosphoSitePlus database (58). To increase the number of annotated phosphorylation sites, 
two kinase predictors were employed: NetworKIN 3 (329) and iGPS v1.0 (330). Both 
predictors combine motif scoring with contextual information (i.e. protein-protein 
interaction scoring downloaded from the STRING database (331)). The kinase predictions 
were further filtered to reach NetworKIN score > 3 or “medium” significance threshold 
in iGPS (i.e. FDR of 6 % for S/T kinases and FDR of 9 % for Y kinases). The significance 
of global changes in kinase activities were evaluated using “1D annotation enrichment” 
tool available in Perseus software v1.5.2.6 (332).  
To further facilitate the interpretation of the results we also downloaded the 
“Regulatory sites” dataset from the PhosphoSitePlus database, which summarizes the 
current up-to-date knowledge about the known functions of specific phosphorylation sites. 
In text, these sites are referred as “regulatory” sites. 
3.3.11. Targeted metabolomic analysis 
3.3.11.1. Sample preparation  
For the quantitative targeted metabolomic analysis, MOLT-4 cells were pre-treated 
either by VE-821 (10 μM) or DMSO (control groups) 30 minutes prior to IR (1.5 Gy). Six 
and twelve hours after irradiation, the cells were counted using a haemocytometer, and a 
cell suspension volume containing 2x106 of cells was pipetted into five sample volumes 
of a pre-cooled (-40 °C) quenching solution (60% methanol, 0.85% ABC, pH 7.4) as 
described previously (333). The samples were gently mixed, and the cells were pelleted 
by centrifugation (1,000 g, 3 minutes). After the centrifugation, supernatant was removed, 
and the cells were resuspended in 150 μl of pre-cooled (-80 °C) methanol, transferred to a 
lyophilisation vial, and lyophilised. Three replicates were prepared for each condition. The 
lyophilisates were dissolved in 100 µl of 80% methanol and centrifuged (14,000 g for 10 
min); a small volume of the sample (10 µl) was collected for quality control (QC) sample 




QC sample was prepared by pooling equal volumes of cell extract sample. QC was 
analysed randomly throughout the run to provide a measurement not only of the system’s 
stability and performance but also of the reproducibility of the sample preparation. 
3.3.11.2. Instrumentation 
The metabolite profiling of cell extracts and the QC samples performed by high-
performance liquid chromatography tandem mass spectrometry enabled the analysis of 354 
intermediary metabolites (acylcarnitines, amino acids, organic acids, saccharides, etc.). 
For separation, an LC system UltiMate 3000 RS (Dionex, Sunnyvale, CA, USA) 
was used. The separation was performed with a LUNA NH2 column 3.0 µm, 2 x 100 mm, 
protected by a guard column, 4 x 2 mm ID, of the same material (Phenomenex, Torrance, 
USA) in normal aqueous phase mode. Mobile phase A consisted of 20 mM ammonium 
acetate at pH 9.75, and mobile phase B consisted of Acn. The gradient program was set as 
follows: 0-7 min: 95% → 10% B; 7-13 min: 10% B; 13-14 min: 10% → 95% B; 14-17 
min: 95% B. The column was maintained at 35 °C, and the flow rate was 0.3 ml/min. 
Detection was performed using a Triple Quad 6500 tandem mass spectrometer (AB Sciex, 
Foster City, CA, USA) fitted with electrospray ionisation in both positive and negative 
mode. To enhance sensitivity, the targeted metabolites were scanned in scheduled multiple 
reaction monitoring mode with prolonged dwell times. Both quadrupoles were set at unit 
resolution. The parameters of the IonDriveTM Turbo V source and gases were as follows: 
curtain gas, 40 psi; collision gas, 8 psi; ion spray voltages, 5500 V/- 4500 V; both ion source 
gases, 40 psi and source temperature, 400 °C. Compound parameters such as the 
declustering potential, entrance potential, collision energy, and collision cell exit potential 
were previously optimized to standards. The instrument was controlled using the Analyst 
v1.6.2 software. 
3.3.11.3. Data processing 
The analytes were detected and identified according to the multiple reaction 
monitoring transitions and retention times in the MultiQuant v3.0 software (AB Sciex, 
Foster City, CA, USA). The peak areas were extracted, and the corresponding peak areas 




3.3.11.4. Data treatment and statistical analysis 
The data were treated and statistically processed in the R program language v3.1.2 
using basic statistical packages (e.g. Biobase, stats, graphics; (334)), the special packages 
XCMS (335–337) and robCompositions (338). The quality control-based robust local 
regression signal correction method was applied to the data (339). The coefficients 
of variation (CV) of the quality control samples were evaluated and features with a CV 
higher than 30% were excluded from the analysis. Zero values were imputed by two-thirds 
of the minimum metabolite value for the appropriate group of samples. The data were 
analysed as compositional using centred logratio transformation (340) and mean centring. 
The p-value for each metabolite was calculated by means of a t-test, and Bonferroni 
correction was applied. Finally, the data were evaluated by means of unsupervised 
(principal component analysis – PCA) and supervised (orthogonal partial least squares 
discriminant analysis – OPLS-DA) multivariate analysis. For clustering analysis, only 
ANOVA significant (permutation-based FDR < 0.05) metabolites were selected and 





4.1. Optimization of metal oxide affinity enrichment 
of phosphopeptides from a standard tryptic peptide 
mixture 
4.1.1. Summary of phosphopeptides detected in the 
optimization experiments 
Commercially available α-casein that we used as the main phosphorylated 
component of our standard peptide mixtures is a mixture of two naturally occurring 
variants, the S1 variant (major component) and the S2 variant (minor component), and the 
preparations are usually contaminated with small amounts of β-casein. The S1 variant has 
nine known phosphorylation sites; the S2 variant has twelve known phosphorylation sites, 
and β-casein has five known phosphorylation sites. Asialofetuin, which we used as the 
second phosphorylated component of our mixture, has six known phosphorylation sites 
previously identified. Phosphopeptides originating from these proteins detected in our 
work are summarized in table 1. In summary, we detected 18 phosphopeptides originating 
from these phosphoproteins; eight of them were detected also in their oxidized form.  





4.1.2. Comparison of enrichment efficiency of different metal 
oxide chromatographic resins 
The evaluation of enrichment efficiency for phosphorylated peptides of different 
chromatographic resins under different buffer conditions was performed by comparing the 
maximal numbers of detected phosphopeptides and repeatability (i.e. repeated detection 
of the same phosphopeptides in three independent experiments).  
Summarized results of the comparison are depicted in figure 4 showing the results 
from the phospho-enrichment of mixture A and B. As shown in the figures, Titansphere® 
particles and NuTips® clearly outperformed the TopTips®. All three kinds of TopTips® 
tested in our experiments provided lower number of detected phosphopeptides than 
Titansphere® particles and NuTips® columns.  
The addition of three different displacers of nonphosphorylated peptides improved 
the enrichment efficiency of TopTips®, but the obtained results were still not fully 
comparable with the NuTips® and Titansphere® enrichment. Whereas the maximal 
numbers of phosphopeptides detected after the phosphoenrichment from mixture A 
by NuTips® and Titansphere® particles ranged between 15 and 17 under the most 
phospho-efficient buffer conditions, TopTips® enrichment led to the detection of only 9 
phosphopeptides under the best buffer/resin conditions. The same trend was observed in the 
enrichment of phosphopeptides from the mixture B. From the three TopTips® 
microcolumns tested, mixed TiO2/ZrO2 TopTips® provided the best enrichment results. 
The most phosphopeptides (17) were detected using NuTips® under the buffer conditions 
4 (figure 6A). 
Figure 5 shows the enrichment efficiency and repeatability for singly- and 
multiply- phosphorylated peptides. While the maximal numbers of mono-phosphorylated 
peptides did not differ substantially when comparing different resins, the only multiply 
phosphorylated peptide detected using TopTips® enrichment was a doubly-phosphorylated 
peptide 1927.69 from α-casein. Other multiply phosphorylated peptides were not detected. 
On the other hand, using NuTips® and Titansphere® particles, we detected several 
multiphosphorylated peptides (with up to 5 modifications; see table 1). Interestingly, 350 
mg/ml DHB had a negative impact on the enrichment of monophosphorylated peptides 
in NuTips® and Titansphere® enrichment. Additionally, in the case of NuTips®, the 
addition of DHB caused a high level of noise in the low m/z region of MALDI-TOF spectra 




Figure 4: Comparison of enrichment efficiency (average number of detected phosphopeptides 
with standard deviation and total sum of phosphopeptides obtained in 3 enrichments) and 
repeatability (number of phosphopeptides repeatedly detected in each of 3 enrichments) of 
phosphopeptide enrichment from peptide mixture A (A) and B (B) using different media and 





Figure 5: Comparison of efficiency (total sum of phosphopeptides obtained in 3 
enrichments) and repeatability (number of phosphopeptides repeatedly detected in each 
of 3 enrichments) of mono-phosphorylated peptides (A) and multiply phosphorylated 
peptides (B) enrichment using different media and applied protocols (see Methods) 






Figure 6: Representative MALDI-TOF MS spectra of peptides obtained by the enrichment 
of phosphopeptides from the peptide mixture A (A) and B (B) using NuTips® under buffer 
conditions 4 (using 65% Acn, 2% TFA and 0.1 M glutamic acid as loading buffer). (C) 
Representative MALDI-TOF MS spectra of peptides obtained by the enrichment 
of phosphopeptides from the peptide mixture B using NuTips® under buffer conditions 3 
(using 65% Acn, 2% TFA and 350 mg/ml DHB as loading buffer). Phosphopeptides are 





4.1.3. Evaluation of binding selectivity for phosphorylated 
peptides under different buffer conditions 
The binding selectivity for phosphorylated peptides was evaluated by comparing 
relative intensities of phosphorylated peptides with those of nonphosphorylated peptides 
in spectra recorded by MALDI-TOF mass spectrometry. The two most intensive 
nonphosphorylated peptides in the representative spectra shown in figure 7 were 1749.66 
(ECCHGDLLECADDR) and 2458.18 (DAIPENLPPLTADFAEDKDVCK) from BSA. 
These two peptides were the most intensive signals originating from nonphosphorylated 
peptides in most of the experiments; therefore, their presence in the spectra served as an 
indicator of enrichment selectivity of a particular resin under particular buffer conditions. 
As shown in the spectra, the intensity of these two unmodified peptides decreased in the 
following order: 5% TFA < 1 M LA < 0.1 M Glu < 350 mg/ml DHB, and thus the 
phosphoenrichment was the most selective when DHB was added into the loading buffer. 
The spectra presented in figure 7 were obtained by analysing the enriched fraction from the 
Titansphere® enrichment; however, the same trend was observed for all chromatographic 
materials tested. The binding selectivity of NuTips® was comparable to the selectivity 
of Titansphere® beads. On the other hand, the spectra resulting from TopTips® enrichment 
of mixture B usually contained high level of nonspecifically bound peptides even under the 






Figure 7: Representative MALDI-TOF MS spectra of peptides obtained by the enrichment 
of phosphopeptides from both peptide mixtures using Titansphere® under indicated buffer 
conditions. Phosphopeptides are marked by arrows. The two most intensive non-
phosphorylated peptides in the spectrum- m/z 1749.66 and m/z 2458.18 from BSA are 






Figure 8: Representative MALDI-TOF MS spectra of peptides obtained by the enrichment 
of phosphopeptides from both peptide mixtures using TopTips® under buffer conditions 4. 
Phosphopeptides are indicated by arrows. TT Ti – TopTips® TiO2, TT Zr – TopTips® ZrO2, 






Figure 9: Comparison of UV-VIS chromatograms obtained after application 
of Titansphere® (panel A) and NuTips® (panel B) along with glutamic acid protocol 
on the “real “- complex samples for enrichment of phosphopeptides from whole-cell lysate 
of HeLa cells. Peptides were separated by reversed phase chromatography using Dionex 
Ultimate 3000 (Thermo Scientific). Peptides were loaded in solvent A (2% Acn, 0.1% TFA) 
followed by 115-min multi-step gradient to 95% solvent B (80% Acn, 0.1% TFA) and 





4.1.4. Application of the two best performing protocols to a real 
sample analysis 
The two best performing protocols were tested in a real complex sample analysis. 
The samples were prepared by digesting 1 mg of HeLa cells lysate using trypsin and 
enriched for phosphopeptides using either NuTips® or Titansphere® particles under buffer 
conditions 4.  
The amount of material in the enriched fractions was estimated using UV-VIS 
chromatography (figure 9). We repeatedly observed that NuTips® were not an adequate 
enrichment media for such a high amount of a complex mixture since the amount 
of material in the eluates was extremely low in comparison to the fractions originating 
from Titansphere® enrichment. Finally, the eluate from Titansphere® particles was 
analysed using RPLC-ESI-MS/MS system, which yielded 898 phosphopeptides passing the 
0.01 false discovery rate cut-off after processing the raw data with MaxQuant. 
4.1.5. Application of the selected protocol to study 
phosphorylation response of irradiated MOLT-4 cells  
A pilot quantitative (SILAC) phosphoproteomic study was performed to evaluate 
the performance of the chosen protocol (i.e. Titansphere® beads under buffer conditions 4) 
in the system of interest (i.e. irradiated MOLT-4 cells). The LC-MS/MS analysis of the 
enriched sample led to identification of 632 phosphorylation sites from 489 peptides 
originating from 335 phosphoproteins. 429 class I sites (localization probability > 0.75) 
were successfully quantified. Among them, 31 sites were upregulated and 32 were 
downregulated one hour after the irradiation by a dose of 1.5 Gy (1.5-fold change). More 






4.2. Radiosensitization of MOLT-4 cells by selective 
ATR and ATM inhibitors VE-821 and KU55933 
4.2.1.  Proliferation/ Viability assays 
Two different proliferation assays were employed to assess the effect of specific 
inhibition of ATM and ATR on proliferation of MOLT-4 cells: WST-1 assay and viable 
cell counting using Trypan Blue exclusion technique. 
4.2.1.1. Single-inhibitor treatment 
A potent and specific inhibitor of ATM by KU55933 was well tolerated 
in concentrations up to 10 µM even when the inhibitor was present in the cell culture media 
for 7 days (figure 10A-G). Unexpectedly, 5 µM KU55933 significantly increased viability 
of MOLT-4 cells in both assays. On the other hand, inhibitor of ATR, VE-821, repeatedly 
inhibited the growth and viability of MOLT-4 cells in a dose dependent manner already 
at lower concentrations than KU55933 (figure 10D-G); a significant growth inhibition was 
achieved by application of 1 µM VE-821 when detected after six days of treatment using 
WST proliferation assay.  
4.2.1.2. Inhibitor combinations and combinations with ionizing radiation 
In WST-1 assays, the irradiation of MOLT-4 cells by a dose of 1 Gy led to growth 
inhibition which resulted in markedly decreased number of viable (metabolically active) 
cells 72 and 144 hours after irradiation (figure 11A-C). The addition of VE-821 in both 1 
µM and 2 µM concentrations further significantly enhanced the antiproliferative effect 
of IR – the number of viable cells was below the limit of detection of the assay in the case 
of VE-821 2 µM and IR combination. Consistently with the single-inhibitor proliferation 
assays, lower concentrations of KU55933 (up to 5 µM) showed a positive effect on cellular 
proliferation, and moreover, they increased the number of viable cells in combination 
with irradiation. Notably, when applied in combination, KU55933 also diminished the 





Figure 10: Characterization of VE-821 and KU55933 treatment effects on proliferation 
of MOLT-4 cells. (A, B, C) Effects of different KU55933 concentrations. Number of viable 
cells and viability (defined as number of viable cells/total number of cells) were assessed 
by a haemocytometer using trypan blue exclusion technique 1, 4, and 7 days after the 
addition of the inhibitor with subsequent dilution to a concentration of 2x105 cells/ml. 
Mean values ± SD from three measurements are presented. (D, E, F) Effects of different 
KU55933 and VE-821 concentrations. Number of viable cells and viability (defined as 
number of viable cells/total number of cells) were assessed by a haemocytometer using 
trypan blue exclusion technique 1, 3, and 6 days after the addition of the inhibitor 
with subsequent dilution to a concentration of 2x105 cells/ml. Mean values ± SD from three 
measurements are presented. (G) Effect of different KU55933 and VE-821 concentrations. 
Viability was examined by WST-1 assay after 24, 72, and 144 hours of continuous inhibitor 
treatment. Data are expressed as percentage of viability of controls for each time interval. 






Additionally, in a cell counting-based proliferation assay, VE-821 significantly 
sensitized cells to IR in 2 μM and 10 μM concentrations even when the inhibitor was 
present in cell culture media only transiently, for the first 24 hours of the treatment (figure 
11D). In contrast to continuous treatment, VE-821 2 μM did not significantly affect the 
proliferation of sham-irradiated cells when washed out after 24 hours; however, it still 
increased the sensitivity of cells to ionizing radiation (1.5 Gy).  
 
 
Figure 11: Radio-sensitization of MOLT-4 cells using ATM and ATR inhibitors. Cells 
were irradiated by the indicated dose. Viability (proportional to number of metabolically 
active cells) was examined by WST-1 assay after 72 hours (A) and 144 hours (B) 
of continuous inhibitor treatment. (C) Table shows an irradiated group/sham-irradiated 
group ratio for each treatment condition depicted in figures C and D. (D) VE-821/DMSO 
were washed out 24 hours after irradiation and the number of viable cells was assessed 
by a haemocytometer 2, 5, and 8 days after irradiation with subsequent dilution to a 
concentration of 2x105 cells/ml. Mean values ± SD from five measurements are presented. 
In (A-D), * indicates statistical significance (p < 0.01) of comparison to non-irradiated 
control; # indicates statistical significance (p < 0.01) of comparison to irradiated control 
group. P-values were calculated using two-sided t-test. In all experiments, the cells were 
pre-treated with inhibitors at indicated concentrations or DMSO in control groups (C) 30 




4.2.2.  Immunoblotting-based detection of ATM and ATR 
activation and inhibition 
To detect activation of both ATM and ATR kinases upon irradiation and their 
specific inhibition by VE-821 and KU55933 pre-treatment, Chk1 Ser 345 and Chk2 Thr 68 
phosphorylation was assessed using immunoblotting one hour after 3 Gy of IR (figure 12). 
Chk2 Thr 68 phosphorylation (marker of activated ATM) was not detected in sham-
irradiated cells; however, it was strongly induced by irradiation. The treatment 
with KU55933 markedly decreased Chk2 phosphorylation in irradiated cells. Chk1 Ser 
345 phosphorylation (marker of activated ATR) was also detected in sham-irradiated cells, 
and upon irradiation, it was slightly upregulated. VE-821 abrogated this phosphorylation 
in a concentration dependent manner. Neither of both inhibitors influenced the expression 
level of Chk1 or Chk2 under given treatment conditions. 
 
Figure 12: Effect of KU55933 and VE-821 on activation of ATM and ATR kinases 
by gamma-irradiation. Cells were collected 1 hour after IR (3 Gy). Activation of both 
kinases and its suppression in the presence of inhibitors was monitored via the detection 
of their specific phosphorylations targets (Chk2 pT68 and Chk1 pS345, ATM and ATR 
respectively). The expression state of Chk1 and Chk2 was also evaluated. The 
representative blots from three independent experiments are shown. β-actin expression was 
analysed as a loading control. 
4.2.3.  DNA content analysis 
To investigate cell cycle effects of ATM and ATR inhibition, DNA content analysis 
was performed using propidium iodide (PI) staining and flow cytometric detection of PI 
fluorescence. The potential perturbation of the cell cycle by either one of the compounds 




As depicted in Figure 13A and 13B, in sham-irradiated cells, none of the conditions 
induced significant cell cycle perturbation except for VE-821 10 μM, which caused a 
significant increase in number of G1 cells (p < 0.01). The irradiation by a dose of 3 Gy led 
to a significant G2/M arrest in MOLT-4 cells. The pre-incubation with VE-821 in both 
concentrations and its combinations with KU55933 disrupted the IR induced G2/M 
checkpoint. On the other hand, KU55933 further increased the accumulation of cells 
in G2/M.  
4.2.4.  Apoptosis assay 
To assess the impact of different inhibitor concentrations on viability of MOLT-4 
cells and IR induced cell death we applied flow-cytometric detection of nonviable cells 
using the Apoptest-FITC kit. The proportions of cells stained either by Annexin V (early 
apoptosis) or Annexin V and PI (late apoptosis and necrosis) were measured 24 and 72 
hours after irradiation by a dose of 1 Gy. The cells were released into inhibitor-free media 
after 24 hours of treatment.   
As shown in figure 13C and 13E, 10 μM VE-821 significantly affected viability 
of MOLT-4 cells 24 hours after the addition of the treatment and/or irradiation. The effect 
induced by 10 μM VE-821 was comparable to 1 Gy of IR; almost 40 % of PI positive cells 
were detected under both treatment conditions. When combined with IR, VE-821 in both 
concentrations significantly increased the IR-induced cell death. Viability was not 
significantly affected in any of the KU55933- and combination- treated groups. 
72 hours after irradiation, further accumulation of nonviable cells was detected 
in VE-821 treated groups (2 and 10 μM, combination with 10 μM KU55933; figure 13D). 
Both inhibitors and their combinations increased IR-induced cell death. The most 
detrimental effect was observed when cells were treated by VE-821 10 μM and by the 
combination of both inhibitors (10 μM +10 μM). Application of these conditions led 






Figure 13: Flow cytometric analysis of MOLT-4 cells radiosensitization using VE-821 
and KU55933: (A, B) Cell cycle effects of ATM and ATR inhibition in irradiated MOLT-4 
cells: Cell cycle perturbation was examined using propidium iodide staining of DNA 
detected by flow cytometry 24 hours after IR (3 Gy). (A) Data are expressed as relative 
proportion of viable cells in different phases of cell cycle. Mean values ± SD from three 
measurements are presented. (B) Representative histograms for each one of the conditions 
are shown. (C, D, E) Apoptosis induction in ATM and ATR inhibitors treated irradiated 
MOLT-4 cells: Cell death was detected by Annexin V/PI staining 24 (C) and 72 hours (D) 
after IR (1 Gy). Mean values ± SD from three measurements are presented. (E) 
Representative dot plots for each one of the conditions from the first measurement (24 
hours after IR) are shown. Approximately 20 000 cells were analysed in each sample. In 
(A, C, D), * indicates statistical significance (p < 0.01) of comparison to non-irradiated 
control; # indicates statistical significance (p < 0.01) of comparison to irradiated control 
group. P-values were calculated using two-sided t-test. In all experiments, cells were pre-
treated with inhibitors at indicated concentrations or DMSO in control groups (C) 30 





4.3. “Dual-omic” analysis of VE-821 treated MOLT-4 
cells 
To describe cellular mechanisms underlying the VE-821-mediated 
radiosensitization of MOLT-4 cells, we employed high-resolution MS to identify and 
quantify changes in proteome, phosphoproteome, and metabolome of irradiated VE-
821-treated cells (figure 14). The metabolomic analysis was done in collaboration 
with Hana Janečková and David Friedecký from the Laboratory for Inherited Metabolic 
Disorders at the University Hospital Olomouc, who performed HPLC-MS/MS analysis 
of our samples and subsequent data processing including data normalization, statistical 
analysis, and KEGG pathways analysis.  
4.3.1. Proteomic and phosphoproteomic analysis of VE-821 
treated MOLT-4 cells 
The quantification on both proteome and phosphoproteome levels was based 
on stable isotope labelling in cell culture ((270)). To specifically enrich for peptides 
modified by phosphorylation, desalted tryptic peptide samples were fractionated using 
hydrophilic interaction liquid chromatography followed by phosphopeptide enrichment 
using titanium dioxide chromatography (222), RPLC-MS/MS detection, and peptide 
identification and quantification using MaxQuant v.1.5.2.8 (316) (figure 14B; figure 14E 
provides details on HILIC separation of phosphorylated peptides and enrichment efficacy 
over the fractions). 
In summary, on a site false discovery rate level of 0.01, we identified 9285 
phosphorylation sites from 3090 protein groups, among them 4504 were quantified in all 
three biological replicates (nearly 63 % of the data set). The phosphosite ratios correlated 
very strongly between the replicates (Pearson correlation coefficient was between 0.8 and 
0.9, figure 15C). Only those sites quantified in all replicates were subjected to a non-
parametric version of a global rank test ((318)) to identify sites with significantly up- or 
down- regulated phosphorylation consistently regulated in all three biological replicates. In 
GRT, we identified 623 regulated phosphorylation sites (455 phosphoproteins); most 





Figure 14: Identification and quantification of the VE-821-regulated phosphoproteome 
and metabolome in irradiated MOLT-4 cells using tandem mass spectrometry: (A) 
Overview of time intervals used for both phosphoproteomic and metabolomic analyses 
of VE-821 perturbed cellular response to ionizing radiation (IR). (B) Overview 
of experimental design and workflow used for quantitative SILAC-based 
phosphoproteomics. (C) Summary of the identified and quantified phosphoproteome. (D) 
Overview of experimental design and workflow used for targeted metabolomics screening. 
(E) Distribution of phosphorylated peptides over the HILIC gradient. Numbers and 
percentage of non-, singly-, doubly-, and triply- phosphorylated peptides in each 





The analysis of the whole proteome samples prepared using the same treatment and 
time interval resulted in quantification of the unmodified fraction of the proteome 
(phosphorylated peptides were not considered for proteome quantification). The analysis 
confirmed our expectations that there would be no significant changes of proteome one 
hour after irradiation combined with VE-821 treatment. As depicted in figure 15A, the 
distribution of normalized log2 SILAC H/L ratios corresponding to quantification 
of unmodified proteins was very narrow, with most values distributed close to zero. 
Moreover, Pearson correlation between the replicates was weak (R 0.24 – 0.387; figure 
15B), which is more likely caused by non-existing trends in an unperturbed system rather 
than by an irreproducibility of the analysis.  
Pearson correlation between normalized log2 SILAC H/L ratios of phosphopeptides 
and log2 normalized SILAC H/L ratios of corresponding proteins was also calculated (the 
calculation was based on 2738 phosphorylation sites which represent almost 30 % of the 
data set), and the low correlation coefficient value (R was -0.013) further confirmed that 
the observed changes on the phosphoproteome level were not dependent on changes of the 
abundance of corresponding proteins (figure 15A).  
The nature of further data analyses implementing multiple bioinformatic tools and 





Figure 15: Comparison and correlation of changes on proteome and phosphoproteome 
level, and their quantitative reproducibility. (A) Violin plots depict log2 transformed 
SILAC H/L ratios distribution in all proteome and phosphoproteome biological replicates. 
(B) Pearson correlation between phosphosite and protein ratios. H/L ratios of 2738 
phosphorylation sites (29 % percent of the identified phosphorylation sites) were plotted 
against H/L ratios of corresponding proteins and the Pearson correlation value (R) was 






4.3.2. Targeted metabolomic analysis of VE-821 treated 
MOLT-4 cells 
Metabolite profiling was performed by a label-free targeted analysis of cellular 
extracts collected 6 and 12 hours after the treatment starting point (figure 14A). A method 
combining high-performance liquid chromatography using aminopropyl stationary phase 
and detection of the metabolites by Triple Quad 6500 tandem mass spectrometer enabled a 
quantitative analysis of 206 intermediary metabolites (figure 14D).  
Hierarchical clustering (figure 17A) and multivariate analyses such as principal 
component analysis (PCA; figure 16A), PLS discriminant analysis (PLS-DA; figure 16B), 
and orthogonal PLS discriminant analysis (OPLS-DA; figure 16C) revealed that both 
treatment groups were clearly separated from each other based on the measured 
quantitative values for the metabolites. Based on sample localization in PCA and PLS-DA 
score plot (figure 16A and 16B), it is obvious that the inhibitor had a more significant 
impact on the group clustering than the incubation time. An overlap of QC samples in the 
PCA score plot showed the repeatability of the measurements (figure 16A).  
Further clustering analysis of ANOVA significant metabolites (126 metabolites 
on 5% permutation-based FDR level) revealed three main clusters showing distinct 
behaviour across the four conditions measured (figure 17):  
 Upregulated in VE-821 treated groups and showing an increasing trend between 
the time intervals in both groups (figure 17B; cluster 1): this group comprised 
metabolites that were accumulated over time in both groups; the inhibitor 
potentiated the effect of IR. Lactate is an example of a metabolite belonging 
to this cluster (figure 17C).  
 Upregulated in VE-821 treated groups with no significant trend between the two 
time intervals (figure 17B; cluster 2): this group comprised metabolites, which 
were altered by VE-821 in irradiated MOLT-4 cells. Glucose (and other hexoses) 
is an example of a metabolite belonging to this cluster (figure 17C). 
 Downregulated in VE-821 treated groups and showing a decreasing trend 
between the time intervals in both groups (figure 17B; cluster 5): this group 
comprises metabolites that were depleted over time in both groups; the inhibitor 
potentiated the effect of IR. ATP is an example of a compound belonging to this 





Figure 16: Targeted metabolomic analysis of VE-821 induced metabolome changes 
in irradiated MOLT-4 cells. Statistical analysis of the results was performed using 
multivariate analyses such as PCA (A), PLS-DA (B), and OPLS-DA (C). DMSO – 
irradiated groups pre-treated with DMSO, VE – irradiated groups pre-treated with 10 µM 
VE-821 
Thus, there were two classes of changes observed in metabolome of irradiated cells 
after VE-821 treatment. First, changes that were observed in both treatment groups and 
showed the same, either decreasing or increasing, trend over time. In such cases, we 
assumed that the inhibitor caused potentiation of metabolism-altering effects of IR. 
Second, changes that showed no trend over time in irradiated control group. We interpreted 
these as alterations in metabolome of irradiated cells caused by VE-821. 
The main significant changes in the metabolome of MOLT-4 cell line occurred 
in group of metabolites involved in cellular antioxidant system; intermediates of glucose 
metabolism and citrate cycle; nucleosides, nucleotides, and deoxynucleotides; free 
amino acids, N-acetylated amino acids, and acylcarnitines. The results will be further 
described and interpreted in the Discussion section in the context of other results obtained 





Figure 17: Hierarchical clustering of significantly changed metabolites: ANOVA 
significant metabolites were clustered (A), and three main row clusters of metabolites were 
identified (B). Examples of metabolites for each cluster are given; distribution 






5.1. Selection of the protocol for phosphopeptide 
enrichment from a standard and a complex 
biological sample 
Since the discovery of the affinity of metal oxides for phosphorylated peptides 
(227), there have been many protocols for a selective phosphopeptide enrichment 
developed. Moreover, there are also many commercial products available that declare high 
selectivity towards phosphorylated peptides and applicability for the enrichment 
of phosphopeptides from complex biological matrices. However, these products are often 
not comparable and might differ in several parameters such as the metal oxide used, the 
amount of chromatographic material (in the case of pre-packed microcolumns), and the 
size and porosity of the chromatographic beads. All of these parameters can affect 
phosphopeptide binding capacity and selectivity.  
To choose the most suitable protocol and chromatographic resin from the plethora 
of protocols and products commercially available, we first performed a series 
of optimization experiments. For these initial experiments, we used two mixtures of tryptic 
peptides originating from two phosphorylated (α-casein and asialofetuin) and 
nonphosphorylated proteins (BSA and myoglobin) in two different molar ratios (1:1:5:5 
and 1:1:50:50), which simulated the relatively low abundance of phosphorylated proteins 
in a biological sample. To detect the peptides resulting from the enrichment step, we used 
MALDI-TOF MS analysis using an ABI 4800 mass spectrometer as it was the only mass 
spectrometer available in our lab in 2011 and 2012 when these initial optimization 
experiments were performed. To test the applicability of the chosen methods to enrich 
phosphopeptides from a complex mixture, we further performed a real complex sample 
enrichment (HeLa cells lysate) and detected the resulting peptides using an LC-MS/MS 
system. The final selected protocol was then used in a pilot quantitative SILAC-based 
phosphoproteomic study of irradiated MOLT-4 cells. 
From the previously published protocols, we selected four different buffer 




mainly differed in the composition of the loading solution (or loading “buffer”) including 
different acidic additives previously reported to enhance the phosphopeptide selectivity 
of the metal oxides. The first protocol involved only 5 % TFA to establish a low pH during 
the loading step, since in the initial MOAC studies it was shown that strongly acidic 
conditions were beneficial for the specificity of phosphopeptide enrichment (222). Three 
further protocols were based on addition of one of the previously reported efficient 
“nonphosphopeptide excluders” – 1 M lactic acid (223), 350 mg/ml DHB (222), or 0.1 M 
glutamic acid (186).  
In the next step, we applied these buffer conditions in order to test 5 different 
commercially available chromatographic resins: Titansphere® 5 μm particles (GL 
Sciences, Torrance, CA, USA), which we used to enrich for phosphopeptides in a 
“microtube format”; TopTips® (TiO2, TiO2/ZrO2 1:1, and ZrO2; Glygen, Columbia, MD, 
USA), which are pre-filled micro-spin columns that can be used for phospho-enrichment 
in a “column format” using either centrifugal force or air pressure to ensure the flow of the 
loading and washing solvents through the beads; and NuTips® (TiO2/ZrO2 1:1) (Glygen, 
Columbia, MD, USA), which are pre-filled “pipette-tips” that can be used for phospho-
enrichment via repetitive pipetting of a peptide solution through the bottom part of the tip 
containing embedded chromatographic resin. The undeniable advantage of using the 
Titansphere® beads in the microtube format or alternatively, in the form of in-house 
columns (which we also tested, but the data are not presented in this thesis), is the fact that 
their amount can be optimized for a specific application while the pre-packed tips are only 
available in two or three different sizes. The effect of a peptide-to-TiO2 ratio has been 
investigated in several studies as an important parameter affecting the specifity of the 
enrichment (244,245). Based on our data (not shown) we decided to use a ratio of 1:8 
for our optimization experiments. 
5.1.1. Titansphere® particles and NuTips® provided markedly 
more efficient phosphopeptide enrichment than the 
TopTips®. 
The evaluation of enrichment efficiency revealed that in our experiments, 
Titansphere® particles and NuTips® clearly outperformed the TopTips® in terms of the 
total and average numbers of phosphopeptides detectable by MALDI-TOF MS in the 




from mixture A were enriched; application of the best protocol for each of the 
chromatographic resins led to detection of 17 phosphopeptides by NuTips®, 15 
phosphopeptides by Titansphere®, but only 9 phosphopeptides by TopTips®. In mixture 
B enrichment, NuTips® provided a total number of 10 phosphopeptides, Titansphere® led 
to the detection of 8 phosphopeptides, and TopTips® provided 7 phosphopeptides in total 
(figure 4).  
Further analysis of the nature of peptides detected by different protocols showed 
that the main differences in numbers of phosphorylated sites detected between the two well 
performing products and TopTips® were caused by lower detectability of multiply-
phosphorylated peptides while the enrichment efficiency for monophosphorylated peptides 
was comparable across the resins and buffer conditions (figure 5). Doubly- phosphorylated 
peptide 1927.69 [M+H]+ from α-S1-casein was observed in most of the enrichments; 
however, multiply phosphorylated peptides were more challenging to detect. These 
peptides were typically observed as low intensity peptide ions in the higher m/z range of the 
MALDI-TOF MS spectra, and were only detected in the low complex mixture A using the 
most specific enrichment protocols.  
TopTips® enrichment usually yielded a high number of nonspecifically bound non-
phosphorylated peptides even under the most efficient buffer conditions tested, which 
might explain the low detectability of multiply phosphorylated peptides in the spectra as 
their ionization/signals were suppressed by the high amount of the nonphosphorylated 
peptides (figure 8).  
5.1.2. 2,5-dihydroxybenzoic acid was the most potent non-
phosphopeptide excluding additive.  
As for one of the goals of this initial optimization study, we aimed to compare how 
binding specificity was modulated by buffer composition. The binding specifity was 
monitored by relative intensity of the most intensive non-phosphorylated peptides 
originating from BSA, 1749.66 [M+H]+ (ECCHGDLLECADDR) and 2458.18 [M+H]+  
(DAIPENLPPLTADFAEDKDVCK), in recorded MALDI-TOF MS spectra. Both 
nonspecifically enriched peptides contained a relatively high number of acidic amino acids 
(as underscored in the sequences), which is in concordance with previously reported fact 
that especially nonphosphorylated peptides containing greater proportions of aspartic and 




In the first protocol used for phosphopeptide enrichment, i.e. buffer conditions 1, 
the loading buffer consisted of 80% Acn that prevented hydrophobic interactions between 
peptides and a sorbent, and 5% TFA to establish a low pH (typically < 2), which should 
minimize the binding of nonphosphorylated peptides by neutralizing negative charges 
of potentially dissociated acidic amino acids. However, as indicated in the recorded 
MALDI-TOF MS spectra, 5% TFA was not strong enough to prevent the nonspecific 
binding of acidic BSA peptides resulting in relatively highly intensive signals of the 
nonphosphorylated peptides (figure 7A and 7B). 
To improve the specifity of the enrichment by preventing nonspecific binding 
of peptides containing greater proportions of acidic amino acids, three different 
“nonphosphopeptides excluders” reported previously in literature were employed. In the 
second protocol, i.e. buffer conditions 2, the loading solution included 1 M lactic acid 
(LA), which was evaluated to be the most efficient additive for phosphopeptide enrichment 
from a panel of hydroxy acids tested in a previous study (223). The level of nonspecific 
binding was notably decreased compared to the first protocol (figure 7C). However, LA as 
an excluder was still not very efficient for more complex peptide mixture B (figure 7D). 
The improved efficacy for excluding nonphosphorylated peptides allowed detection 
of more multiply phosphorylated peptides but with a poor reproducibility. Therefore, in our 
study, 1 M LA did not seem efficient enough to prevent unspecific binding of non-
phosphorylated peptides. We also tested a higher concentration of LA than it was originally 
recommended (i.e. 2 M), however the increase in LA concentration did not lead to any 
significant improvement in the performance of the second protocol (data not shown).  
The third enrichment protocol, i.e. buffer conditions 3, included the addition 
of glutamic acid (Glu) in the sample loading buffer as an effective nonphosphorylated 
peptides-excluding agent (figure 7G and 7H). Glu has been reported previously as an 
efficient loading buffer additive (186); its potency for enhancing specifity of MOAC is 
caused by its competition with Glu residues of peptides. In our setting, the addition of 0.1 
M Glu was more effective than the addition of LA, and it led to improved efficiency and 
reproducibility of the enrichment, but it was still surpassed by the effect of DHB.  
In 2005, Larsen and his co-workers investigated the effect of different aromatic 
carboxylic acids and aliphatic carboxylic acids added into loading buffer 
for phosphopeptide enrichment. DHB and other substituted aromatic carboxylic acids 




of nonphosphorylated peptides (222). DHB was also found to be the most potent additive 
in another study (224). In the fourth protocol, buffer conditions 4, DHB was added to the 
loading buffer in a concentration of 350 mg/ml (close to a saturated solution) for complex 
mixtures of peptides according to the recommendation in Larsen’s protocol. We observed 
that DHB was the most potent excluder for nonphosphorylated peptides when added during 
phosphopeptide enrichment using Titansphere® particles and TopTips® since the relative 
intensities of nonphosphorylated peptides were very low (figure 7E and 7F). Additionally, 
multiply phosphorylated peptides were more clearly detected than in other MALDI-TOF 
MS spectra obtained by different phosphopeptide enrichment protocols probably because 
of lowered ion suppression, which is normally affecting the signals of multiply 
phosphorylated peptides during MALDI-TOF MS. On the other hand, 
monophosphorylated peptides were slightly less reproducibly enriched when DHB was 
used, which might indicate that weaker bound monophosphorylated peptides could be also 
displaced from metal oxide surface by this potent “excluder” (figure 5A).  
Thus, the non-phosphopeptide excluding efficiency of the additives increased in the 
following order: 5% TFA < 1 M LA < 0.1 M Glu < 350 mg/ml DHB.  
5.1.3. The addition of glutamic acid into the loading buffer 
provided the best phospho-enrichment efficiency. 
Even though DHB was shown to provide the highest non-phosphopeptide exclusion 
efficiency among the additives tested, it was actually 0.1 M Glu that enabled the detection 
of the most phosphorylated peptides. Although the signals of multiply phosphorylated 
peptides were not as clear as in the case of the DHB protocol, glutamic acid MOAC 
chromatography seemed to have the highest enrichment efficiency within the four 
protocols tested. The addition of glutamic acid led to detection of 17 and 15 
phosphopeptides in total in NuTip® and Titansphere® enrichment, respectively, which 
were the highest numbers of detected phosphopeptides in our optimization study. 
Additionally, the protocol that included Titansphere® particles and glutamic acid reached 
the best repeatability among all the protocols tested with 15 phosphopeptides repeatedly 
detected in all three independent enrichments.  
The lower yields of phosphopeptides detected in DHB enriched eluates were mostly 
caused by aforementioned lower recovery of monophosphorylated peptides in the presence 




phosphorylated peptides, we also observed a high level of noise in the low m/z region 
of MALDI-TOF MS spectra recorded from the samples enriched using NuTips® and DHB 
as an additive. This observation has been already reported in a previous study that also 
evaluated the performance of NuTips® for phosphopeptide enrichment (341). We are 
aware of the fact that this issue could have been further addressed by testing lower 
concentrations of DHB; however, such investigation was far beyond our interests.  
Moreover, it has been reported previously (223) that DHB added to loading buffer 
decreased the number of nonspecifically bound nonphosphorylated peptides but also the 
number of identified phosphopeptides because it caused problems in the RPLC-ESI-
MS/MS system used in the study. Therefore, it might be risky to use DHB in cases when 
the samples are supposed to be injected into an LC-MS/MS system. On the contrary, Glu 
is a compound that does not have such a strong affinity for hydrophobic reversed phase, 
and thus its use in such system is more feasible. Therefore, we selected the glutamic acid 
including protocol for further studies. 
5.1.4.  Titansphere® particles outperformed NuTips® in the 
real sample analysis. 
We further tested the two best performing protocols in an analysis of a real complex 
sample. The real peptide samples were prepared by digesting 500 µg of HeLa cells lysate 
using trypsin, and the samples were enriched for phosphopeptides using either NuTips® or 
Titansphere® particles and the Glu containing protocol (i.e. buffer conditions 4). Enriched 
fractions resulting from these enrichments were analysed using an RPLC-ESI-MS/MS 
system. 
Surprisingly, we repeatedly observed that NuTips® were not an adequate 
enrichment media for such a high amount of a complex mixture since the amount 
of material in the eluates was extremely low in comparison to the fractions obtained 
by Titansphere® enrichment. According to the description provided by the manufacturer, 
ZrO2/TiO2 NuTips® 10-200 μl have a binding capacity of 2.5 μg which in our opinion 
should be sufficient for the enrichment of phosphopeptides from 500 µg of unfractionated 
whole cell lysate. We also tried to use multiple tips for sequential enrichment of the same 
sample (i.e. the flow-throughs were re-loaded onto the column), but this modification did 
not bring any improvement observable in the UV-VIS chromatography spectra (data not 




in UV-VIS chromatography. NuTip® might have an excellent selectivity and outperform 
Titansphere® in the analysis of low complex samples, but in the analysis of a highly 
complex mixture of peptides, the amount of the beads embedded into the tips is probably 
not sufficient to robustly enrich phosphorylated peptides.    
On the contrary, Titansphere® particles, which can be easily adjusted for any 
sample volume and amount of starting material, yielded 898 phosphopeptides passing the 
0.01 false discovery rate cut-off. Thus, in our hands, Titansphere®, proved as the most 
efficient media for analysis of a highly complex real sample.  
5.1.5.  Application of the optimized protocol to study 
phosphorylation response of irradiated MOLT-4 cells led 
to identification of more than 600 hundred 
phosphorylation sites.  
To further evaluate the performance of the chosen protocol for phosphopeptide 
enrichment in the system of interest, i.e. irradiated leukemic cells, we performed a pilot 
study investigating the phosphorylation response in MOLT-4 cells that were irradiated by a 
dose of 1.5 Gy chosen on the basis of our previous work (342). In the presented experiment, 
the quantification of phosphorylation changes between the irradiated and control cells was 
achieved using SILAC labelling. After mixing the samples 1:1, tryptic digestion of the 
protein mixture and phosphopeptide enrichment using the Titansphere® particles at a 
peptide-to-TiO2 ratio 1:8 under buffer conditions 4 (100 mM glutamic acid as an additive), 
and a LC-MS/MS analysis of the resulting fraction, we identified 632 phosphorylation sites 
from 489 peptides originating from 335 phosphoproteins (summary of the results is given 
in figure 18).  
Among the identified sites, 476 were classified as class I phosphosites (based on the 
localization confidence defined by localization probability calculated by MaxQuant; figure 
18A). The total number of successfully quantified class I sites was 429; the relative 
distribution of phosphorylated S, T, and Y were similar to values reported in previous 
studies (figure 18B; (201,273)). Applying the previously reported 1.5 and 0.5 heavy/light 
ratio cut-offs (normalized SILAC H/L ratios without any log transformation; (343)), we 
assessed that 31 sites were upregulated and 32 were downregulated one hour after the 




set we were able to find statistically over-represented signalling pathways (figure 18D) and 
kinases that were up- and downregulated in response to IR (figure 18E).  
-  
Figure 18: Summary of the results obtained in the pilot study of irradiated MOLT-4 
cells: (A) Classification of the phosphorylation sites based on their localization 




subset. (C) Pie chart depicting proportion of up- and down-regulated phosphorylation sites 
in the quantified class I sites subset. (D) Signalling pathways overrepresentation analysis. 
Up- (green) or down- (blue) regulated sites were annotated by the pathways membership 
using ConsensusPathDB and statistically evaluated (hypergeometric testing, default 
background). (E) Kinase activity analysis. Kinases phosphorylating the 429 quantified 
class I sites were predicted using Networkin 2.0; statistical analysis and visualization was 
conducted using PhosphoSiteAnalyzer; colour code indicates statistical significance of a 
finding – low p-values are depicted with dark purple. (F) Chk2 Ser 379 and Ser 260 were 
found in the upregulated dataset. Using PhosphoSitePlus database, we confirmed the 
biological relevance of these phosphorylation events in the context of irradiation. 
 
As for the over-represented signalling pathways, most of them were pathways 
involved in DDR – for instance activation of ATM- and p53 signalling pathways, cell death 
by apoptosis, and activation of cell cycle checkpoints. In the kinase activity analysis, we 
found ATM_ATR group significant among the upregulated kinases and CDKs among the 
downregulated kinases, which is in concordance with the well-known roles of ATM/Chk2 
and ATR/Chk1 in regulation of cell cycle checkpoints in response to genotoxic stress. 
Two examples of significantly upregulated phosphorylation sites are given 
in figure 18F. Two strongly upregulated (11-fold) phosphorylation sites were observed 
in Chk2 after IR. Data mining using the most comprehensive phosphorylation database 
PhosphoSitePlus (58) revealed that these two phosphorylation sites were localized in the 
kinase activation loop of Chk2 (344,345), and Ser 379 phosphorylation has been previously 
shown to be IR-triggered (346). 
As these results were fully in concordance with known facts about the IR-triggered 
cellular response, we could conclude that our workflow was capable of identification and 
quantification of phosphorylation changes in irradiated leukemic cells. It also proved that 
it enabled further analysis of the acquired data using bioinformatic tools to describe 





5.2. Radiosensitization of MOLT-4 cells by selective 
ATR and ATM inhibitors, VE-821 and KU55933 
To investigate the radiosensitizing potential of ATR inhibitor, VE-821, and 
compare it to the effects of ATM inhibitor, KU55933, the MOLT-4 cell line was chosen. 
MOLT-4 is a T-cell acute lymphoblastic leukaemia (T-ALL) cell line. The effects of IR 
and other DNA damage inducing agents in this cell line have been extensively studied, 
especially at our department and the collaborating Department of Radiobiology at the 
Faculty of Military Health Sciences (347–350,342,351–357). In these studies, it has been 
shown that MOLT-4 cells are relatively radiosensitive cells with D0 value (dose reducing 
survival to 37 %) of 0.87 Gy, and the cells express wild-type p53 and possess a functional 
ATM/p53 pathway, which is triggered in a dose-dependent manner (342,347,353). After 
irradiation, the cells have been shown to die by both pre- and post-mitotic apoptosis 
(348,358). Notably, it has been suggested that MOLT-4 cells could have some defect 
in DNA repair pathways promoting their radiosensitivity (a possible defect in Nbs1 
phosphorylation have been discussed previously (351)). The cells have been also already 
used to study radiosensitizing effects of several kinase inhibitors such as caffeine (low 
potent ATM/ATR inhibitor; (354,359)), U0126 (MEK1/2 inhibitor; (359), and DNA-PK 
inhibitors NU7026 and NU7441 (355,357) in leukemic cell lines, where MOLT-4 cells 
were chosen to represent a p53 wt model cell line. 
To get an overview of MOLT-4 cell line genetic background, we extracted MOLT-
4 relevant data from the COSMIC (Catalogue of somatic mutations in cancer) database, 
which is the most comprehensive database of somatic mutations in human cancer (360). 
The database search revealed 1476 entries; among them, 56 were mutations in census genes 
(i.e. genes known to be involved in cancer). Importantly, MOLT-4 cells suffer 
from mutations of signal transduction pathways which are known to be frequently mutated 
in T-ALL leukaemia such as NOTCH1, IL7R-JAK-STAT, RAS-MEK-ERK, and 
(PTEN)-PI3K-AKT pathways (reviewed in (361)). The only census gene that was 
detected with homozygous deletion was the Phosphatase and tensin homolog PTEN, which 
is a tumour suppressor gene commonly mutated in a wide range of cancers (362). It acts as 
an important negative regulator of the PI3K-AKT-mTOR pathway, which is responsible 
for regulation of cellular metabolism, proliferation and survival. Therefore, the inactivation 




ultimately leading to cancer (reviewed in (363). Furthermore, MOLT-4 cells suffer 
from multiple heterozygous mutations in several DDR genes such as ATM, BRCA1, 
FANCA, and TP53. Together, these data indicated that the PI3K-AKT pathway might be 
dysregulated, and the DNA repair capacity might be impaired in MOLT-4 cells. 
5.2.1.  Both VE-821 and KU55933 treatment abrogated the 
radiation-induced phosphorylation of corresponding 
checkpoint kinases. 
To confirm the inhibitory effect of VE-821 and KU55933 on ATR and ATM 
kinases, respectively, we assessed phosphorylation of two downstream effector kinases: 
Checkpoint kinase-1 (Chk1) Ser 345 and Checkpoint kinase-2 (Chk2) Thr 68. As 
expected, both phosphorylation sites were upregulated upon irradiation (3 Gy, one hour 
after irradiation). Chk2 phosphorylation, which is a marker of DNA DSBs-activated ATM, 
was markedly decreased with increasing concentration of KU55933. Accordingly, the 
status of Chk1 Ser 345 phosphorylation site, which is a widely-accepted marker of ATR 
activation, was proportionally inhibited by increasing concentration of VE-821. Therefore, 
we confirmed that in our cell line model the pre-incubation with VE-821 and KU55933 
specifically inhibited ATR and ATM kinase, respectively, without any off-target effect 
towards the other kinase. Such observation was not surprising, as the IC50(ATR) 
of KU55933 was assessed to be 100 μM (364), and the Ki(ATM) of VE-821 is 16 µM 
(IC50 has not been assessed; (11)). Additionally, the selectivity of VE-821 towards ATR 
has been confirmed in previous studies (11,134). 
5.2.2.  KU55933 treatment was not toxic for sham-irradiated 
cells and enhanced the IR induced growth inhibition and 
cell death of MOLT-4 cells. 
KU55933 was the first potent and selective ATM inhibitor with IC50 of 13 nM 
(364). As well as its more recent analogues, it has been shown to sensitize cells to IR and 
DSB-inducing drugs without sensitizing cells derived from A-T patients (364–366). 
Radiosensitization using KU55933 and its derivatives is not specifically targeting cancer 
cells; however, ATM inhibition alone has been shown to be nontoxic for normal tissues 
outside the radiation field (366). The p53-dependency was investigated, but the results are 




well tolerated by the p53-wt expressing MOLT-4 cells in concentrations up to 10 μM; 
to induce a significant perturbation of cell growth, it was necessary to apply at least 20 μM 
KU55933. Interestingly, 5 μM KU55933 significantly increased the number of viable 
metabolically active cells six days after the start of the treatment in two independent 
proliferation assays (figure 10) without affecting the number of nonviable cells and the cell 
cycle (figure 13) confirming that KU55933 was not toxic for sham-irradiated MOLT-4 
cells in concentrations up to 10 μM.  
Since MOLT-4 cells express a wild-type p53 and possess a functional ATM/p53 
pathway (342,347,353), and cellular response to DNA DSBs is to a great extent ATM/p53 
pathway dependent, we expected that ATM inhibition would sensitize MOLT-4 cells to IR. 
In concordance with our expectation, 10 μM KU55933 caused a significant decrease 
in MOLT-4 cells proliferation when combined with IR and detected 6 days after irradiation 
(figure 11) and increased the IR-induced cell death 3 days after irradiation (figure 13). 
KU55933 showed no effect on the G2/M cell cycle arrest triggered by IR, which was 
in concordance with the known fact that the intra-S and G2/M DNA damage checkpoints 
are mainly directed by the ATR/Chk1 pathway (reviewed in(110).  
5.2.3. VE-821 is a more potent inhibitor of MOLT-4 cells 
growth than KU55933 in both single treatment and 
combination with irradiation. 
While ATM mainly responds to severe DNA lesions, ATR is an indispensable 
regulator of cellular proliferation as it responds to stress that cells undergo during normal 
replication of DNA as well as replicative stress caused by exposure to genotoxic agents. It 
has been shown to be essential for viability; homozygous mutation of ATR caused peri-
implantation embryonic lethality in mice (85,86). However, transient inhibition of ATR 
by VE-821 has been proven to cause mere reversible growth arrest in normal cells, which 
was abrogated when the inhibitor was removed from the cultivation media (11). 
Importantly, the newest highly potent and specific ATR inhibitors have been shown 
to directly eradicate or sensitize cancer cells to a variety of genotoxic agents without 
affecting normal, non-tumour, cells (8,11,12,138,139). The sensitivity of cancer cells 
to ATR inhibitors has been already explained by several cancer-specific defects such as 
loss of functional ATM/p53 pathway (8–12) and elevated levels of replication stress 




In the presented study, VE-821 significantly inhibited proliferation of p53-wt 
MOLT-4 cells already at 1 μM concentration although such concentration caused only a 
partial ATR inhibition when detected as a Chk1 Ser 345 phosphorylation using western 
blotting (figure 12). This effect was further accented in correlation with increasing 
inhibitor concentration (figure 10). Thus, in MOLT-4 cells, continuous inhibition of ATR 
by VE-821 has a significantly stronger effect on proliferation than the inhibition of ATM.  
In combination with IR, VE-821 significantly abated the number of viable cells 
in both irradiated groups already 72 hours after irradiation. As both concentrations used 
in our experiments directly affected the proliferation of sham-irradiated cells, we further 
calculated a ratio between irradiated and sham-irradiated group for each inhibitor treated 
condition to resolve if the combination of irradiation and the inhibitor has a more profound 
effect on proliferation than the inhibitor itself (figure 11). Whereas the irradiation caused 
nearly 50 % decrease of control cells viability after 72 hours of treatment, the irradiation 
of pre-treated cells (2 μM VE-821) led to almost 75 % loss of viability in comparison 
to inhibitor treated cells, suggesting an additive effect of VE-821 and IR combination. 
Additionally, we also observed that VE-821 in 2 μM and 10 μM concentrations modulated 
the proliferation of irradiated MOLT-4 cells when the inhibitor was present in cell culture 
media only transiently, for the first 24 hours of the treatment, and then it was washed out 
(figure 11D). In contrast to continuous treatment, 2 μM VE-821 did not significantly affect 
the proliferation of sham-irradiated cells when washed out after 24 hours; however, it still 
enhanced the antiproliferative effects of IR. Taken together, these data showed that VE-
821 strongly affected proliferation of p53-wt MOLT-4 cells, and in combination with IR, 
the proliferation was influenced even when the inhibitor was present only transiently.  
5.2.4. Both KU55933 and VE-821 increased the ionizing 
radiation-induced cell death in MOLT-4 cells. 
As mentioned above, KU55933 did not induce any significant changes in viability 
of both sham-irradiated cells and irradiated cells after 24 hours (figure 13); however, 
VE-821 affected the viability of the cells significantly. Strikingly, the combination of both 
inhibitors diminished this detrimental effect of VE-821. This is consistent with the results 
of proliferation experiments, in which we observed similar trend. When applying three 
different inhibitor combinations, we observed that KU55933 suppressed the VE-821 




groups. However, in contrast with WST-1 assay, which does not distinguish between the 
changes of viable cells numbers caused by cell cycle effects, changes in metabolic activity, 
or cell death inducing effects of a tested compound, these results indicated that in our short-
term incubation experiments, KU55933 prevented VE-821 induced cell death. Similar 
observations were reported in a study investigating the effect of caffeine, a low potent and 
unspecific ATM inhibitor, on mitoxantrone induced cell death in MOLT-4 cells. 
Incubation with caffeine temporarily protected the cells by delaying the onset of cell death, 
most likely by the inhibition of p53-dependent apoptosis (359).  
Three days after irradiation, in the VE-821 treated groups, the percentage of cells 
with compromised viability further decreased despite the absence of the inhibitor 
in cultivation media (figure 13). On the contrary, we did not notice the “protective” effect 
of KU55933 that we observed 24 hours after irradiation when the inhibitor was not present. 
Such finding further confirms that ATM inhibition only delayed the onset of cell death. 
Importantly, both inhibitors and their combinations increased sensitivity of MOLT-4 cells 
to IR. The most detrimental effect was observed when cells were treated by 10 μM VE-821 
and by the combination of both inhibitors (10 μM +10 μM). Application of these conditions 
led to more than 90% decrease in viability of MOLT-4 cells 72 hours after irradiation. In 
conclusion, both inhibitors led to increased cell death when combined with IR in an 
appropriate experimental design (i.e. appropriate dose and incubation time) and thus 
radiosensitized MOLT-4 cells. 
5.2.5. VE-821, but not KU55933 disrupted ionizing radiation-
induced G2/M arrest in MOLT-4 cells. 
As one of the proposed mechanism of radiosensitization using ATR inhibitors is the 
disruption of the G2/M checkpoint in G1 checkpoint-deficient cells (11), we investigated 
modulation of the cell cycle by ATR and ATM inhibition (figure 13). None of the 
conditions we applied affected the cell cycle in sham-irradiated cells except for 10 μM VE-
821 and its combination with KU55933, which repeatedly caused a significant increase 
in number of cells in G1. In concordance with our previous results (367), irradiation by the 
dose of 3 Gy led to a significant G2/M arrest in viable MOLT-4 cells 24 hours after 
irradiation. The pre-incubation with VE-821 and with the inhibitor combinations led to a 
significant disruption of G2/M checkpoint in the viable fraction of cells. On the other hand, 




together with corresponding significant decrease in the number of cells in G1. The 
abrogation of the G2/M checkpoint by VE-821 10 μM was also achieved when a lower 
dose of irradiation was applied (1.5 Gy; data not shown). As it has been reported 
previously, caffeine disrupted mitoxantrone induced G2/M arrest in MOLT-4 cells(359) . 
After examining the effects of specific ATM and ATR inhibition, we suggest that the G2/M 
block disruption was rather caused by “non-specific” ATR-inhibiting effects of caffeine, 
which was originally proposed as an ATM inhibitor; however, it has been shown that it 
also inhibits ATR, although with a lower potency (IC50(ATM): 0.2 mM; IC50(ATR): 1.1 
mM). Altogether, these results confirmed that ATR is the main kinase controlling the 




5.3. Phosphoproteomic analysis of VE-821 treated 
MOLT-4 cells 
5.3.1. Selection of the experimental design 
for phosphoproteomic and metabolomic inhibitor studies 
As described in the previous chapter, both VE-821 and KU55933 increased MOLT-
4 cells sensitivity to IR. However, there were several reasons why we selected 
to preferentially use ATR inhibition by10 µM VE-821 for further experiments: 
1) ATM/p53 pathway is the key mechanism in cellular response to IR-induced 
DSBs, and therefore, its inhibition was assumed to cause radiosensitization 
in wt-p53 expressing cell line. On the contrary, ATR is mostly known 
to respond to “milder” types of stress and it is not dominant in response to IR. 
Even though it has been already described to sensitize cells towards IR, the 
mechanism is not deeply understood, and it is mostly described as S- and G2/M 
checkpoints dysregulation in ATM/p53 deficient or higher levels of replication 
stress-suffering cells. In our opinion this explanation was too simplistic and 
needed further investigation.  
2) As described in the Introduction section (chapter 1.3.1), ATR inhibitors offer a 
great promise in oncology. Two of the most recent potent and selective ATR 
inhibitors are currently being tested in phase I clinical trials. Better 
understanding of the mechanism of action might be beneficial for future use 
of the drugs in clinics. For instance, if a novel pathway affected by the inhibitor 
treatment is identified, such knowledge can help to predict potential synthetic 
lethality in tumours with specific genetic background and therefore, increase the 
range of tumours which might be treated using the inhibitors of ATR.  
3) Moreover, we detected two distinct phenotypes caused by VE-821: the first was 
observed after 2 µM VE-821 treatment and was mostly characterized 
by enhancing of the IR-induced cell viability and growth inhibition – disrupting 
the IR-triggered G2/M checkpoint and increasing the IR-induced cell death. In 
experiments with shorter incubation times (i.e. 24 hours) and inhibitor-only 
treatment, this concentration was not proven to significantly affect viability 




perturbation of the cell cycle. The second phenotype was induced by 10 µM 
VE-821 and characterized by marked proliferation inhibition and decreased 
viability of MOLT-4 cells in both single inhibitor treatment and its combination 
with IR, which led to more than a 90 % decrease of viability in 3 days. This 
inhibitor concentration also affected the cell cycle of treated cells inducing a 
slight, but significant, accumulation of cells in the G1 phase. Hence, using the 
combination of two high-throughput -omic techniques we aimed to provide a 
deep insight into underlying molecular mechanisms of the potent 
antiproliferative activity of 10 µM VE-821 in MOLT-4 cells.  
5.3.2. Phosphoproteomic analysis of VE-821-modulated 
cellular response to ionizing radiation identified and 
quantified thousands of phosphorylation sites.  
To describe cellular mechanisms underlying the VE-821-mediated 
radiosensitization of MOLT-4 cells, we employed high-resolution MS to identify and 
quantify changes in proteome, phosphoproteome, and metabolome of irradiated VE-821-
treated cells (figure 14). The quantification on both proteomic levels was based on SILAC 
(270)). To specifically enrich for peptides modified by phosphorylation, desalted tryptic 
peptide samples were fractionated using HILIC followed by phosphopeptide enrichment 
using titanium dioxide chromatography (222), RPLC-MS/MS detection, and peptide 
identification and quantification using MaxQuant v.1.5.2.8 (316). Using this approach, we 
identified 9285 phosphorylation sites from 3090 protein groups at a site FDR level of 0.01, 
among them 4504 were quantified in all three biological replicates (nearly 63 % of the data 
set). In GRT, we identified 623 regulated phosphorylation sites (455 phosphoproteins); 
among them the majority were upregulated (431). As discussed previously (133), the higher 
number of phosphorylation sites upregulated than downregulated in response to a kinase 
inhibitor treatment was probably caused by the length of the treatment (one hour), which 
was chosen to rather identify signalling pathways rewired by ATR inhibition in irradiated 
cells than phosphorylations that are directly dependent on ATR kinase activity in response 
to IR.  
In the analysis of the whole proteome samples prepared using the same treatment 
and time interval we detected no significant changes on the proteomic level (figure 15). 




phosphorylation response in cells treated with IR, and that the observed changes were not 
induced by the changes on the proteome level – since the proteome remained unperturbed. 
5.3.3.   Gene ontology enrichment analysis of regulated 
phosphoproteins provided a general description of VE-821 
modulated phosphoproteome. 
To functionally classify phosphoproteins identified and quantified in our study and 
statistically evaluate enriched categories, we performed a functional annotation and over-
representation analysis using ConsensusPathDB over-representation analysis web tool 
(319,320). By this tool, proteins were annotated using GO terms level 4 and the over-
representation was evaluated using hypergeometric testing.  
At first, we analysed all phosphoproteins identified in our study against a default 
background reference set to characterize the phosphoproteome detectable using our 
experimental design. While the over-representation of nuclear and cytosolic proteins and 
under-representation of membrane proteins was probably caused by sample preparation 
and better detectability of soluble proteins, over-representation of GO terms related to cell 
cycle (especially mitosis), DNA repair and replication, and gene expression confirmed the 
essential role of phosphorylation in regulation of these processes (data not shown).  
Then, a list of 455 phosphoproteins containing VE-821-regulated sites was tested 
against a custom background reference set derived from our data comprising all 
phosphoproteins with at least one phosphorylation site quantified in all three biological 
replicates. In this analysis, we identified over-represented biological processes (BP), 
cellular compartments (CC), and molecular functions (MF). As shown in figure 19A, 
regulated phosphoproteins were over-represented in nucleus, specifically in chromosomes, 
mitotic spindle, and replication fork and involved in chromatin organization, DNA repair 
and metabolism, cell cycle, and regulation of transcription factors.  
5.3.4. Signalling pathways annotation and over-representation 
analysis revealed several pathways possibly dysregulated 
by VE-821 treatment. 
Using the ConsensusPathDB tool, we also mapped regulated phosphoproteins 
to signalling pathways from three different pathways databases: KEGG (321,322), 




(figure 19B). The list of pathways containing proteins with VE-821-regulated 
phosphorylation sites, and thus pathways potentially modulated by VE-821 treatment 
contained pathways involved in DNA repair, replication, and telomeres synthesis (e.g. 
“DNA replication”, “Fanconi anaemia pathway”, “BARD1 signalling events”, “ATM/ATR 
pathway”, “DNA double strand breaks response”, “DNA strand elongation”, and 
“Extension of telomeres”), apoptosis (e.g. “Caspase Cascade in Apoptosis or “Apoptotic 
execution phase”), regulation of mitosis (“Aurora A/B and signalling”, “PLK1 signalling 
events”, “Mitotic metaphase and anaphase”, and “Kinesins”), transcription factors 
regulation (“ATF-2 transcription factor network”, “Activation of AP-1 family 
of transcription factors”, and “Regulation of cytoplasmic and nuclear SMAD2/3 
signalling”), chromatin regulation via histones modification (“Signalling events 
mediated by HDAC class I”), but also pathways primarily related to cellular metabolism 
(“AMPK signalling pathway” and “mTOR signalling).  
 
Figure 19: Selected results from Gene Ontology level 4 terms and signalling pathways 
overrepresentation analysis. Functional annotation of proteins with phosphorylation sites 
significantly affected by VE-821 treatment and over-representation analysis were done 
using ConsensusPathDB overrepresentation-analysis online tool. (A) Overrepresented GO 
terms (FDR < 0.05, all proteins quantified in our study were used as a statistical 
background). (B) Regulated phosphoproteins were mapped to signalling pathways from 3 
different databases (KEGG, REACTOME, and PID) and pathway-coverage was calculated 
for overrepresented pathways (FDR < 0.05, all proteins comprised in detected pathways 
were used as a statistical background). 
5.3.5. Network analysis revealed the complexity of cellular 
response and multiple functionally related clusters affected 
by VE-821. 
Using the SubExtractor algorithm (325), we extracted multiple subnetworks 




treatment. The largest subnetwork is depicted in figure 20. For each group 
of interconnected nodes, we further performed functional annotation enrichment analysis 
to better understand its functions. To simplify the interpretation, the clusters were divided 
into two groups.  
The first one can be concisely described as a multi-level stress induced regulation 
of gene expression: regulation of RNA biogenesis, its modification and stability, and 
translation. Namely, SubExtractor extracted a cluster that contains chromatin modifying 
enzymes (mostly histone acetylation and methylation) and thus contributes to regulation 
of gene expression. Furthermore, transcription initiation and elongation complexes were 
also extracted. The largest module centred around Protein mago nashi homolog 
(MAGOH) comprises many proteins from the mRNA splicing machinery. And finally, 
VE-821 treatment also affected phosphorylation of ribosomal proteins suggesting that it 
might also alter protein synthesis. The ribosomal cluster is further tightly linked to a cluster 
that mostly contains members of the mTOR pathway indicating that this pathway might be 
dysregulated by VE-821 treatment, and consequently, result in affected cell growth and 
proliferation. 
The second group is mostly related to already known functions of ATR; it contains 
clusters corresponding to DNA damage response including both DNA damage repair 
proteins and proteins involved in stress-induced cell cycle regulation. As shown in figure 
20 we detected a densely interconnected cluster composed of members 
of minichromosome maintenance complex (MCMs), origin recognition complex subunits 
(ORCs), and DNA polymerases; this cluster also includes several known ATR-interacting 
proteins and corresponds to the regulation of origin firing and S-phase progression by ATR 
in response to stress. Further hubs in the extracted network comprised four cell cycle 
regulating kinases – cyclin dependent kinase 1 (CDK1), cyclin dependent kinase 1 
(CDK2), Serine/threonine kinase PLK1 (PLK1), and Aurora kinase A (AURKA) - and 
their regulated substrates extracted as their interactors. These kinases refer to the disruption 
of IR induced DNA damage cell cycle checkpoints and dysregulation of mitosis and cell 
division by VE-821 treatment as detected by the DNA content analysis. Unexpectedly, the 
algorithm also extracted a small cluster containing enzymes from the de novo pyrimidine 
synthesis metabolic pathway connected to the DNA repair cluster suggesting that 





Figure 20: Protein network extracted using SubExtractor algorithm and visualized 
in Cytoscape. Protein-protein interactions with STRING score above 900 were used as an 
input for the algorithm and regulated subnetworks were extracted (FDR < 0.005). Proteins 
in rectangles were identified and quantified in our study; proteins in ellipses were added 
to the network by the algorithm. Proteins with downregulated phosphorylation are 
depicted in blue; proteins with upregulated phosphorylations are depicted in pink. The 
colour intensity corresponds to the degree of regulation (combined z-score). 
 
The complexity of the extracted network containing multiple cellular mechanism 
pointed out the multi-layered nature of cellular response to stress affected by VE-821 
treatment. Moreover, we identified multiple protein kinases in the centres of extracted 
modules indicating a possible dysregulation of these kinases by the treatment. This was not 
unexpected; inhibition of one protein kinase in a cell naturally leads to dysregulation of its 




kinome dysregulation induced by VE-821 treatment, we performed sequence motif 
analysis and kinase activity analysis together with statistical evaluation of the possible 
changes, and the results of these analyses are presented below.  
5.3.6.  Sequence motifs analysis identified global trends in VE-
821 induced phosphorylation changes. 
To characterize the detected phosphorylation sites, we first calculated the 
distribution of phosphorylated serines (pS), threonines (pT), and tyrosines (pY) identified 
and quantified in all three biological replicates. As depicted in figure 21A, the distribution 
was very similar to values reported previously, in studies employing comparable phospho-
enrichment strategies and sample analysis (i.e. 87.6 % of pS, 11.8 % of pT, 0.6 % of pY). 
Interestingly, when we calculated the same distribution ratio for sites that were significantly 
regulated after VE-821 treatment, we found that pT were over-represented in the regulated 
data set (19.3 % of all regulated sites, enrichment factor of 1.65, FDR of 9.97x10-10 
calculated using Fisher exact test). We observed the same trend in our previous data (133), 
and the over-representation of pT has been also reported in another study investigating 
genistein induced phosphorylation changes in breast cancer cell line, which mostly affected 
cell cycle regulation and DDR (294). Since in the sequence logos of CDK1 and CDK2 
generated using their known substrates (PhosphoSitePlus database) it is apparent that pT is 
overrepresented in comparison to the regular distribution of pT usually detected 
in phosphoproteomes (figure 22A), we assume that in our case, the over-representation 
of pTs might be caused by a high number of regulated sites phosphorylated by these 
kinases - they were predicted to phosphorylate between 27 – 37 % of the regulated dataset, 
and about 40 % of these sites are phosphorylated threonines (figure 22B). 
Next, we analysed and visualized sequence motifs using iceLogo tool (327) and 
motif-x algorithm (328). When analysing all class I sites identified in our study 
with SwissProt average amino acid frequencies as a background reference set, we found a 
significant bias of our data towards proline-directed motifs (figure 21B). Furthermore, 
basic and acidic amino acids (R, K, and E) were slightly overrepresented, and hydrophobic 
amino acids were slightly underrepresented (L). The slight bias towards the hydrophilic 
residues and underrepresentation of hydrophobic ones might be caused 
by chromatographic methods used for peptide fractionation, phosphopeptide enrichment, 




CDK2 substrates in our data, which both contain basic amino acids in their sequence motifs 
(figure 22). In the upregulated dataset, proline-directed motifs followed by basic amino 
acids were significantly over-represented, which corresponds well to the known sequence 
logo of CDK 1 and 2 (figure 22A). On the other hand, from the sequences surrounding 
downregulated sites, SQ motif was extracted using motif-x providing a confirmation of the 
downregulation of DNA repair kinases-mediated phosphorylation as this motif is typical 
for PI3K-related kinases ATM, ATR, and DNA-PK (figure 1).  
Taken together, sequence motifs analyses identified global trends in VE-821 
induced phosphoproteome changes with dominant representation of upregulated CDKs and 





Figure 21: Sequence motif and kinase activity analyses: (A) Pie charts depict proportions 
of STY phosphorylations in the whole class I (localization probability > 0.75) dataset and 
in the regulated fraction. (B) Sequence motif analysis was performed using IceLogo and 
motif-x. Amino acid sequences of differentially up- or down- regulated phosphorylation 
sites were analysed against a statistical background comprising all class I sites quantified 
in our study. Depicted motifs were found enriched at indicated significance levels. In 
IceLogo analysis, amino acids that were more frequently observed in the proximity of a 
regulated phosphorylation site are indicated over the middle line, whereas the amino acids 
with lower frequency are indicated below the line; phosphorylated amino acid is located 
at position 0 (C) Kinase activity analysis. Phosphorylation sites were annotated with their 
known kinases using PhosphoSitePlus database if available. iGPS v1.0 and Networkin 3 




indicated. Venn diagram shows the overlap between phosphorylation sites annotated 
by each method and applying desired filtering criteria. Boxplots depict SILAC H/L ratios 
distribution of phosphorylation sites assigned to each kinase/group. The distribution, 
median, and/or outlier-shifts to positive values indicate a possible upregulation of kinase 
activity; trends toward negative ratio values show a possible downregulation of kinase 
activity. Statistical analysis was performed using 1D enrichment analysis in Perseus (v 
1.5.2.6), and the test FDR value for each kinase/group was used to rank the boxplots 
in ascending order. The higher color intensity corresponds to the lower 1D enrichment 
FDR value and vice versa. 
 
 
Figure 22: Characterization of sequences phosphorylated by CDK1 and CDK2. (A) 
Sequence logos for CDK1 and CDK2 were downloaded from the PhosphoSitePlus 
database. (B) Sequence logos were generated in IceLogo for sequences that were either 
known CDK1/2 substrates or predicted by iGPS or Networkin 3, and the percentage 






5.3.7.  Kinase activity analysis confirmed the downregulation 
of PIKKs substrates after VE-821 treatment. 
5.3.7.1. VE-821 specifically inhibited ATR kinase and did not affect the IR-triggered 
ATM signalling. 
In addition to SQ/TQ motifs enriched among downregulated sites in both sequence 
motif analyses, 1D enrichment analysis of known and predicted kinase motifs repeatedly 
indicated that the SILAC H/L ratio distribution of the ATM/ATR group substrates shows 
a significant declining trend (figure 21C). From these ratio shifts, the activity 
of ATM/ATR group might be inferred as downregulated. Even though both kinases share 
the same phosphorylation motif, both prediction algorithms clearly favour ATM over ATR. 
This bias is probably introduced by a better annotation of ATM substrates and protein-
protein interactions in the databases.  
Nevertheless, using an antibody against Chk2 Thr 68 phosphorylation, which is a 
widely-used marker of ATM kinase activation in response to ATM activating stress, we 
showed that 10 µM VE-821 did not inhibit ATM signalling in our experiments (figure 12). 
Furthermore, we found additional pieces of evidence of unaffected ATM signalling in our 
phosphoproteomic data: ATM Ser 2996 autophosphorylation site, which has been 
previously shown to be rapidly induced by IR (43), was not affected by the treatment. 
Similarly, two IR-induced  autophosphorylation sites of a downstream ATM target Chk2, 
Ser 260 and Ser 379 (344,345), were also not significantly changed. 
On the contrary, known ATR targets located within the Chk1 regulatory domain 
were observed to be downregulated upon VE-821 treatment: Ser 345 phosphorylation was 
detected by western blotting (figure 12), and Ser 317 phosphorylation was quantified in our 
phosphoproteomic experiment. An important marker of Chk1 activity, the 
autophosphorylation site Ser 296, was not detected in our study. Chk1 itself was evaluated 
as significantly downregulated in the 1D enrichment analysis of the known substrates, 
providing further evidence of downregulated ATR/Ckh1 pathway. Considering the high 
selectivity of VE-821 towards ATR kinase (IC50 (ATR): 26 nM, Ki (ATR): 13 nM, Ki 
(DNA-PK): 2.2 µM, Ki (ATM): 16 µM), we can assume that significant changes within 
SQ/TQ phosphorylations motifs assigned to ATM_ATR group can be explained 




DNA-PK, which is also known to share the glutamine directed phosphorylation 
motif (figure 1), was evaluated to be significantly downregulated using the iGPS 
predictions. However, we did not find any known site of DNA-PK that would be 
downregulated in our study (the only known DNA-PK phosphorylation site was Ser 430 
on Vimentin, which was unchanged). Moreover, 10 µM VE-821 was proven to leave DNA-
PK signalling unaffected in a cell-based assay (11), and thence, we assume that the DNA-
PK inhibition is rather unlikely.  
In all three experimental replicates, we identified and quantified 21 downregulated 
SQ/TQ class I phosphorylation sites; among them eleven were known substrates 
of ATM/ATR kinases or predicted by iGPS or Networkin 3. Most of the downregulated 
sites were located on proteins with confirmed roles in DDR; however, potential functions 
of some of them have not been elucidated yet.  
5.3.7.2. VE-821 treatment altered phosphorylation of MRN and BRCA1-
BRCT/Abraxas complexes and several other proteins with known role in DNA 
damage response. 
On the list of regulated ATM/ATR targets, we found two VE-821 responsive 
phosphorylation sites on MRN complex, the major sensor of DNA DSBs and ATM kinase 
activator, which has been also shown to be required for ATR activation after IR (368). 
Double-strand break repair protein MRE11A (MRE11) Ser 678 is a known ATM 
substrate essential for homology directed repair (369);  Ser 397 phosphorylation of Nibrin 
(NBS1) has been previously detected, but the phosphorylation of this site does not have 
any known function. Furthermore, phosphorylation of BRCA1-BRCT/Abraxas complex 
was also shown to be altered by ATR inhibition; we detected two downregulated 
phosphorylation sites on Breast cancer type 1 susceptibility protein (BRCA1) - Ser 1239 
and Ser 1524 - the latter one has been shown to be important for cellular response to DSBs 
(370) and phosphorylated by either ATM or ATR depending on the source of the stress 
(371). In addition to BRCA1,  BRCA1-A complex subunit Abraxas (FAM17A) Thr 365 
was also found to be dephosphorylated after ATR inhibition – this phosphorylation 
of FAM17A does not have any known function; however, phosphorylation has been shown 
to be essential for Abraxas regulation very recently (372).  
Another instances of VE-821-regulated phosphorylations, and thus potential ATR 
targets, are Ser 319 of an important member of Fanconi Anaemia pathway Fanconi 




RAD18 (RAD18), an important E3 ubiquitin ligase responsible for monoubiquitination 
of Proliferating cell nuclear antigen (PCNA) in response to stress (373). Moreover, we 
also found a markedly downregulated SQ site in RAD51-associated protein 1 
(RAD51AP1) (Ser 120), which has been detected and validated in another very recent 
phosphoproteomic study using ATR inhibitors in combination with replication stress 
induced by hydroxyurea (135). 
5.3.8.  Dysregulation of cyclin-dependent kinases and aurora 
kinases was responsible for the disruption of G2/M 
checkpoint and faster progression through mitosis. 
In the DNA content analysis, we showed that VE-821 disrupted IR-induced G2/M 
arrest in MOLT-4 cells. Cells treated with ATR inhibitor were not able to activate the 
G2/M checkpoint, which in turn led to faster progression into mitosis with unrepaired IR-
induced DNA damage. Such progression has been shown to cause mitotic catastrophe and 
apoptotic cell death in haematological malignant cell lines (134,313,374). Using 
phosphoproteomics, we aimed to elucidate, which kinases were dysregulated by ATR 
inhibition and thus may contribute to the G2/M checkpoint disruption. As depicted 
in figure 21C, the combination of kinase annotation and 1D enrichment analysis revealed 
a possible upregulation of G2/M checkpoint controlling CDK1 kinase, mitotic kinases 
Aurora A and B, and kinases from the NEK family, particularly Serine/threonine protein 
kinase NEK2 (NEK2) kinase.  
5.3.8.1. VE-821 caused CDK1 upregulation and increased phosphorylation of many 
known CDK1 targets involved in G2/M transition and mitosis in irradiated 
MOLT-4 cells. 
Sequence motif analysis showed overrepresentation of phosphorylated amino acids 
followed by proline and basic amino acids – a well-known motif of cyclin dependent 
kinases. And indeed, the kinase activity analysis confirmed a significant upregulation 
of cyclin dependent kinases, predominantly CDK1 (or CDC2), with a median ratio only 
slightly deviated to positive values, but many outliers strongly upregulated after VE-821 
pre-treatment (figure 21C). Many of these outliers were classified as so-called “regulatory” 
sites (i.e. sites with previously discovered and experimentally validated effects on the 




elucidated yet, but the corresponding phosphoproteins have been shown to have important 
roles in the onset of mitosis and mitotic progression. Examples of the most interesting 
CDK1-phosphorylated sites and their functions are given.  
Seven phosphorylation sites were detected on Stathmin (STMN1); three of them 
were upregulated in our study (Ser 16, Ser 25, and Ser 63). There are multiple kinases 
known or predicted to phosphorylate the upregulated sites; CDK1 dysregulation might be 
responsible for elevated Ser 25 phosphorylation. These STMN1 sites have been shown 
to be phosphorylated in a cell cycle specific manner and essential for G2/M transition and 
proper spindle formation (375). Nevertheless, increased Ser 16 and Ser 63 phosphorylation 
have been also observed after apoptosis induction (376). Protein regulator of cytokinesis 
1 (PRC1) is a key regulator of cytokinesis shown to be phosphorylated by CDK1 in early 
mitosis. Increased phosphorylation of a “regulatory” Thr 481 site was detected, previously 
described to regulate PRC1 interaction with another mitotic kinase, Polo-like kinase 1 
(PLK1) (377). Thr 926 phosphorylation of Kinesin-like protein KIF11 (KIF11)  is a 
mitosis-specific phosphorylation conducted by CDK1 which regulates KIF11 interaction 
with mitotic spindle and thus regulates mitosis (378). Another example of an elevated 
mitosis-specific phosphorylation detected in our study is Ser 1213 phosphorylation 
of DNA topoisomerase 2-alpha (TOP2A). Ser 1213 has been shown to be phosphorylated 
by proline-directed kinases (CDK1 or ERKs) inducing the localization of  TOP2A 
to mitotic chromosomes (379). Sororin (CDCA5) is CDK1-phosphorylated in mitosis (Ser 
75 and Ser 79), and this modification causes its release from chromatin while affecting 
sister chromatid cohesion (380). 
Protein phosphorylation of N-terminal domain of Nucleolin (NCL)  has been 
shown to be essential for normal proliferation (381); Thr 121 detected in our study has been 
already detected as a substrate of CDK1 in high-throughput phosphoproteomic screen 
for CDK1 substrates (382). Nuclear ubiquitous casein and cyclin-dependent kinase 
substrate 1 (NUCKS1) - Ser 181 phosphorylation – is another example of a CDK1 
substrate identified in a high-throughput experiment (382). Furthermore, Bensimon et al. 
showed that phosphorylation of NUCKS1 Ser 181 after neocarzinostatin (NCS) treatment 
was ATM-dependent (42), and it has been shown recently that NUCKS1 plays a role 
in homology directed repair of damaged DNA (383). Lamina-associated polypeptide 2, 




and might be important for post-mitotic nuclear assembly (384). However, Ser 424 
upregulated in our study does not have any known function.  
Components of nuclear lamina are known to be hyper-phosphorylated to induce 
reversible disintegration of nuclear envelope. We detected four upregulated 
phosphorylation sites of nuclear lamins: Lamin-B1 (LMNB1; Ser 23, Thr 20, and Thr 5) 
and Lamin-B2 (LMNB2; Ser 37) induced by VE-821 pre-treatment of irradiated cells. 
Additionally, unscheduled CDK1 activity in G1 phase has been shown to trigger 
apoptosis in X-irradiated MOLT-4 cells (385). In our data, VE-821 significantly affected 
viability of MOLT-4 cells itself and in combination with IR and increased the number 
of early- and late- apoptotic cells. It is possible that in addition to G2/M checkpoint 
disruption and induction of post-mitotic cell death, the dysregulation of CDK1 by ATR 
inhibition contributes to the increased rate of apoptosis in MOLT-4 cells. 
5.3.8.2. VE-821 upregulated Aurora A and B kinases further contributing 
to dysregulation of mitosis. 
Kinases from the Aurora kinases family - Aurora kinases A and B - are master 
regulators of mitosis progression and onset of cytokinesis, whose activities require tight 
spatial and temporal regulation, and their dysregulation might cause errors in mitosis, faster 
progression through abscission checkpoint, and affect postmitotic genome surveillance. In 
our analysis, we found that the activities of these two kinases might be upregulated by VE-
821 treatment (figure 21C). As in the case of CDKs, examples of the most interesting 
phosphorylation sites are given. 
Targeting protein for Xklp2 (TPX2) is a spindle assembly factor, whose activity 
is tightly interconnected with Aurora kinase A activity. TPX2 contributes to Aurora A 
activation (386), and the other hand, Aurora A has been shown to phosphorylate TPX2 
on Ser 121 and Ser 125 to regulate mitotic spindle length and control microtubule flux 
(387). In addition to these two known “regulatory” sites we detected three more 
upregulated phosphorylation sites on this protein that were predicted to be possible 
substrates of Aurora A (Ser 486, Thr 369, and Ser 738).  
Kinesin-like protein KIF2C (KIF2C) Ser 115 has been shown to be 
phosphorylated by Aurora B previously, and this phosphorylation regulates KIF2C 
interaction with centromeres and kinetochores and its microtubule depolymerisation 
activity. Thus, it regulates the turnover of microtubules at the kinetochore and chromosome 




in our study was Chromobox protein homolog 5 (CBX5) that has been previously shown 
to be hyper-phosphorylated during mitosis (389).  
Notably, we found hyper-phosphorylation of Antigen KI-67 (MKI67) (from 22 
sites detected, 12 upregulated in GRT), with most of the sites predicted to be substrates 
of Aurora A, CDK1, or NEK kinases by Networkin 3. MKI67 is a protein essential 
for normal cellular proliferation (390) and has been shown to interact with known mitotic 
proteins (391).  
Taken together, our data indicate that ATR inhibition induced dysregulation of the 
main mitotic kinases. The results are in concordance with previous data, which were 
obtained using similar treatment in a different leukemic cell line HL-60 (133), in which 
dysregulation of CDK1, PLK1, and NEK2 was observed. Data mining in published studies 
confirmed that many of the substrates assigned to each one of these mitotic kinases have 
already been described as the essential players in cell cycle and mitosis control. Moreover, 
we found multiple regulated phosphorylation sites on these proteins, which might be worth 
functional validation in further studies. 
5.3.9. Downregulated mTOR and its downstream p70s6k 
kinase indicate possible impact of VE-821 on cellular 
growth and metabolism. 
5.3.9.1. The key regulator of cellular metabolism, Serine/threonine protein kinase 
mTOR, was inhibited by 10 µM VE-821 treatment, possibly contributing to the 
growth inhibition. 
To our surprise, in the 1D enrichment analysis of kinases assigned to their 
substrates based on known kinase-substrate relationships, we found a significant 
downregulation of the Serine/threonine protein kinase mTOR (mTOR). The protein 
kinase mTOR is the principle regulator of cellular metabolism promoting anabolic 
processes and inhibiting catabolic processes such as autophagy. It integrates signals 
from different upstream pathways triggered by a wide variety of signals including 
nutrients, hormones, growth factors, and also cellular stresses to regulate cell growth, 
metabolism, cell survival, protein synthesis, and transcription (reviewed in (31)). In total, 
we found seven known direct mTOR targets downregulated in our study and several other 
proteins included in “mTOR signalling pathway” from KEGG pathway database (depicted 




Four of the mTOR-phosphorylated proteins are involved in transcription and 
translation regulation and thus contribute to regulation of cell growth and proliferation. 
Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) Ser 65 is a 
known “regulatory” site targeted by mTOR or MAPK-driven pathways. Together 
with phosphorylation of Thr 70, Ser 65 phosphorylation affects translation initiation – 
when hypo-phosphorylated, EIF4EBP1 strongly binds to EIF4E, an essential member 
of the translation initiation EIF4 complex (392). Furthermore, we found four 
downregulated phosphorylation sites on Protein PAT1 homolog 1 (PATL1; Ser 179 and 
Ser 184) and La-related protein 1 (LARP1; Ser 766 and Ser 774); both proteins have been 
described as downstream mTOR targets involved in regulating mRNA stability and 
degradation (393,394). Both of them were also identified as rapamycin sensitive 
phosphorylation sites in a high throughput phosphoproteomic screen for potential mTOR 
substrates (395). Moreover, we also detected downregulation of an mTOR mediated 
phosphorylation of Repressor of RNA polymerase III transcription MAF1 homolog 
(MAF1) a previously described regulator of transcription; Ser 75 phosphorylation has been 
described as a “regulatory” protein modification decreasing RNA polymerase III (Pol III) 
transcription repressing ability of MAF1 (396).  
In addition to proteins involved in translation regulation, we also identified 
significantly changed phosphorylation of two phosphoproteins linked to autophagy, an 
evolutionarily conserved process that enables degradation and recycling of proteins or 
whole organelles to maintain cellular homeostasis under both normal and stress conditions 
(reviewed in (397)). Death-associated protein 1 (DAP1) is a suppressor of autophagy 
in growing cells that is functionally silenced through mTOR dependent phosphorylations 
on Ser 3 (downregulated in our study) and Ser 51. Inactivation of mTOR has been shown 
to rapidly reduce phosphorylation of these sites and activation of the repressor function 
of DAP1 (398). Serine/threonine-protein kinase ULK1 (ULK1) is a protein kinase that 
plays a key role inducing autophagy in response to starvation. Under normal growth 
condition, ULK1 is phosphorylated and negatively regulated by mTOR. Serine 450, 
detected in our study and predicted to be a substrate of mTOR by the iGPS prediction 
algorithm, has been shown to be dephosphorylated upon starvation (399). Unfortunately, 
we did not detect the Ser 638/758 that have been further validated as functional 






Figure 23: Significant changes in mTOR signalling pathway. Proteins with significantly 
changed phosphorylation sites were mapped onto KEGG signalling pathways (A). 
Summary of all phosphorylation sites comprised in “mTOR signalling pathway” pathway 
in KEGG database and phosphorylation sites that are known mTOR substrates or known 
to be mTOR-dependent (B). Immunoblotting analysis of mTOR activity (C). Cells were 
collected 2 hour after IR (1.5 Gy). Activity of mTOR was monitored via the detection of its 
target pT389 of p70S6K (S6K, RPS6KB1). The expression state of p70S6K was also 





To further validate and investigate the VE-821-mediated mTOR inhibition 
predicted from our SILAC data, we performed a confirmation experiment using an 
antibody detection of a regulatory Ribosomal protein S6 kinase beta-1 (p70s6K) Thr 389 
phosphorylation site that is commonly used to examine the activity of mTOR in molecular 
biology studies. As shown in figure 23C, while irradiation by a dose of 1.5 Gy did not 
affect p70S6K phosphorylation, mTOR-dependent p70S6K phosphorylation was almost 
diminished after 10 µM VE-821 treatment in both irradiated and sham-irradiated cells. On 
the other hand, 2 µM VE-821 did not have any significant effect on Thr 389 
phosphorylation site. 
The mTOR inhibition by 10 µM VE-821 and not 2 µM treatment might correlate 
with the results of our proliferation and DNA analysis experiments and explain the 
difference we observed between the 2 µM and 10 µM VE-821 treated groups. While both 
concentrations of the inhibitor radiosensitized MOLT-4 cells, 10 µM had much stronger 
inhibitory effect on the number of viable (metabolically active) sham-irradiated cells 
(figures 10 and 11). Likewise, while both concentrations caused the disruption of the IR-
induced G2/M arrest, it was only the higher concentration, which caused a significant 
accumulation in G1 phase in sham-irradiated cells (figure 13). These conclusions are 
supported by the fact that mTOR inhibition triggers G1 metabolic checkpoint and inhibits 
cell growth and proliferation (reviewed in (400). The mTOR inhibition by 10 µM VE-821 
might also explain the high sensitivity of MOLT-4 cell line to VE-821 treatment. It has 
been shown that PTEN-deficient tumours were more likely to be sensitive to mTOR 
inhibition (401,402), and as it was mentioned above, MOLT-4 cells suffer 
from homozygous deletion of PTEN.  
5.3.9.2. P70S6K, an important downstream effector of mTOR, was inhibited 
by 10 µM VE-821 treatment and likely contributed to translation inhibition. 
In addition to the downregulation of mTOR, we also observed a significant 
downregulation of the p70S6K (or RPS6KB1) in all kinase activity analyses (figure 21C). 
P70S6K is an important kinase that acts downstream of mTOR to promote protein 
synthesis and cellular proliferation (403,404).  In addition to the western blotting detection 
of changes in Ser 379 phosphorylation (figure 23C) induced by VE-821 treatment, we also 
detected another downregulated mTOR dependent “regulatory” phosphorylation site (Ser 
427) in our phosphoproteomic data. From the known p70s6k substrates, we detected three 




235, Ser 236, and Ser 240. These phosphorylation sites are phosphorylated by ribosomal 
kinases to initiate translation (405), and thus the inhibition of their phosphorylation causes 
inhibition of protein synthesis. Moreover, iGPS and Networkin 3 predicted two more 
members of the translation machinery to be downregulated substrates of RSKs - 
Eukaryotic translation initiation factor 3 subunit A (EIF3A) Ser 584 and Eukaryotic 
translation initiation factor 4B (EIF4B) Ser 119, providing further evidence 
for translation inhibition caused by inhibitor treatment. 
5.3.9.3. The downregulation of dihydroorotase phosphorylation, a substrate 
of p70S6K, showed a possible link to nucleotide synthesis alteration induced 
by VE-821 treatment.  
Surprisingly, on the known/predicted p70S6K substrates list detected in our study, 
we did not find phosphoproteins involved solely in protein synthesis. Dihydroorotase 
(CAD) is an enzyme required for the first steps of de novo pyrimidine synthesis. 
Phosphorylation on Ser 1859 by p70S6K downstream of mTOR stimulates dihydroorotase 
activity of CAD to induce pyrimidine synthesis (406). Ser 1859 was detected to be 
downregulated in our study, suggesting that VE-821 treatment might also hamper synthesis 
of nucleotides, which are necessary for both cellular proliferation and DNA repair after 
DNA damage induction.  
Based on this striking possibility of nucleotide synthesis dysregulation induced 
by VE-821 treatment, we further examined our data to search for regulated 
phosphorylation sites located on enzymes included in nucleotide synthesis pathways. In all 
three replicates, we identified two additional regulated phosphorylation sites on proteins 
from the de novo purine synthesizing pathway: Phosphoribosylglycinamide 
formyltransferase (GART) Tyr 348 and Phosphoribosylaminoimidazole carboxylase 
(PAICS) Ser 27; the latter one has been identified as a potential substrate of CDKs in two 
high-throughput  phosphoproteomic screenings (407,408); however, none of these 
enzymes has been proven to be regulated by phosphorylation, and thus we can only 
speculate whether these two phosphorylation events might have some effect on de novo 





5.4. Metabolomic analysis of VE-821 treated 
MOLT-4 cells 
In the phosphoproteomic analysis of VE-821 treated irradiated cells, changes in the 
mTOR activity were detected via kinases activity analysis and further confirmed 
by western blotting. As mTOR is the principal regulator of cellular metabolism (reviewed 
in (31)), this finding raised an intriguing question – whether the inhibitor treatment 
modulates cellular metabolism after irradiation. We further examined our data and found 
several metabolic enzymes containing phosphorylation sites affected by VE-821.   
The metabolic responses of different cell lines to various doses of IR have been 
investigated in several studies (409–411). Briefly, these studies showed that IR triggered 
production of free oxygen radicals by radiolysis of water induced changes in glutathione 
levels, disturbed energetic metabolism resulting in a rapid decrease of cellular ATP levels, 
and increased levels of free amino acids, choline, and lipids, which are produced 
by degradation of damaged proteins and membranes. However, to our knowledge, no study 
has been published yet investigating the modulation of this response by small molecular 
kinase inhibitor of any of the PIKKs family. Therefore, we performed a metabolomic 
analysis of irradiated MOLT-4 cells, whose response to IR was modulated by ATR (and 
mTOR) inhibition by 10 µM VE-821.  
Hierarchical clustering of the measured metabolomic data revealed two main 
patterns of behaviour induced by VE-821. In the first case, the metabolites showed 
significant either decreasing or increasing trend between the two time intervals (six and 
twelve hours after IR), and this trend was further potentiated by the addition of the 
inhibitor. In the second case, the metabolites showed no significant trend over time 
in irradiated groups and the inhibitor significantly altered the response of MOLT-4 cells 
to IR (figure 17). The main significant changes in the metabolome of MOLT-4 cell line 
occurred in a group of metabolites involved in cellular antioxidant system, intermediates 
of glucose metabolism and citrate cycle, nucleosides, nucleotides, deoxynucleotides, free 




5.4.1. Exposure to VE-821 potentiated changes in cellular 
antioxidant defence, degradation of proteins and 
membranes, and damage to mitochondria induced by IR. 
When cells are exposed to IR, cellular structures can be damaged by ionization 
directly by deposition of energy, but also indirectly by water radiolysis and stimulation 
of nitric oxide synthases and NADPH oxidases, which leads to generation of highly 
reactive oxygen and nitrogen species (ROS/RNS) secondarily attacking nucleic acids and 
other biomolecules such as proteins and lipids contained in membranes (reviewed 
in (412)). Reduced glutathione (GSH) is an important cellular antioxidant, and the 
reduced/oxidized glutathione ratio (GSH/GSSG) is a sensitive biomarker of oxidative 
stress (413). It has been reported previously that radiation induced a significant decrease 
in cellular glutathione levels (409,410). In our study, we observed a decrease in GSH over 
incubation time and this decrease was amplified by inhibitor exposure (figure 24A). 
However, GSSG was also depleted as well as important precursors of GSH biosynthesis 
(glutamate and glycine, figure 25A). Therefore, we assume that the overall decrease 
of GSH/GSSH pair was caused by increased turnover of GSH and missing precursors at the 
same time. Additionally, we observed increased levels of allantoin and decreased levels 
of taurine. Allantoin can be formed in the presence of ROS by non-enzymatic reactions, 
and similarly to GSH, it can be used as a marker of oxidative stress (414). Taurine in an 
intermediate in metabolism of methionine and an anti-oxidant, and its decrease might 
indicate its elevated consumption in VE-821 treated cells as a part of preventive 
mechanisms counter-acting oxidative stress. Taken together, our data provide indirect 
evidence that the cellular response to oxidative stress induced by IR might have been 
affected by the pre-incubation with the inhibitor.  
In addition to the changes in cellular redox system, direct effects on proteins and 
membranes were also observed. Increased levels of several amino acids (phenylalanine, 
proline, tryptophan, tyrosine, valine, isoleucine, and methionine) indicate increased 
turnover of proteins which were damaged by ROS/RNS exposure (figure 25). Elevated 
levels of docosahexaenoic acid and choline provided evidence for the increased membrane 
degradation induced by the inhibitor treatment (figure 24B). IR induces autophagy 
by inhibition of mTOR (415) probably via a pathway involving ATM and AMPK (416). 
VE-821 10 µM, but not 2 µM inhibited mTOR in both sham-irradiated and irradiated 




phosphorylations in autophagy-regulating proteins. Thus, we can hypothesize that the 
treatment might have induced degradation of damaged structures (potentially via 
autophagy), resulting in increased accumulation of degradation products in cells. 
 
Figure 24: VE-821 induced changes in cellular response to oxidative stress (A), 
degradation of membranes (B), and acylcarnitine profile (C). GSH – glutathione, GSSG 
– glutathione disulphide (oxidised glutathione), IR – irradiated cells pre-treated 
with DMSO, VE – irradiated cells pre-treated with 10 µM VE-821  
We further observed prominent changes in the acylcarnitine profile (figure 24C), 




of long-chain acylcarnitines (tetradecanoyl-, palmitoyl-, and stearoyl- carnitine) and 
decreased levels of free carnitine, isovaleryl-/ methyl- butyrylcarnitine, and malonyl-/ 3-
hydroxy- butyrylcarnitine were observed. Acylcarnitine changes have been already 
observed in a study investigating metabolic effects of low dose (20 mGy) X-irradiation 
(411) and in a targeted lipidomic study investigating changes in livers of irradiated mice 
(417). Moreover, it has been shown that L-carnitine acts as a free-radical scavenger 
protecting irradiated mice from oxidative damage in response to IR (418). Our observation 
of the lipid changes in mitochondrial membrane might be explained by lipid peroxidation 
induced by increased ROS generation in VE-821 treated cells, which was evidenced above 
as decreased GSH and altered allantoin and taurine levels. 
 
Figure 25: Changes in free amino acids levels in irradiated and VE-821 treated cells. IR 





5.4.2. VE-821 potentiated the energy metabolism disruption 
induced by IR. 
IR has been shown to disturb energetic metabolism demonstrated by a rapid 
decrease of cellular ATP levels in irradiated cells (409,419) and serum ATP levels 
in irradiated mice (420). In our study, we found decreased levels of nucleoside 
triphosphates (NTPs; ATP, GTP, CTP, and UTP), diphosphates (NDPs; ADP and UDP), 
and their derivatives (UDP-hexoses, GDP-hexoses, and UDP-N-acetylglucosamine) and 
on the contrary, increased levels of ribonucleosides (adenosine, guanosine, and 
pseudouridine) and bases (uracil). The overview of changes in purine and pyrimidine 
metabolism induced by VE-821 is given in figures 26 and 27.  
 
Figure 26: Changes in purine metabolism induced by VE-821 in irradiated cells. IR – 
irradiated cells pre-treated with DMSO, VE – irradiated cells pre-treated with 10 µM VE-





Figure 27: Changes in metabolism of pyrimidine induced by VE-821 in irradiated 
MOLT-4 cells. IR – irradiated cells pre-treated with DMSO, VE – irradiated cells pre-
treated with 10 µM VE-821. HEX - hexose 
Decreased levels of high-energetic phosphorylated compounds might indicate 
disruption in energy metabolism induced by exposure to IR. Importantly, VE-821 
amplified the energy depletion caused by IR. It is not clear from our data, whether the 
observed time-dependent decrease is due to increased utilization of NTPs needed as a 
“molecular fuel” for cellular signalling, reparation processes, and programmed cell death 
following DNA damage induction by IR or by their decreased synthesis in damaged 
mitochondria. 
Significant changes were also found in glycolysis (figure 28). Increased glucose 
and decreased intermediates of glycolysis (glucose 6-phosphate, 3-phosphoglycerate, and 
phosphoenolpyruvate) could probably reflect inhibition of hexokinase - the first step 
of glycolysis. The aforementioned insufficiency of ATP for an initial deposit energy into 
the first reaction could be the reason. On the other hand, decreased intermediates 




could be supported by pronounced time-dependent increase of lactate in irradiated control 
and VE-821-treated cells. We also detected an activating phosphorylation 
on phosphofructokinase 1 (PFKL) Ser 775 in two experimental replicates of our 
phosphoproteomic analysis, which has been previously shown to be responsive to insulin 
treatment and activating glycolysis (421), suggesting that the metabolic flux through 
glycolysis might be increased one hour after irradiation. However, further metabolomic and 
phosphoproteomic experiments covering multiple time points would be necessary to fully 
understand the temporal regulation of glycolysis upon IR and VE-821 treatment. We also 
observed significant modulation of citric acid cycle metabolites (figure 28). Markedly 
lower levels of aconitate, malate, and citrate/isocitrate were found in VE-821 treated cells; 
moreover, citrate/isocitrate showed a time-dependent decrease in control irradiated-only 
cells. On the contrary, succinate and fumarate were slightly increased in VE-821 treated 
cells. We assume that these intermediates could have been replenished by anaplerotic 





Figure 28: Selected metabolites included in metabolism of glucose and citric acid cycle. 
IR – irradiated cells pre-treated with DMSO, VE – irradiated cells pre-treated with 10 µM 
VE-821. PEP - phosphoenolpyruvate 
5.4.3. VE-821 affected deoxynucleotide pools in irradiated 
cells. 
Decreased levels of deoxynucleoside diphosphates (dNDPs; dADP and dTDP) and 
triphosphates (dNTPs; dATP, dGTP, and dTTP) were found in VE-821 treated irradiated 
cells. dCTP was also decreased due to VE-821; moreover, time-dependent reduction was 
observed in irradiated control cells. We also found several purine and pyrimidine bases and 
ribosides (xanthine, inosine, cytidine, uridine, and thymidine) elevated in VE-821 treated 
cells; nucleoside monophosphates (AMP and GMP) were slightly reduced (figure 26 and 
27).  
Deoxyribonucleotides arise either via de novo pathways, which involve step-by-
step assembly of purine and pyrimidine rings and formation of deoxyribonucleosides 
diphosphates from their corresponding ribonucleosides diphosphates precursors, or 




by nucleic acid degradation (reviewed in (422)). Thus, in principle, the deoxynucleotide 
levels might have decreased either by downregulation of their de novo synthesis or due 
to their degradation and downregulation of the salvage pathways. Importantly, dNTPs 
damaged by IR and oxidised due to increased levels of ROS in irradiated cells are degraded 
by hydrolysis, largely contributing to dNTPs depletion upon irradiation.  
As discussed above, in our study, we observed a time-dependent decrease in NDPs 
and NTPs, i.e. the precursors of dNDPs and dNTPs in de novo pathways, which was further 
amplified by the inhibitor, supporting the idea that the decrease in dNTPs might have been 
induced by insufficiency of the precursors for their de novo synthesis. Furthermore, we also 
detected a significantly decreased stimulating phosphorylation on CAD Ser 1859, an 
important regulator of de novo pyrimidine synthesis, and two phosphorylations on two 
enzymes involved in de novo purine biosynthesis (GART and PAICS) with unknown 
functions. The salvage pathways could have been also affected by the inhibitor treatment; 
this idea is supported by a recent study showing that activity of deoxycytidine kinase 
(dCK) is ATR-dependent after stress induction (423). dCK catalyses the first and rate 
limiting step of the deoxyribonucleotide salvage pathway (424), and as a consequence of its 
broad substrate specificity (which comprises deoxycytidine, deoxyadenosine, and 
deoxyguanosine), it is the main enzyme in the salvage of deoxyribonucleotides (reviewed 
in (425)). Beyaert et al. investigated the dCK activity dependency on ATM and ATR after 
different stress inducing stimuli. VE-821 significantly reduced upregulation of dCK 
induced by various genotoxic agents. Importantly, after irradiation, dCK activity was 
dependent on ATR only in ATM-deficient cells (423). However, it is necessary to note that 
the authors examined short time intervals after irradiation (two hours), when ATM 
signalling is predominant. It is possible that after longer incubation with the inhibitor, VE-
821 might inhibit dCK even in irradiated cells with functional ATM pathway – since the 
basal activity of dCK has been shown to be significantly downregulated by ATR silencing 
(423). Thus, it is apparent that several mechanisms could contribute to dNTPs depletion 
upon IR in VE-821 treated cells. Further validation experiments would be necessary 





6. Summary of the most important 
findings 
 From the plethora of protocols for selective enrichment of phosphopeptides 
published so far, we selected four, which were applied for phospho-enrichment 
using different chromatographic resins with subsequent detection of enriched 
phosphopeptides by MALDI-TOF MS. After the first tests, where we evaluated 
the selectivity for phosphopeptides and enrichment efficiency from low complex 
samples composed of standard phosphorylated and non-phosphorylated peptides, 
Titansphere® particles and NuTips® were selected for further testing using 
more complex samples. Protocol including 200 mM glutamic acid as a 
selectivity-enhancing additive was selected as the most beneficial.  
 Using HeLa cell line lysate as the more complex sample, Titansphere® particles 
were shown to be more efficient and advantageous than the NuTips®, and hence 
they were selected for further studies investigating the phosphorylation response 
of MOLT-4 cells to the combination of IR and DDR inhibitor treatment.  
 We showed that MOLT-4 cells were radiosensitized by both high potent 
inhibitors of ATM and ATR, KU55933 and VE-821, respectively. While the 
effect of KU55933 was shown to be mostly radiosensitizing without affecting the 
proliferation and viability of sham-irradiated cells, treatment with VE-821 
induced two distinct phenotypes depending on the dose.  
 Treatment with 2 µM VE-821 caused mostly radiosensitization and disruption 
of the G2/M arrest without affecting the viability of sham-irradiated cells. On the 
other hand, 10 µM VE-821 treatment was characterized by marked proliferation 
inhibition (with slight, but significant G1 arrest) and decreased viability 
of MOLT-4 cells in both single inhibitor treatment and its combination with IR. 
 Phosphoproteomic analysis revealed the complexity of the cellular response to IR 
modulated by 10 µM VE-821 treatment. In this analysis, we detected 9285 
phosphorylation sites from 3090 protein groups. By applying GRT, we 
identified 623 differentially regulated phosphorylation sites; most of them were 




comprehensively, which protein kinases and signalling pathways might be 
affected by the inhibitor treatment upon irradiation.  
 Gene ontology terms over-representation analysis revealed that proteins 
with regulated phosphorylation sites were significantly over-represented 
in nucleus, specifically in chromosomes, mitotic spindle, and replication fork; 
involved in chromatin organization, DNA repair and metabolism, cell cycle, 
and regulation of transcription factors.  
 Signalling pathways over-representation analysis identified pathways involved 
in DNA repair, replication, telomeres synthesis, apoptosis, regulation of mitosis, 
transcription factors regulation, and chromatin regulation via histones 
modification, but also pathways primarily related to cellular metabolism. 
 Based on kinase activity inference, we detected a decreased activity of ATR, 
which was in concordance with our expectations and antibody-based detection 
of ATR activity using western blotting and thus provided an important 
confirmation of the validity of our data. Among the known and predicted ATR 
substrates detected in our study, several DDR proteins were detected 
with significantly downregulated phosphorylation sites, such as members of the 
MRN complex, BRCA1-BRCT/Abraxas complex, and members of the 
Fanconi anaemia pathway.  
 The activity of several mitotic kinases was modulated by VE-821 treatment, 
which was in concordance with previous knowledge of the dominant role 
of ATR/Chk1 pathway in triggering the S- and G2/M phase checkpoints. In 
addition to CDKs upregulated in the response to VE-821 treatment, we found 
known or predicted substrates of Aurora A, Aurora B, and NEK kinases 
with upregulated phosphorylation. We found multiple regulated phosphorylation 
sites on known “mitotic proteins” such as CBX5, CDCA5, KIF2C, KIF11, 
PRC1, STMN1, TOP2A, and TPX2.  Thus, the inhibitor treatment might affect 
both progression through G2/M checkpoint and mitosis.  
 After irradiation, 10 µM VE-821 was shown to inhibit the main regulator 
of cellular metabolism - mTOR, together with its downstream effectors P70S6K 
and CAD. Their inhibition was inferred from downregulation of several of their 
phosphorylation targets: CAD, EIF3A, EIF4B, EIF4EBP1, LARP1, MAF1, 




in proliferation and viability assays and indicate that the inhibitor might cause 
protein and nucleotide synthesis inhibition. Moreover, a possible link 
to autophagy modulation has been found suggested by phosphorylation changes 
on DAP1 and ULK1.   
 In western blotting analysis, the addition of sham-irradiated controls and 
treatment with 2 µM VE-821 showed that the inhibition of mTOR occurred also 
in sham-irradiated cells, and the lower concentration of the inhibitor did not 
induce any mTOR inhibition detectable by western blotting. Therefore, we 
assume that the mTOR inhibition was most likely induced by an off-target 
of the inhibitor. This finding is of the utmost importance as in several studies 
VE-821 has been used in 10 µM concentration, and possible contribution 
of mTOR inhibition to the observed phenotype has not been considered. 
 Importantly, we provide the first metabolomic profile of cells treated with a 
PIKKs family kinase inhibitor. To our knowledge, no such study has been 
published yet providing an insight into metabolic pathways modulated by ATR 
inhibitor in response to DNA damage. In our targeted metabolomic analysis, 206 
intermediary metabolites were quantified, and two trends were observed – 
first, 10 µM VE-821 potentiated the effects of IR and second, 10 µM VE-821 
modulated the metabolism of irradiated cells.  
 VE-821 potentiated the metabolic disruption induced by IR affecting the levels 
of NDPs, NTPs and intermediates of glycolysis (glucose 6-phosphate, 3-
phosphoglycerate, phosphoenolpyruvate), and lactate. IR induced oxidative 
stress might be increased upon the addition of VE-821 as demonstrated 
by changed GSH and allantoin levels. VE-821 also induced changes in citric 
acid cycle intermediates.  
 VE-821 induced decrease in dNDPs and dNTPs levels. As we did not observe 
any time-dependent decrease in irradiated cells, we assumed that the changes 
were probably not caused entirely by the insufficiency of NDPs and NTPs in their 
de novo synthesis. Lately, the enzymatic activity of dCK, which is the main 
regulator of nucleotide salvage pathways, has been proven to be dependent upon 
ATR after DNA damaging stress. Therefore, the downregulation of salvage 
pathways by ATR inhibition might be the main cause of the decrease of dNTPs 





DNA damage induction by either radio- or chemo- therapy has been the most 
widely used approach in oncology exploiting one of the hallmarks of cancer: genomic 
instability. However, such treatment is very unspecific and often accompanied by collateral 
damage to healthy tissues. In recent years, much effort has been focused on discovery and 
development of tumour specific treatment, which would only specifically target cancer 
cells and not affect the normal tissues. A promising concept that has been developed 
recently is to take advantage of the tumour specific abnormalities in DDR, and target the 
DDR kinases from the PIKKs family - ATM, ATR, and DNA-PK.  
In the presented doctoral thesis, we aimed to elucidate molecular mechanisms 
underlying radiosensitization of MOLT-4 cell line (T-ALL) by PIKKs inhibitors. To do so, 
we tested two highly potent inhibitors of two kinases from the PIKKs family - ATR and 
ATM, VE-821 and KU55933, respectively for their effects on proliferation, viability, and 
cell cycle of sham-irradiated and irradiated MOLT-4 cells. In these initial tests, both 
inhibitors proved to radiosensitize MOLT-4 cells and furthermore, 10 µM VE-821 was 
shown to act as a strong antiproliferative agent in sham-irradiated MOLT-4 cells. 
To further describe cellular mechanisms underlying the VE-821-mediated 
radiosensitization of MOLT-4 cells, we employed high-resolution MS to identify and 
quantify changes in proteome, phosphoproteome, and metabolome of irradiated 
VE-821-treated cells. As the detection and quantification of phosphorylated peptides 
in complex biological samples is challenging due to their low stoichiometry, first of all we 
optimized protocol for the enrichment of phosphorylated peptides from their mixture 
with their nonphosphorylated counterparts. Several commercially available 
chromatographic materials and published protocols were selected and tested using MALDI-
TOF MS detection of phosphorylated peptides enriched from standard tryptic peptides 
mixtures. The most successful protocols were further evaluated using complex samples, 
such as HeLa cells lysate and SILAC-labelled MOLT-4 cells lysate. Based on the 
optimization part, a protocol including the Titansphere® particles and loading buffer 
containing 200 mM glutamic acid as a specificity and efficiency enhancer was compiled 
for further experiments. 
The optimized protocol was then successfully applied to study VE-821-dependent 




not cause any significant changes on the proteome level. However, we detected 623 
differentially regulated phosphorylation sites; most of them (431) were upregulated 
in response to the inhibitor treatment. Using bioinformatic tools, we described, which 
protein kinases and signalling pathways might be affected by the inhibitor treatment upon 
irradiation. These analyses revealed changes in DDR related pathways and kinases, but 
also pathways and kinases involved in maintaining cellular metabolism. Notably, we 
found a downregulation of mTOR, the main regulator of cellular metabolism, which was 
also confirmed by western blotting. Although there are multiple signalling pathways 
connecting IR-induced DDR and mTOR regulation that might be potentially regulated 
by ATR inhibition, we assumed that in our case the downregulation was most likely caused 
by an off-target effect of VE-821 at 10 µM concentration. We further concluded that 
mTOR inhibition could be one of the factors contributing to the phenotype we observed 
after treating MOLT-4 cells with 10 µM VE-821, which was different from a lower, mTOR 
non-inhibitory, concentration. 
To our best knowledge, no study has been published yet investigating the 
modulation of cellular metabolism by small molecular kinase inhibitor of any of the PIKKs 
family kinases. Therefore, we performed a targeted metabolomic analysis of irradiated 
MOLT-4 cells, whose response to IR was modulated by 10 µM VE-821. In this analysis, 
206 intermediary metabolites were quantified. Subsequent data analysis showed that 
VE-821 potentiated the metabolic disruption induced by IR and increased the IR induced 
oxidative stress. Our data also indicated that in response to IR, recovery of dNTPs might 
be affected by VE-821 possibly hampering the DNA repair by dNTPs insufficiency.  
Thus, in this thesis we described a complex scenario of cellular events that might 
be dependent on ATR or triggered by ATR inhibition in irradiated MOLT-4 cells. This 
thesis raised several research questions.  
 Which of the mitotic kinases are regulated by ATR, in which phase of mitosis, 
and how? Is it only the G2/M checkpoint dysregulated by VE-821 treatment 
in irradiated cells?  
 How exactly does VE-821 regulate the mTOR activity? Is it only the off-target 
effect, or are there also any other pathways contributing to mTOR regulation 
affected? Several upstream kinases are involved in mTOR regulation in response 
to stress, such as AMPK, PI3K/Akt, or p38 MAPK. Is there any link between 




inhibited mTOR? Is the sensitivity of MOLT-4 cells to the mTOR-inhibiting dose 
of VE-821 caused by PTEN deficiency? 
 What is the reason for VE-821-mediated potentiation of metabolic disruption 
induced by IR and increase of oxidative stress? Is it just increased mitochondrial 
stress? 
 Is ATR necessary for dNTPs salvage pathways in irradiated cells? Does ATR 
inhibition affect their de novo synthesis, and is phosphorylation involved 
in regulation of these metabolic pathways?  
 
Unfortunately, addressing these questions is beyond the extent of this doctoral 
thesis. However, data presented in this work might serve as a resource for follow-up studies 
and provide a platform for future work with other (more potent or specific) inhibitors.  
Taken together, we conclude that using ATR inhibitors to radiosensitize cancer cell 
seems to be an effective anti-tumour strategy. Nevertheless, even using a highly specific 
inhibitor might lead to a complex response and similar MS-based studies are suitable 
to reveal additional information on off-target effects and provide insights into other 
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